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Abstract 
 
This thesis focuses on the mechanism of mitophagy and the 
initiation of mitophagy in various cell models derived from patients 
harbouring pathogenic mutations in the mitochondrial genome. 
Mitochondrial DNA mutations are maternally inherited and present 
with considerable clinical heterogeneity. Pathogenic cases can be 
homoplasmic or heteroplasmic; the latter of which means that wild-
type and mutant mitochondria coexist. Particularly in cases of 
heteroplasmy, it is unclear how critical levels of mutant load can be 
reached, despite the presence of mitochondrial quality control 
pathways such as mitophagy. Mitophagy is a quality control process 
which facilitates the complete elimination of dysfunctional 
mitochondria.  
 
Mitophagy is known to be stimulated by a loss of mitochondrial 
membrane potential, however other triggers of the process are well 
less characterised. Here, the compound Rhodamine 6G was used 
to demonstrate the triggering of mitophagy independently of 
membrane potential in a Parkin-overexpressing neuroblastoma cell 
line model. Further analysis suggested that this compound 
generates mild oxidative stress and deep-sequencing of 
mitochondrial genome revealed the presence of mtDNA mutations 
upon exposure to Rhodamine 6G. 
 
The role of mitophagy in primary mitochondrial DNA disease is 
poorly understood. Using several patient fibroblast lines containing 
different mutations, significant impairments were identified in the 
ubiquitination of mitofusins upon stimulation of the mitophagy 
pathway and a considerable activation of mitochondrial biogenesis 
was observed, which did not occur in control fibroblasts. Further 
 6 
experiments were performed focusing on the m.7472insC mutation, 
in which similarities in morphology and function were identified 
between these and PINK1 mutant fibroblasts. The m.7472insC 
fibroblasts were reprogrammed to induced pluripotent stem cells 
and differentiated to cortical neurons and myoblasts. Using a 
mitochondrial uncoupler, significant reductions in the accumulation 
of PINK1 and degradation of mitofusin 1 were observed in mutant 
myoblasts, however this was not seen in the mutant neurons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
Contents 
Table of Contents 
 
Acknowledgements ....................................................................................... 3 
Abstract .......................................................................................................... 5 
Contents ......................................................................................................... 7 
Abbreviations ............................................................................................... 14 
Introduction .................................................................................................. 17 
Mitochondria ......................................................................................... 17 
Structure and Function of Mitochondria ....................................................... 17 
Glycolysis and Oxidative Phosphorylation ................................................... 20 
Mitochondrial DNA ....................................................................................... 25 
Mitochondrial Quality Control Processes ..................................................... 30 
The Mechanism of Mitophagy .............................................................. 35 
PINK1 ........................................................................................................... 35 
Parkin ........................................................................................................... 36 
PINK1/Parkin-dependent mitophagy ........................................................... 37 
PINK1 and/or Parkin-independent mitophagy ............................................. 40 
Mitochondrial DNA disease .................................................................. 43 
Objectives of thesis .............................................................................. 49 
Methods ........................................................................................................ 51 
Cell culture ........................................................................................... 51 
Molecular Biology techniques .............................................................. 51 
Mitochondrial isolation ................................................................................. 51 
Cell lysate preparation ................................................................................. 53 
Western blotting ........................................................................................... 54 
Immunocytochemistry .................................................................................. 58 
Antibodies .................................................................................................... 60 
DNA extraction ............................................................................................. 62 
Long-range PCR and quantification ............................................................. 62 
Nextera library preparation .......................................................................... 63 
 8 
Sanger Sequencing ..................................................................................... 65 
Mitochondrial membrane potential ............................................................... 67 
Mitochondrial network analysis .................................................................... 69 
GSH levels by live imaging .......................................................................... 71 
EM imaging .................................................................................................. 72 
RNA extraction ............................................................................................. 73 
cDNA synthesis ........................................................................................... 74 
Q-PCR reaction ............................................................................................ 74 
MtDNA copy number ................................................................................... 77 
Primer Sequences ....................................................................................... 78 
Complex I activity assay .............................................................................. 79 
IPSC and Differentiation techniques .................................................... 81 
Stemgent microRNA-Enhanced mRNA Reprogramming System ............... 81 
Karotyping iPSC .......................................................................................... 85 
Culturing IPSC ............................................................................................. 85 
Cortical neuron differentiation ...................................................................... 86 
Myogenic differentiation ............................................................................... 90 
Assessing mitophagy in differentiated cell types ......................................... 94 
Chapter 1 ...................................................................................................... 96 
Mechanistic insights into the mitophagy pathway .................................... 96 
1.1 Introduction .................................................................................... 96 
1.1.1 Methods to induce mitophagy .......................................................... 96 
1.1.2 Methods to study mitophagy ............................................................... 97 
1.1.3 Aims and hypothesis ......................................................................... 100 
1.2 Results ......................................................................................... 103 
1.2.1 Rhodamine 6G causes PINK1 stabilisation, Parkin translocation, and 
triggers mitophagy ..................................................................................... 103 
1.2.2 Ubiquitination of mitofusin 1 is PINK1/Parkin dependent ................. 109 
1.2.3 Rhodamine 6G does not induce membrane depolarisation, but PINK1 
stabilisation is caused by oxidative stress ................................................. 111 
1.2.4 Deep-sequencing reveals mitochondrial DNA mutations are caused by 
Rhodamine 6G ........................................................................................... 114 
1.2.5 PINK1-dependent mitofusin 1 ubiquitination can be detected in human 
fibroblasts, but not PINK1-dependent mitophagy ...................................... 116 
1.2.6 Complex V mitochondrial staining is loss first upon induction of 
mitophagy in non Parkin-overexpressing cell systems .............................. 118 
 9 
1.3 Discussion .................................................................................... 123 
1.3.1 Key findings in the mitophagy pathway ............................................ 123 
1.3.2 Mitochondrial membrane depolarisation-independent mitophagy .... 125 
1.3.3 Oxidative stress and mitochondrial DNA mutations as an inducer of 
mitophagy .................................................................................................. 127 
1.3.4 Detecting mitophagy: what causes loss of Complex V signal in 
immunocytochemistry? .............................................................................. 128 
1.3.5 Future perspectives .......................................................................... 130 
Chapter 2 .................................................................................................... 131 
Fibroblast models of mtDNA disease and novel phenotypic findings .... 131 
2.1 Introduction .................................................................................. 131 
2.1.1 Models of primary mtDNA disease ................................................... 131 
2.1.2 Examples of uses of mtDNA disease fibroblast models ................... 134 
2.1.3 Therapeutic strategies for mtDNA disease and targeting heteroplasmy
 ................................................................................................................... 135 
2.1.4 Mitophagy in mtDNA disease ........................................................... 137 
2.1.5 Aims and hypothesis ......................................................................... 139 
2.2 Results ......................................................................................... 140 
2.2.1 Clinical description of patients with primary mitochondrial disease .. 140 
2.2.2 Maintenance of mitochondrial membrane potential in cultured mtDNA 
disease fibroblasts ..................................................................................... 143 
2.2.3 Mitochondrial dynamics in cultured mtDNA disease patient fibroblasts
 ................................................................................................................... 150 
2.2.4 Similarities in EM imaging and Complex I activity in tRNA Serine 
mutants and PINK1 mutant fibroblasts ...................................................... 156 
2.2.5 PINK1, Parkin and mitochondrial biogenesis in mtDNA disease patient 
fibroblasts .................................................................................................. 159 
2.3 Discussion .................................................................................... 164 
2.3.1 Mitochondrial dynamics in mtDNA disease patient fibroblasts ......... 164 
2.3.2 Assessing mitophagy in fibroblast models ........................................ 167 
2.3.3 Similarities between tRNA serine mutants and PINK1 mutants ....... 170 
2.3.4 mtDNA disease and PD pathogenesis ............................................. 172 
2.3.5 Biogenesis and mitophagy in mtDNA disease .................................. 172 
2.3.6 Future perspectives .......................................................................... 174 
Chapter 3 .................................................................................................... 176 
 10 
Neuronal and Myogenic models of tRNA serine m.7472insC pathogenic 
mutation ................................................................................................. 176 
3.1 Introduction .................................................................................. 176 
3.1.1 Induced Pluripotent Stem Cell models of mtDNA disease ................ 176 
3.1.2 Reprogramming to iPSC – mtDNA bottleneck theory ....................... 178 
3.1.3 Neuronal and muscle cell types in mtDNA disease .......................... 180 
3.1.4 Aims and hypothesis ......................................................................... 181 
3.2 Results ......................................................................................... 183 
3.2.1 Characterisation of induced Pluripotent Stem Cells (iPSCs) ............ 183 
3.2.2 Characterisation of iPSC-derived cortical neurons ........................... 187 
3.2.3 Mitochondrial physiology and function in mtDNA disease derived 
cortical neurons ......................................................................................... 191 
3.2.4 Characterisation of iPSC-derived myotubes ..................................... 197 
3.2.5 Mitochondrial physiology and function in mtDNA disease derived 
myotubes ................................................................................................... 200 
3.3 Discussion .................................................................................... 206 
3.3.1 Limitations of iPSC derived mitochondrial disease models .............. 206 
3.3.2 Phenotypes in cortical neurons containing tRNAserine mtDNA 
mutation ..................................................................................................... 208 
3.3.3 Phenotypes in myogenic cells containing tRNAserine mtDNA mutation
 ................................................................................................................... 210 
3.3.4 Differences in the effect of the same mutation in different cell types – 
fibroblasts, cortical neurons and myotubes ............................................... 212 
3.3.5 Working hypothesis for the effect of m.7472insC mutation on 
mitochondria in myotubes .......................................................................... 215 
3.3.6 Does mitophagy occur in neurons and myotubes? ........................... 217 
3.3.7 Future perspectives .......................................................................... 218 
Discussion .................................................................................................. 219 
Appendix ..................................................................................................... 225 
References .................................................................................................. 227 
 
 
 
 
 
 11 
 
Table of Figures 
 
Figure 1: Structure of the Mitochondrion ........................................................ 18	
Figure 2: Pathway of glycolysis, divided into three stages ............................. 22	
Figure 3 Oxidative Phosphorylation at the inner mitochondrial 
membrane ............................................................................................... 24	
Figure 4: Mitochondrial genome structure ..................................................... 27	
Figure 5: Schematic diagram to show the processes of fusion and 
fission ...................................................................................................... 31	
Figure 6: Mechanisms of mitochondrial quality control .................................. 34	
Figure 7: PINK1 and Parkin domain architecture ........................................... 36	
Figure 8: PINK1 stabilisation and phosphorylation ........................................ 39	
Figure 9: Fluorescence assay based on the pH change from cytosol 
to lysosome for detecting mitophagy ...................................................... 42	
Figure 10: The origin of genomic encoding of the respiratory chain 
complex subunits .................................................................................... 44	
Figure 11: Vegetative Segregation of mtDNA in dividing cells ....................... 46	
Figure 12: Rhodamine 6G induces PINK1 accumulation ............................. 104	
Figure 13: Rhodamine 6G stimulates Parkin translocation, p62 
recruitment and the degradation of mitofusin 1 .................................... 107	
Figure 14: Rhodamine 6G induces mitophagy ............................................. 109	
Figure 15: Mitofusin 1 ubiquitination stimulated by Rhodamine 6G is 
dependent upon PINK1 and Parkin ...................................................... 110	
Figure 16: Rhodamine 6G does not depolarise the mitochondrial 
membrane but induces oxidative stress to cause PINK1 
stabilisation ........................................................................................... 114	
Figure 17: Rhodamine 6G induces mutations in the mitochondrial 
genome ................................................................................................. 116	
Figure 18: PINK1-dependent mitophagy cannot be detected in 
fibroblasts ............................................................................................. 117	
 12 
Figure 19: Differences in the loss of mitochondrial proteins in non 
over-expressing Parkin systems ........................................................... 122	
Figure 20 Schematic of the generation and use of cybrids for 
modelling mtDNA disease .................................................................... 132	
Figure 21: Mitochondrial membrane potential basal measurement in 
mtDNA disease patient fibroblasts ........................................................ 146	
Figure 22: Maintenance of mitochondrial membrane potential .................... 150	
Figure 23: Mitochondrial volume and mtDNA copy number in 
mtDNA disease patient fibroblasts ........................................................ 152	
Figure 24: Ubiquitination of mitofusins in stressed mtDNA patient 
fibroblasts ............................................................................................. 155	
Figure 25: tRNA serine mutants and PINK1 homozygous mutant, 
comparison of morphology and function ............................................... 158	
Figure 26: Endogenous Parkin levels in mtDNA patient fibroblasts 
and healthy controls .............................................................................. 160	
Figure 27: mRNA expression of PINK1 and PGC1α in mtDNA 
disease patient fibroblasts .................................................................... 163	
Figure 28: Mitochondrial DNA Germline Bottleneck .................................... 180	
Figure 29: Characterisation of induced Pluripotent Stem cells .................... 185	
Figure 30: Characterisation of induced Pluripotent Stem cells .................... 186	
Figure 31: Characterisation of induced Pluripotent Stem cells by 
qPCR .................................................................................................... 187	
Figure 32: Sanger sequencing chromatogram of the m.7472insC 
mutation in iPSC-derived cortical neurons ............................................ 189	
Figure 33: Characterisation of iPSC-derived cortical neurons ..................... 190	
Figure 34: Quantification of mitochondrial membrane potential and 
complex I activity in cortical neurons .................................................... 192	
Figure 35: Stimulation of cortical neurons with CCCP and 
quantification of mitochondrial protein levels ........................................ 195	
Figure 36: Stimulation with CCCP in the presence of proteasome 
inhibitor MG132 in iPSC-derived cortical neurons ................................ 196	
Figure 37: Confirmation of presence of m.7472insC mutation and 
characterisation of iPSC-derived myotubes .......................................... 199	
 13 
Figure 38: Quantification of mitochondrial membrane potential and 
complex I activity in iPSC-derived myotubes ........................................ 201	
Figure 39: Quantification of PINK1 levels in myotubes stimulated 
with mitochondrial uncoupler CCCP ..................................................... 203	
Figure 40: Quantification of mitochondrial protein levels in myotubes 
stimulated with 48 H CCCP .................................................................. 205	
 
 
 
 
 
Table of Tables 
 
Table 1: BigDye Terminator Cycle Sequencing reaction ............................... 66	
Table 2: High Capacity cDNA Reverse Transcriptase reaction ..................... 74	
Table 3: Fast SYBR green QPCR reaction .................................................... 76	
Table 4: SYBR Green PCR reaction .............................................................. 78	
Table 5: Complex I activity assay program settings ....................................... 80	
Table 6: mRNA reprogramming cocktail components ................................... 82	
Table 7 Neural maintenance media components .......................................... 88	
Table 8 Neural induction media components ................................................. 88	
Table 9 Myogenic differentiation media ......................................................... 91	
Table 10 Day 3 Myogenic differentiation media ............................................. 91	
Table 11 Day 4-6 Myogenic differentiation media .......................................... 92	
Table 12 Day 7 Myogenic differentiation media ............................................. 92	
Table 13 Terminal Myogenic differentiation media ........................................ 93	
Table 14 Myogenic maturation media ............................................................ 94	
Table 15 Clinical Information reported on mtDNA disease patients 
whose fibroblasts were used in this study. ........................................... 142	
 
 
 
 
 14 
 
Abbreviations 
ADP Adenosine diphosphate 
ANT Adenine nucleotide translocase 
ATP Adenosine triphosphate 
BER Base excision repair 
CCCP Carbonyl cyanide m-chlorophenyl hydrazine 
cDNA Complementary DNA 
CMT Charcot-Marie-Tooth 
COX Cytochrome c oxidase 
COXICA65 Cytochrome c oxidase subunit I gene  
D-loop Displacement loop 
dHMN Distal hereditary motor neuropathy  
DMEM Dulbecco’s Modified Eagle Serum 
DNA Deoxyribonucleic Acid 
dNTPs Deoxynucleotide triphosphates 
Drp1 Dynamin-related protein 
dsDNA Double-stranded DNA 
DTT Dithiothreitol 
ECL Enhanced chemiluminescence  
EM Electromagnetic 
ER Endoplasmic reticulum 
ETC Electron transport chain 
FA Folic acid 
FAC Fluorescence-activated cell sorting 
FADH2 Reduced flavin adenine dinucleotide 
FBS Fetal Bovine Serum 
FCCP Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone  
FDA Food and Drug Administration 
FGF Fibroblast growth factor 
Fis1 Mitochondrial fission 1 protein 
 15 
GFP Green Fluorescent protein 
GSH Reduced glutathione 
HBSS Hank's Balanced Salt Solution 
HGF Hepatocyte growth factor 
HRP Horseradish peroxide 
HSP Heavy strand promoter 
IGF Insulin-like growth factor 
IMM Inner mitochondrial membrane 
iPSC Induced pluripotent stem cell 
ITS Insulin-transferrin-selenium 
KD Knockdown 
KLF4 Kruppel-like factor 4 
KO Knockout 
LAMP1 Lysosomal-associated membrane protein 1 
LHON Leber hereditary optic neuropathy 
LSP Light strand promoter 
MCB Monochlorobimane 
MDVs Mitochondrial-derived vesicles  
MEF Mouse embryonic fibroblast 
MELAS 
Mitochondrial encephalopathy with lactic acidosis and stroke-like 
episodes  
MERFF Myoclonic epilepsy with ragged-red fibers 
Mff Mitochondrial fission factor 
Mfn1 Mitofusin 1 
Mfn2 Mitofusin 2 
MRGs Mitochondrial RNA granules 
mRNA Messenger RNA 
mtDNA Mitochondrial DNA 
NAC N-acetyl-L-cysteine 
NADH Reduced nicotinamide adenine dinucleotide 
NGS Next generation sequencing 
Oct 4 Octamer-binding transcription factor 4 
OMM Outer mitochondrial membrane 
 16 
OPTN Optineurin 
OSCP Oligomycin-sensitivity conferring protein 
OXPHOS Oxidative phosphorylation 
PAGE Polyacrylamide gel electrophoresis 
PARL Presenilin-associated rhomboid-like protein 
PBS Phosphate-buffered saline 
PCR Polymerase Chain Reaction 
PD Parkinson's disease 
PFA Paraformaldehyde 
PGC Peroxisome proliferator-activated receptor-gamma coactivator 
PINK1 Phosphatase and tensin homolog-induced putative kinase 1  
R6G Rhodamine 6G 
Rho7 Rhomboid-7 
RING Really interesting new gene 
RNA Ribonucleic Acid 
ROCK Rho-associated protein kinase 
ROS Reactive oxygen species 
rRNA Ribosomal RNA 
RT Room temperature 
SEM Standard error of mean 
shRNA Short hairpin RNA 
ssDNA Single-stranded DNA 
TALENs Transcription activator-like effector nucleases  
TFAM Mitochondrial transcription factor A  
TIM Translocase of the inner membrane 
TMRM Tetramethylrhodamine methyl ester  
TOM Translocase of the outer membrane 
tRNA Transfer RNA 
UV Ultraviolet 
WT Wild-type 
ΔΨm Mitochondrial membrane potential 
 
 
 17 
Introduction 
Mitochondria 
 
Structure and Function of Mitochondria 
 
Mitochondrial Structure 
 
Mitochondria are double-membrane bound organelles that have 
essential roles in several cellular processes, such as energy 
production through oxidative phosphorylation (OXPHOS). The 
mitochondrion comprises of an outer (OMM) and inner membrane 
(IMM), and between these membranes are the matrix (within the 
IMM) and the intermembrane space between the IMM and OMM 
(Figure 1).  
 
The two membranes are structurally and functionally distinct, with 
the IMM forming cristae structures and the OMM having a more 
homogeneous structure. The IMM is the site of oxidative 
phosphorylation, and contains the electron transport chain and 
numerous channels, such as the mitochondrial Ca2+ uniporter and 
the inner membrane anion channel (Zoratti et al. 2009). The OMM 
contains fewer proteins, all of which are encoded for in the nucleus, 
including pore forming proteins, enzymes and proteins involved in 
fission and fusion processes (Walther & Rapaport 2009; Zahedi et 
al. 2005; Burri et al. 2006; Schmitt et al. 2006). The OMM is porous 
and therefore unlike the IMM, there is no membrane potential 
across the outer membrane. The translocase of the outer 
mitochondrial membrane (TOM) and the equivalent on the inner 
mitochondrial membrane (TIM) form a large conductance channel, 
with partial cation selectivity through which large molecules can be 
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imported (Grigoriev et al. 2004). For molecules to pass the IMM, 
selective membrane transport proteins are required to cross the 
tight diffusion barrier. Consequently, a membrane potential is 
formed across the IMM due to the ion selectivity and 
electrochemical gradient that forms.  
 
The matrix of mitochondria maintains a high pH, which contributes 
to the electrochemical gradient across the IMM required for 
oxidative phosphorylation, and is the area that houses mitochondrial 
DNA (mtDNA) and where mtDNA replication and transcription 
occurs. In addition it is the site of many biosynthetic reaction, 
catalysed by numerous enzymes. The intermembrane space is a 
gap of approximately 20nm between the inner and outer 
mitochondrial membranes, through which all molecules pass to 
reach the IMM and matrix. The TOM/TIM complexes span across 
the intermembrane space. 
 
 
Figure 1: Structure of the Mitochondrion 
Diagram depicts the size and structure of a mitochondrion, showing the 
position of the major structural features, such as the inner membrane which 
is the site of oxidative phosphorylation. Diagram obtained from BMC 
Biology (Kühlbrandt 2015). Creative Commons License: 
http://creativecommons.org/licenses/by/4.0/ 
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Functions of mitochondria 
 
Mitochondria generate adenosine triphosphate (ATP) in eukaryotic 
cells via the process of oxidative phosphorylation (OXPHOS) at the 
IMM and in the matrix.  An electrochemical gradient is established 
across IMM via the transfer of electrons across respiratory 
complexes fixed within the inner membrane and the movement of 
protons out of the matrix. This gradient facilitates the passive 
movement of protons through the ATP synthase into the matrix for 
the conversion of adenosine diphosphate (ADP) to ATP, as well as 
enabling buffering of Ca2+, another essential function of 
mitochondria. 
 
Mitochondria import Ca2+ into the mitochondrial matrix via a 
mitochondrial calcium uniporter from the plasma membrane and 
endoplasmic reticulum, a finding first established in 1992 (Rizzuto et 
al. 1992; De Stefani et al. 2011; Baughman et al. 2011). The 
process of calcium buffering by mitochondria is critical for the 
release of neurotransmitters and the generation and plasticity of 
neurons, as well as the Ca2+ signalling that facilitates muscle 
contraction. These processes cause a rise in intramitochondrial 
Ca2+ via the mitochondrial calcium uniporter, which is then released 
back to the cytosol via a sodium/calcium exchanger (Cai & Lytton 
2004). The concentration of calcium in the matrix subsequently 
affects the rate of ATP generation, with higher intramitochondrial 
calcium concentrations causing an up-regulation of oxidative 
phosphorylation to supply the energy-demanding activities that 
stimulate the uptake of calcium. 
 
Mitochondria also play a crucial role in the activation of apoptosis, 
through the release of cytotoxic proteins, such as cytochrome c. 
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Soluble proteins are released from the intermembrane space of the 
mitochondria to the cytosol, initiating caspase activation. 
 
Glycolysis and Oxidative Phosphorylation 
 
Glycolysis 
 
Glycolysis is a series of reactions that converts glucose into 
pyruvate, forming two ATP molecules and two NADH molecules. 
This pathway occurs in both prokaryotic and eukaryotic cells. In 
eukaryotes, glycolysis occurs in the cytosol of the cell and can be 
divided into three stages (Figure 2).  
 
The first stage involves the phosphorylation of glucose by ATP, 
which is catalysed by hexokinase. This is followed by an 
isomerisation and a second phosphorylation to produce fructose 
1,6-bisphosphate. The glucose 6-phosphate ring structure is 
opened before isomerisation can occur, and needs to be returned to 
its cyclic form before the next phosphorylation. Isomerisation 
converts aldoses to ketones, and is catalysed by phosphoglucose 
isomerase, producing fructose 6-phosphate. Fructose 6-phosphate 
subsequently undergoes phosphorylation by ATP to form fructose 
1,6-bisphosphate, catalysed by phosphofructokinase. 
 
The second stage involves the cleavage of fructose 1,6-
bisphosphate into glyceraldehyde 3-phosphate and 
dihydroxyacetone phosphate, the former of which consists of three-
carbon units. Dihydroxyacetone is converted to glyeraldehyde 3-
phosphate, as the remaining reactions in glycolysis require a three-
carbon unit. This conversion occurs via isomerisation, catalysed by 
triose phosphate isomerase in a quick and reversible reaction. 
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The third stage of glycolysis involves the oxidation of the three-
carbon units, and the generation of ATP. Glyceraldehyde 3-
phosphate is converted into 1,3-bisphosphoglycerate, catalysed by 
glyceraldehyde 3-phosphate dehydrogenase, which reduces NAD+ 
to produce NADH. Following this, ATP is generated in the donation 
of the phosphoryl group of 1,3-bisphosphoglycerate to ADP, 
catalysed by phosphoglycerate kinase. Due to the conversion of 
dihydroxyacetone by triose phosphate isomerase, two ATP 
molecules are generated in this process, which balances the two 
ATP molecules that were used in the two phosphorylation reactions 
that occur in stage 1. 
 
The generation of extra ATP occurs during the conversion of 3-
phosphoglycerate, formed by the loss of the phosphate group of 
1,3- bisphosphoglycerate in the previous step. The 3-
phosphoglycerate is first rearranged, so that a dehydration reaction 
can occur to produce phosphenolpyruvate, catalysed by enolase. 
The phosphoryl group can then be transferred to ADP, forming ATP 
and pyruvate. Overall this results in a net formation of two ATP 
molecules and two pyruvate molecules per glucose molecule. 
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Figure 2: Pathway of glycolysis, divided into three stages 
Diagram obtained from Biochemistry 5th Edition, Berg JM, Tymoczko JL, 
Stryer L; 2002. 
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Krebs Cycle 
 
The process of glycolysis results in a net generation of two pyruvate 
molecules, two ATP molecules and two NADH molecules in the 
cytoplasm of the cell. The Krebs cycle, or citric acid cycle, occurs in 
the matrix of mitochondria. Pyruvate is oxidised to acetyl CoA whilst 
NAD+ is reduced, in preparation for the Krebs cycle. The aim of the 
Krebs cycle is to generate the inputs for oxidative phosphorylation: 
NADH and FADH2. To do this, acetyl CoA, a 2-carbon molecule, 
combines with oxaloacetate, a 4-carbon molecule, to form citric 
acid, a 6-carbon molecule. Citric acid is oxidatively decarboxylated 
twice, with the two carbon atoms leaving the cycle as carbon 
dioxide. The electrons lost from citric acid through oxidation are 
used to form NADH and FADH2 through reduction. 
 
Oxidative Phosphorylation 
 
Oxidative phosphorylation is the generation of ATP culminating from 
a series of energy transformations. The IMM contains protein 
complexes embedded within it that constitute the electron transport 
chain (Figure 3). Electrons from NADH and FADH2 combine with O2 
in oxidation/reduction reactions, which release energy for the 
synthesis of ATP. The electron transport chain comprises four 
protein complexes and a final fifth complex, termed the ATP 
synthase, which facilitates the generation of ATP.  
 
The process begins at complex I, where electrons from NADH are 
transferred to flavin mononucleotide in the complex, then to an iron-
sulfur protein and subsequently to coenzyme Q, otherwise known 
as ubiquinone. Coenzyme Q is situated in the membrane as 
complex II, and carries electrons from complex I through the 
membrane. The electrons are then passed to complex III, from 
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cytochrome b to cytochrome c, which is a peripheral membrane 
protein, and onto complex IV. 
 
As electrons pass along the complexes, energy is released which 
facilitates the movement of protons out of the matrix into the 
intermembrane space. This creates an electrochemical gradient 
across the IMM due to the movement of protons against their pH 
and charge gradient. The gradient that is created enables an influx 
of protons into the matrix, however since the phospholipid bilayer is 
impermeable to ions, protons must enter via the ATP synthase. The 
influx of protons facilitates the conversion of ADP to ATP. 
 
The amount of ATP generated from oxidative phosphorylation is 
considerably greater than that from glycolysis. Movement of 
electrons from NADH across the electron transport chain supports 
the generation of between 30 and 36 ATP molecules.  
 
 
Figure 3 Oxidative Phosphorylation at the inner mitochondrial membrane 
Electron carrier complexes I-IV generate an electrochemical gradient across 
the IMM through a series of oxidation/reduction reactions, which cause 
protons to enter the intermembrane space. This gradient then enables the 
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movement of protons through the ATP synthase which converts ADP to 
ATP. Diagram obtained from CNX.org 
 
Mitochondrial DNA 
 
Mitochondria are unique organelles in that they house a small 
amount of their own DNA, separate to the majority present in cell 
nuclei. The expression of mitochondrial DNA (mtDNA) has been 
shown to be essential for the process of oxidative phosphorylation 
(Larsson et al. 1998).  
 
The mitochondrial nucleoid 
 
MtDNA encodes 37 genes and is organised along with various 
proteins into nucleoids contained in the matrix of the mitochondrion. 
The nucleoid containing DNA does not have a classical membrane 
and it remains unknown how it separates itself from the 
mitochondrial matrix (Kolesnikov 2016). The nucleoids in human 
mitochondria appear to be of a spherical or ellipsoid shape, 
measuring up to 100 nm in diameter (Kukat et al. 2011). It has been 
shown that nucleoids in mammalian mitochondria each contain 1 or 
2 molecules of mtDNA, however this can be up to 4 times greater in 
embryonic cells compared to somatic (Kukat et al. 2011). Since 
mitochondria exist in dynamic networks, it is not estimated how 
many nucleoids there are per mitochondrion, however it is known 
that depending on the cell type, there can be 500-12900 nucleoids 
per human cell (Bogenhagen 2012). 
 
Proteins also present in the mitochondrial nucleoid are required for 
functions such as compressing mtDNA at least 20 times within the 
nucleoid, for replication and transcription of mDNA, and also for 
protection of mtDNA from nucleases. Mitochondrial transcription 
factor A (TFAM) is one such ‘packaging’ protein, which enables the 
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formation of loops by bending the mitochondrial genome in short 
stretches, termed U-turns (Rubio-Cosials et al. 2011; Ngo et al. 
2011). 
 
It remains unclear however how the mitochondrial nucleoid is 
organised and whether it has an internal structure (Kolesnikov 
2016). 
  
The mitochondrial genome 
 
The mitochondrial genome is 16,569 base pairs in length and 
contains 37 genes, which encode for 13 mitochondrial peptide 
subunits, 2 ribosomal RNAs and 22 transfer RNAs. Mitochondrial 
DNA forms a small closed-circular structure, which is double 
stranded. The two strands have different densities due to their GT 
base composition and are labelled ‘heavy’ and ‘light’ (Kasamatsu & 
Vinograd 1974).  
 
The outer heavy chain contains the genes for the ribosomal RNAs, 
14 of the transfer RNAs and 12 of the polypeptides, with the 
remainder being coded for on the inner light chain. The 
mitochondrial genome is spatially efficient, with coding regions 
accounting for approximately 93% of the genome, no introns being 
present and even regions of overlap between two genes (Turnbull et 
al. 1999). The non-coding areas of genome are mainly confined to 
the displacement loop (D-loop), termed as such due to the presence 
of a third strand which holds apart one strand of the double-
stranded DNA and contains a complimentary sequence to it, thus 
displacing the other main strand. Whilst it appears that at least a 
quarter of this area is dispensable, the D-loop contains the origins of 
strand replication and the major promoters for transcription (Behar 
et al. 2008). 
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Figure 4: Mitochondrial genome structure 
A schematic of the mitochondrial genome showing the distribution of the 
coding regions and the non-coding region. NCR, noncoding region; HSP, 
heavy strand promoter; LSP, light strand promoter; OH, initiation site for 
heavy strand synthesis; OL, initiation site for light strand synthesis. 
Diagram obtained from (Holt & Reyes 2012), © 2012 Cold Spring Harbor 
Laboratory Press. 
 
 
Mitochondrial DNA inheritance and processing 
 
Mitochondrial DNA is maternally inherited (Giles et al. 1980). After 
fertilisation, the oocyte contains both paternal and maternal 
mitochondria however paternal mitochondria are not transmitted to 
offspring, therefore it is thought that the paternal mitochondria is 
either diluted out by maternal mitochondria, or that the paternal 
mitochondria is specifically degraded. Studies in numerous animal 
models have put forward several potential mechanisms and time-
points for degradation, including ubiquitin-mediated degradation 
 28 
after fertilisation or degradation by endonuclease G during 
spermatogenesis (DeLuca & O’Farrell 2012; Schatten et al. 1999; 
Sutovsky et al. 2000). 
 
MtDNA replication is in general poorly understood however it is 
thought that replication is initiated at the D-loop region beginning 
with the leading strand (heavy strand) and then subsequently 
starting the lagging strand (light strand) once the leading strand 
replication is about one third from finishing (Clayton 1982). At this 
point, a stem-loop structure is formed from the single stranded DNA 
molecule at OL (initiation site for light strand synthesis) to which 
mitochondrial RNA polymerase binds to in order to start the 
replication of the lagging strand (Wanrooij et al. 2008; Wanrooij et 
al. 2012). 
 
Transcription involves the mitochondrial RNA polymerase, TFAM 
and mitochondrial transcription factor B2. Two polycistronic 
transcripts are generated from transcription by mitochondrial RNA 
polymerase, originating from H strand promoter (HSP) and L strand 
promoter (LSP), which are then processed to separate the individual 
mRNAs, rRNAs and tRNAs (Ojala et al. 1981). Transcript 
processing has been hypothesised to occur in mitochondrial RNA 
granules (MRGs) which house the mitochondrial 5’-processing 
machinery; this is thought to occur before a second round of 
processing elsewhere in the mitochondrial matrix (Antonicka et al. 
2013; Jourdain et al. 2013). 
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Mitochondrial DNA damage and repair mechanisms 
 
Mitochondrial DNA is more vulnerable to damage than nuclear DNA 
for several reasons. Reactive oxygen species (ROS) are formed as 
a by-product of oxidative phosphorylation due to side reactions 
between electrons and oxygen directly generating the hydroxyl 
radical. Therefore the close proximity of mtDNA to a site of ROS 
production makes it at greater risk of damage. Furthermore, the 
nature of the gradient across the IMM means that lipophilic 
positively charged toxic chemicals, such as 8-oxoguanine, more 
readily accumulate in mtDNA compared to nuclear DNA (Beckman 
& Ames 1996). Mutations in mtDNA can also occur due to mistakes 
in DNA replication, or from the amplification of age-related mtDNA 
rearrangements (Hayakawa et al. 1996; Kajander et al. 2000). 
 
For a long time it was thought that mitochondria did not have DNA 
repair mechanisms, due to a study showing the lack of repair of 
pyrimidine dimers caused by UV-irradiation (Clayton et al. 1974). 
However, it is now known that several mtDNA repair pathways exist. 
One of which is known as base excision repair (BER), which 
involves a series of reactions and is the mechanism most commonly 
used to repair oxidative damage (Lan et al. 2004). The steps of BER 
include base excision, DNA end processing, base replacement and 
end-ligation. The damaged base is removed by DNA glycosylases 
and DNA cleaved by apurinic/apyrimidinic endonuclease 1. DNA 
polymerase replaces the removed base and the ends are ligated by 
DNA ligase. 
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Mitochondrial Quality Control Processes 
 
Mitochondria exist in large networks within cells, and due to their 
vulnerability to oxidative damage, require quality control processes 
to maintain efficient functioning. Extensive mitochondrial damage 
will trigger apoptosis, however in attempt to combat this, several 
mechanisms of repair and damage control occur within 
mitochondria, which will be discussed in this section.  
 
Fission and Fusion 
 
It is well known that mitochondria are highly dynamic organelles, 
which constantly undergo two opposing processes of fission and 
fusion (Figure 5). Together these processes enable the movement 
of mitochondrial contents between mitochondria to preserve a 
homogenous population.  
 
During the process of fusion, the OMM and IMM of two 
mitochondria merge simultaneously, which facilitates the mixing of 
the intermembrane space and mitochondrial matrix. In human cells, 
proteins OPA1 and mitofusins 1and 2 (Mfn1 and Mfn2) are essential 
mediators for this process. The Mfn1 and Mfn2 are transmembrane 
GTPases embedded in the OMM and therefore mediate outer 
membrane fusion. OPA1 is a dynamin-related GTPase embedded 
in the IMM, which mediates inner membrane fusion. OPA1 
heterozygous mutations have been associated with the autosomal 
dominant disease optic atrophy, in which degeneration occurs of 
retinal ganglion cells. Missense mutations in Mfn2 cause the 
peripheral neuropathy Charcot-Marie-Tooth disease type 2A 
(Züchner et al. 2004). 
 
Studies using mouse embryonic fibroblasts (MEFs) carrying null 
alleles of mitofusins show that fusion of both the outer and inner 
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mitochondrial membranes is lost, however OPA1-null MEFs 
continue to exhibit outer mitochondrial membrane fusion (Song et 
al. 2009). This finding indicated that there is a sequential process of 
fusion in mammalian cells, which are readily uncoupled (Song et al. 
2009). For outer mitochondrial membrane fusion, mitofusins are 
required on both mitochondria that are fusing, however inner 
membrane fusion only requires OPA1 to be present on one 
mitochondrion, i.e. a wild-type mitochondrion can fuse with an 
OPA1 deficient mitochondrion (Koshiba et al. 2004; Meeusen et al. 
2004; Song et al. 2009). 
 
 
Figure 5: Schematic diagram to show the processes of fusion and fission 
The process of two adjacent mitochondria joining to enable mixing of 
mitochondrial contents is known as fusion. The separation of one 
mitochondrion into two daughter mitochondria is known as fission. 
 
An extended antiparallel coiled coil on the C-terminal of mitofusin 1 
enables mitochondria to be brought together with a gap of only 100 
Å. Oligomerisation is then mediated by mitofusin 1 and it is thought 
that GTP hydrolysis facilitates conformational changes that enable 
membrane fusion (Koshiba et al. 2004; Chan 2012). 
 
Fission is the opposite process of fusion, in which daughter 
mitochondria are created from the division of one mitochondrion. 
This process involves dynamin-related protein (Drp1), a protein that 
resides in the cytosol, and mitochondrial proteins including 
mitochondrial fission 1 protein (Fis1) and mitochondrial fission factor 
(Mff). The mechanism of fission is less well understood and studies 
have shown that some types of mitochondrial fission do not require 
the presence of Drp1 (Ishihara et al. 2009; Wakabayashi et al. 
Fusion 
Fission 
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2009). Cytosolic Drp1 is recruited to mitochondria, thought to be 
caused by Fis1 although that has also been disputed, after the initial 
mitochondrial constriction (Stojanovski et al. 2004; Yoon et al. 2003; 
Yu et al. 2005; Otera et al. 2010). Mff is a well established Drp1 
receptor, separate from Fis1, which mediates recruitment of Drp1 to 
mitochondria (Otera et al. 2010).  
 
Importantly for maintenance of a healthy mitochondrial network, 
fission and fusion enable the segregation of damaged mitochondria 
for complete removal, and sharing of healthy mitochondrial 
contents. Healthy mitochondria can be fused to the existing network 
or eliminated if the organelle is damaged. The mitochondrial 
membrane potential of the mitochondria is considered the 
determining factor by which fusion or fission occurs; it has been 
shown previously that a hyperpolarised mitochondrion is more likely 
to undergo fusion than a depolarised mitochondrion (Twig, Elorza, 
Anthony J. A. Molina, et al. 2008; Horbay & Bilyy 2016). The 
process by which damaged mitochondria are eliminated is known as 
mitophagy.  
 
Proteolytic and Proteasomal degradation  
 
Mitochondria have a proteolytic system, which consists of AAA 
protease complexes embedded in the inner mitochondrial 
membrane, whose catalytic sites face outwards on either side of the 
inner membrane (Langer et al. 2001). AAA protease complexes are 
present to degrade unfolded membrane proteins in order to prevent 
their toxic accumulation. Molecular chaperones in mitochondria also 
participate in the degradation of mitochondrial proteins by 
resolubilising aggregated polypeptides (Voos 2013). The 
degradation of unfolded proteins normally occurs in the 
mitochondria, however the removal of damaged outer mitochondrial 
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membrane proteins is achieved using the cytoplasmic ubiquitin 
proteasome system. 
 
Mitochondrial-derived vesicles 
 
It has been shown that defective mitochondrial components can be 
directly passed on to the lysosome for elimination via mitochondrial-
derived vesicles (Soubannier, G. L. McLelland, et al. 2012). These 
vesicles bud from mitochondrial tubules and sequester 
mitochondrial cargos under basal conditions. This mechanism of 
quality control is known also to be upregulated in the presence of 
oxidative stress, and enables the organelle to remain intact whilst 
oxidised mitochondrial proteins are eliminated. Importantly, the 
generation of mitochondrial-derived vesicles has been found to be 
dependent upon the presence of PINK1 and Parkin, two key 
proteins involved in the process of mitophagy, which is described in 
detail in the following section (McLelland et al. 2014). It has been 
suggested that MDVs provide an initial mechanism of defence 
before the process of mitophagy is activated (Sugiura et al. 2014).  
 
Mitophagy 
 
When damage to mitochondria is beyond the removal of a subset of 
mitochondrial proteins, mitophagy is employed to eliminate an entire 
organelle. Mitophagy ensures optimal cellular energy production 
through the selective degradation of damaged mitochondria in order 
to avoid toxic accumulation. This process will be discussed in detail 
in the following section. 
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Figure 6: Mechanisms of mitochondrial quality control 
Subsets of mitochondrial proteins can be removed by protease degradation 
or the budding of vesicles from mitochondrial tubules to deliver damaged 
contents to the lysosomes. Alternatively entire damaged mitochondrial 
organelles can be removed by mitophagy. (Ashrafi & Schwarz 2013) © 2013 
Macmillan Publishers Limited 
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The Mechanism of Mitophagy 
 
The current model of the mitophagy pathway involves two essential 
mediators: phosphatase and tensin homolog-induced putative 
kinase 1 (PINK1) and Parkin. 
 
PINK1 
 
The PINK1 gene contains 8 exons and encodes for a 581-amino 
acid protein. Mutations in the PINK1 gene cause autosomal 
recessive early-onset Parkinson’s disease, and over 50 mutation 
sites having been identified in the kinase and carboxyl-terminal 
regulatory domains (the former of which are shown in Figure 7). 
 
PINK1 is synthesised in the cytosol and imported through TOM into 
the mitochondria due to its mitochondrial targeting sequence at its 
N-terminus. PINK1 is ubiquitously expressed and maintained at a 
low level under physiological conditions through degradation by 
Rhomboid-7/Presenilin-associated rhomboid-like protein (Rho-
7/PARL) processing and also degradation in the mitochondrial 
matrix by protease Lon ((Thomas et al. 2014; Whitworth et al. 2008; 
Jin et al. 2010).  
 
In the mitochondria, whilst at very low levels, expression of PINK1 
under basal conditions can be detected in the outer and inner 
mitochondrial membranes (Gandhi et al. 2006; Silvestri et al. 2005). 
PINK1 can also be detected in the cytosol and the endoplasmic 
reticulum (Fedorowicz et al. 2014; Weihofen et al. 2008).  
 
PINK1 knockout mice have a phenotype of decreased oxidative 
phosphorylation and reduced mitochondrial respiration, suggesting 
that PINK1 has a protective function against oxidative stress 
(Gautier et al. 2008).  
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Figure 7: PINK1 and Parkin domain architecture 
Schematic diagram showing the regions of PINK1 and Parkin, MTS: 
mitochondrial targeting sequence, TM: transmembrane domain, INS: 
insertion, CTD: C-terminal domain, UBL: ubiquitin-like domain, RING: really 
interesting new gene domain, BRcat: benign-catalytic domain, Rep: 
repressor element, Rcat: required for catalysis domain. (McWilliams & Muqit 
2017) 
 
Parkin 
 
Parkin is a cytosolic E3 ubiquitin ligase and under basal conditions 
it’s activity is repressed as it resides in the cytosol (Lazarou et al. 
2012). The Parkin structure includes an ubiquitin-like domain at the 
N-terminus, and belongs to the RING-between-RING group of E3 
ubiquitin ligases (Figure 7). Parkin is folded into an auto-inhibited 
conformation under physiological conditions. Autosomal recessive 
Parkinson’s disease is most often caused by loss of function 
mutations in the Parkin gene, and more than 120 different mutations 
in this gene have been identified and linked to the disease (Durcan 
& Fon 2015). 
 
The process of ubiquitination involves three enzymes. First E1 
ubiquitin-activating enzymes use ATP to enable ubiquitin to 
conjugate, before being delivered to E2 ubiquitin conjugating 
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enzymes, which interact with E3 ubiquitin ligases. E3 ubiquitin 
ligases transfer ubiquitin to the amino groups of substrates, which 
can then be the start of the formation of ubiquitin chains.  
 
PINK1/Parkin-dependent mitophagy 
 
As previously described, under basal conditions PINK1 is imported 
into mitochondria, cleaved and degraded. However, upon loss of 
mitochondrial membrane potential, which can be induced through 
the use of mitochondrial uncouplers such as carbonyl cyanide m-
chlorophenyl hydrazine (CCCP), PINK1 is not imported through the 
TIM complex but becomes stabilised on the OMM. The presence of 
full-length PINK1 on the outer surface of damaged mitochondria 
enables these to be marked for degradation, separated from the 
healthy unmarked mitochondria. PINK1 at the OMM is positioned so 
that the kinase domain remains accessible to cytosolic substrates, 
however the mechanism by which is occurs is not fully understood 
(Pickrell & Youle 2015; Zhou et al. 2008). 
 
Parkin was first associated with mitophagy from experiments in 
immortalised cell lines, which showed that cytosolic Parkin could be 
recruited to depolarised mitochondria after stimulation with CCCP 
(Narendra et al. 2008; Narendra et al. 2010; Vives-Bauza, Zhou, 
Huang, Cui, Rosa L. A. de Vries, et al. 2010). 
 
PINK1 and Parkin functioning in a common pathway 
 
The involvement of PINK1 and Parkin in a common mitochondrial 
quality control process was implicated through several observations 
and experiments. Autosomal recessive Parkinson’s disease (PD) is 
known to be caused by mutations in PINK1 and Parkin, and post-
mortem analysis of PD patient brains revealed an accumulation of 
damaged mitochondria (Keeney et al. 2006; Perier & Vila 2012). 
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Studies using Drosophila with loss of PINK1 or Parkin showed flies 
to have a strong mitochondrial dysfunction phenotype, male sterility 
and mitochondrial morphology defects, which could be ameliorated 
in PINK1-KO Drosophila with the overexpression of human PINK1 
or Parkin (Clark et al. 2006; Park et al. 2006; Yang et al. 2006). 
Interestingly, the phenotype seen in Parkin-KO Drosophila could not 
be reversed with the overexpression of PINK1, only human Parkin, 
suggesting that in the mechanistic pathway Parkin acted down-
stream of PINK1. 
  
PINK1 activation of Parkin 
 
Recent studies have shown that upon translocation of cytosolic 
Parkin to damaged mitochondria, PINK1 phosphorylates Parkin and 
ubiquitin at their serine 65 residues (Kane et al. 2014; Kazlauskaite 
et al. 2014; Koyano et al. 2014) (Figure 8). The phosphorylation of 
both Parkin and ubiquitin by PINK1 is necessary for the activation of 
Parkin’s E3 ubiquitin ligase activity.  
 
The kinase activity of PINK1 is activated by self-phosphorylation, 
however the precise mechanism by which this occurs is unknown 
(Okatsu et al. 2012; Aerts et al. 2015). The involvement of other 
PINK1 substrates in the activation of Parkin was indicated when 
mutation of Parkin serine (including Ser65) and threonine sites did 
not completely block Parkin translocation (Kane et al. 2014). 
Phosphorylation of ubiquitin by PINK1 was identified using mass 
spectrometry, and phospho-ubiquitin was shown to directly activate 
Parkin, revealing a feed-forward mechanism of activation (Kane et 
al. 2014). 
 
Activated Parkin ubiquitinates numerous mitochondrial proteins, in 
particular proteins residing in the outer mitochondrial membrane 
and in addition is thought to elongate pre-existing ubiquitin chains 
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creating, among others, K48 and K63 ubiquitin linkages (Sarraf et 
al. 2013; Chan et al. 2011; Ordureau et al. 2014). These 
polyubiquitin chains can then be phosphorylated by PINK1, 
amplifying the activation of Parkin and driving the removal of 
dysfunctional mitochondria in a feed-forward amplification 
mechanism. If there is a particular role of each type of linked 
ubiquitin chain (Lys 6, 11, 48 and 63) it remains unknown. 
 
 
 
Figure 8: PINK1 stabilisation and phosphorylation 
Schematic diagram to show the stabilization of PINK1 upon loss of 
mitochondrial membrane potential. PINK1 kinase activity is stimulated 
following autophosphorylation, which in turn causes the phosphorylation of 
ubiquitin and Parkin at Ser65. Phosphorylation and the activity of phospho-
ubiquitin cause activation of Parkin’s E3 ubiquitin ligase activity which 
leads to the formation of polyubiquitin chains on mitochondrial substrates. 
Diagram adapted from (McWilliams & Muqit 2017). 
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Recruitment of autophagic machinery 
 
Ubiquitin-binding autophagy receptor proteins are recruited to the 
damaged mitochondria and are directly responsible for the ultimate 
clearance of mitochondria. These include p62/SQSTM1, optineurin 
(OPTN), NDP52 and AMBRA1 (Geisler et al. 2010; Lazarou et al. 
2015; Strappazzon et al. 2015). Recently it has been shown that 
PINK1 can recruit OPTN and NDP52 via phosphorylated ubiquitin 
independently of Parkin (Lazarou et al. 2015). Mutations in OPTN 
have been associated with amyotrophic lateral sclerosis (ALS), a 
neurodegenerative disease (Maruyama et al. 2010). 
 
PINK1 and/or Parkin-independent mitophagy  
 
As described above, a recent study showed the recruitment of 
OPTN and NDP52 caused by PINK1, that occurs independently of 
Parkin (Lazarou et al. 2015). This finding called to question whether 
Parkin is completely necessary for mitophagy or rather an amplifier 
of the process in mammalian cells. Interestingly in PINK1 KO flies, 
overexpression of human Parkin was found to restore mitochondrial 
function, suggesting that in this system it is PINK1 that is 
dispensable (Clark et al. 2006).  
 
Whilst PINK1 and Parkin mutations are a known cause of early-
onset Parkinson’s disease, targeting dopaminergic neurons, iPSC-
derived dopaminergic neurons show mitochondrial dysfunction but 
not an increase in mitochondrial mass as would be expected with 
the involvement of these proteins in mitophagy (Rakovic et al. 2015; 
Shaltouki et al. 2015). This strongly suggests that alternative PINK1 
and Parkin independent mechanisms of mitochondrial clearance 
exist. 
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In the dissection of the mitophagy pathway, many experiments have 
made use of Parkin-overexpression systems to enable easier 
identification of the process. Using the hypothesis that Parkin is an 
amplifier of mitophagy, these systems create predictable timeframes 
for conducting experiments; the workings of the mitophagy pathway 
can be easily detected after 1.5 hours of stimulation by CCCP. 
Moreover, Parkin-overexpression in immortalised cell lines enables 
the development of convenient biochemical assays, which can be 
used to detect inhibitors of mitophagy, as a result of the significant 
response induced by mitochondrial uncouplers. Detecting increased 
mitophagy is more difficult in these assays since, for example, 10 
µM CCCP can cause the complete loss of mitochondrial proteins in 
Parkin-overexpressing SH-SY5Y cells within 24 hours; therefore a 
maximal response may already have been reached. In a study 
aiming to avoid any problems that may occur with using 
overexpressed Parkin, or to prevent this masking any so far 
unknown processes, a mitophagy assay was developed which 
utilised fluorescently tagged mitochondria, which changed colour 
once delivered to the acidic environment of the lysosome (Allen et 
al. 2013). This was achieved by using a tandem mCherry-GFP tag, 
which under basal conditions would fluoresce red and green, but 
under acidic condition only red since the low pH would quench the 
GFP signal only (Figure 9). Using this non Parkin-overexpressing 
system, the authors showed that the iron chelator deferiprone 
caused a significant increase in the percentage of cells undergoing 
mitophagy, seemingly independent of PINK1 or Parkin (Allen et al. 
2013). Whilst the signalling pathway by which this occurs remains 
unknown, this observation has been of great interest since 
deferiprone is an FDA-approved drug for treating blood disorders 
known as thalassemias, therefore a phase 3 clinical trial is currently 
recruiting PD patients to assess tolerability. The study involves 17 
centres across the world and is expected to be completed in 2020. 
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Figure 9: Fluorescence assay based on the pH change from cytosol to 
lysosome for detecting mitophagy 
Schematic to show the red and green fluorescence from the tandem 
mCherry-GFP tag in the cytosol, and the red fluorescence caused by the 
quenching of the GFP signal in the acidic environment of the lysosome. 
Diagram adapted from (Allen et al. 2013). 
Another mitochondrial clearance mechanism not dependent on 
PINK1 and Parkin is the activation of NIX and BNIP3 in response to 
hypoxia, during erythrocyte maturation and more recently during cell 
differentiation (Ney 2015; Esteban-Martínez & Boya 2017). These 
proteins function as autophagy receptors and cause the opening of 
the mitochondrial permeability transition pore, which triggers 
depolarisation of the mitochondrial membrane potential and 
stimulates envelopment of mitochondrial within autophagosomes. 
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Mitochondrial DNA disease  
 
Prevalence of mitochondrial DNA mutations 
 
The first pathogenic mutations in the mitochondrial genome were 
reported in 1988, and since then numerous other mutations in 
mitochondrial DNA have been associated with disease (Holt et al. 
1988; Wallace et al. 1988). Despite early assumptions, diseases 
caused by mitochondrial DNA mutations are not exceptionally rare 
and instead affect approximately 1 in 4,300 of the population 
(Gorman et al. 2015; Chinnery et al. 2000). A study of just adults in 
the North East of England found mtDNA mutations in occur with a 
prevalence of 6.57/100,000, of which around half of those presented 
with Leber hereditary optic neuropathy (LHON) (Schaefer et al. 
2008). This study highlighted the prevalence of mtDNA diseases, 
revealing them to be among the most common genetic disorders 
and also a substantial burden on medical and social services. 
 
Presentation of mitochondrial DNA diseases 
 
Mutations in the mitochondrial genome have the potential to affect 
all organs in the body, however they most often present as 
neuromuscular or neurodegenerative diseases as the tissues 
affected in these disorders rely heavily on an efficiently functioning 
mitochondrial network. Not only do mitochondrial diseases present 
with great clinical heterogeneity, they also have a variable age of 
onset. In general, the age of onset is relative to the severity of the 
mitochondrial defect.  
 
Mitochondrial diseases can be divided into primary and secondary 
diseases; of which the former are caused by mutations in the 
mitochondrial genome and the latter caused by mutations in the 
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nuclear genome. As can be seen in Figure 10, all complexes in the 
respiratory chain except for complex II have subunits encoded for 
by both mitochondrial and nuclear DNA; therefore mutation in 
nuclear genes can affect the functioning of oxidative 
phosphorylation.  
 
 
 
Figure 10: The origin of genomic encoding of the respiratory chain complex 
subunits 
Schematic showing the number of subunits encoded for by the 
mitochondrial genome and the nuclear genome for each respiratory chain 
enzyme complex. Adapted from (DiMauro & Davidzon 2005). 
 
 
 
Heteroplasmy in Primary mtDNA disease 
 
As there are numerous copies of the mitochondrial genome within 
cells, compared to the single copy of the nuclear genome, in the 
vast majority of primary mitochondrial DNA disease cases the 
pathogenic mutation is not present in all copies of the genome.  
 
Primary mitochondrial diseases can be homoplasmic, where the 
mtDNA mutation is present in all copies of the genome, or 
heteroplasmic, where mutated mtDNA coexists with wild-type 
mtDNA. 
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In cases of heteroplasmy, there is a threshold at which a certain 
number of genomes must contain the mutation for there to be a 
biochemical effect. Whilst this threshold level is typically between 
60-90% mutant load, in reality it varies considerably depending on 
both the mutation itself and the tissue in which the mitochondria are 
found. In theory, the threshold is predicted to be lower in cell types 
more reliant on oxidative phosphorylation for energy production, 
compared to those which can be maintained using glycolysis. 
Although a greater mutant load would suggest a more severe 
biochemical defect, there is not consistently a direct correlation 
between level of heteroplasmy and clinical severity (Wong 2007). 
 
Despite there being exceptions, in general heteroplasmic mtDNA 
mutations cause biochemical dysfunction in several different organ 
systems at a time, such as the muscle, endocrine organs and the 
brain, and homoplasmic mtDNA point mutations have a milder effect 
in a single tissue (Stewart & Chinnery 2015). Furthermore, deletions 
of the mitochondrial genome are always heteroplasmic (Chinnery et 
al. 2004). 
 
The mutant load level in cells can both decrease and increase 
overtime, as a result of vegetative segregation. This process is the 
mechanism by which daughter cells gain differing amounts of wild-
type and mutant mitochondrial DNA during cell division (Figure 11). 
The selection is random, except however if the effect of the 
mutation has a negative impact on replication, for example, in which 
case there will be a natural selection against the mutation. In post 
mitotic cells, which are not dividing, changes in heteroplasmy level 
can occur due to uneven replication of mtDNA.  
 
The direction of mutant load change may not be the same in all 
tissues. In rapidly dividing cells, such as blood cells, mutations are 
likely to be lost overtime, however in postmitotic tissues such as 
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skeletal muscle, mutant load is more likely to increase, even from 
very low starting levels (Payne et al. 2013). 
 
 
 
Figure 11: Vegetative Segregation of mtDNA in dividing cells 
Vegetative segregation is the mechanism by which daughter cells receive a 
proportion of mutant (depicted in green) and wild-type mtDNA (depicted in 
blue) that may differ from the dividing cell, and cause the increase or 
decrease of heteroplasmy levels. The presence of mutant mtDNA must 
reach a threshold level before it has a damaging biochemical effect. 
Diagram adapted from (Stewart & Chinnery 2015). 
 
 
Molecular mechanisms of mitochondrial DNA disease 
 
Mutations in the mitochondrial genome typically cause reduced 
cellular respiration and ATP synthesis, as well as inefficient 
respiratory chain complex activity. Since the mitochondrial genome 
contains no introns, mutations will most often affect a coding region.  
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Although tRNA genes account for only 9% of the genome, it has 
been reported that two thirds of pathogenic mtDNA mutations are 
found in these genes, of which they are most often heteroplasmic 
(Wittenhagen & Kelley 2003; Scaglia & Wong 2008). Mutations in 
tRNA genes are more likely to be inherited than protein-coding gene 
mutations, since a purifying selection has been shown to select 
against mtDNA protein-coding genes (Stewart et al. 2008). 
Mitochondrial transfer RNAs are required for translation and they 
fold into a characteristic cloverleaf shape structure, which forms four 
domains; the correct formation of this structure is essential for its 
function. One of the most common tRNA mutations, m.3243A>G, 
which most often presents as mitochondrial encephalopathy with 
lactic acidosis and stroke-like episodes (MELAS) has been found to 
interfere at the transcription termination site leading to unprocessed 
RNA intermediates (Hess et al. 1991; King et al. 1992).  
 
Other consequences of mitochondrial DNA mutations are 
transcriptional responses to the biochemical dysfunction. It has 
been found that in response to mitochondrial impairments, ubiquitin-
mediated protein degradation is inhibited in addition to mitochondrial 
and nuclear ribosomal protein synthesis (Jahangir Tafrechi et al. 
2005; Alemi et al. 2007). 
 
Clinical manifestations of mitochondrial DNA diseases 
 
The variable clinical features of mitochondrial DNA diseases make 
initial diagnosis sometimes difficult, however the involvement of 
multiple systems and a maternal family history are key clues. 
Diagnosis is usually confirmed with histochemical and biochemical 
analysis to identify common features such as cytochrome c oxidase 
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respiratory chain complex activity. Sequencing of the mitochondrial 
genome is used to confirm the mutation and gauge mutant load. 
 
Common features of paediatric mitochondrial DNA diseases include 
optic atrophy, failure to thrive, hepatic failure, renal tubular defects, 
adrenal failure, biventricular hypertrophic cardiomyopathy, anaemia, 
psychomotor retardation, spasticity and epilepsy (Taylor & Turnbull 
2005). Common features of mitochondrial DNA diseases in adults 
include migraine, strokes, sensorineural deafness, epilepsy, irritable 
bowel, heart failure, respiratory failure, thyroid disease, ovarian 
failure, optic atrophy and cataracts (Taylor & Turnbull 2005).  
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Objectives of thesis 
 
Mitochondrial DNA diseases have several unique features and are 
particularly complex to understand. In this thesis, the objective is to 
provide data which helps to better understand two such unique 
features of mitochondrial DNA disease.  
 
The first characteristic of mtDNA diseases is that mutant mtDNA 
can coexist with wild-type mtDNA, above a certain threshold of 
which will result in the patient presenting with a phenotype. As 
described in the introduction, mitophagy is a quality control process, 
which aims to selectively remove defective mitochondria. Therefore, 
I hypothesise that the process of mitophagy may be impaired in 
mtDNA disease patients, which enables high ratios of mutant to 
wild-type mtDNA to persist. To explore this, chapter one focuses on 
triggers of the mitophagy pathway. Since a lot of what is known 
about mitophagy has been discovered using the mitochondrial 
uncoupler CCCP, an alternative compound was used in this chapter 
to highlight potential misconceptions on the requirements of 
mitophagy induction, such as the loss of mitochondrial membrane 
potential, mitochondrial DNA mutations and oxidative stress. 
Moreover, in chapter two, the induction of the mitophagy pathway is 
studied in a wide range of patient fibroblasts. The patient fibroblasts 
used had various clinical phenotypes, a range of mutant loads and 
different locations of the mutation in the mitochondrial genome. The 
aim was to use mitochondrial uncoupling to assess the recruitment 
and response of mitophagy related proteins, in comparison to both 
wild-type fibroblasts and PINK1 and Parkin mutant fibroblasts.  
 
The second unique feature of mitochondrial DNA diseases is that 
within a patient, the presence of mutant mtDNA can cause a 
phenotype in some tissues but not others. I hypothesise that iPSCs 
derived from patient fibroblasts can be differentiated into various cell 
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types with differing phenotypes, thus creating a valid disease model 
which can be used to better understand this phenomenon. Taking 
the results from chapter two, a patient fibroblast line and a control 
fibroblast line were reprogrammed into iPSCs in chapter 3. IPSCs 
were then differentiated into both cortical neurons and myotubes 
and the same experiments performed in both to compare 
phenotypes. 
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Methods 
 
Cell culture 
 
Human neuroblastoma cell line SH-SY5Y was cultured in 
Dulbecco’s Modified Eagle Serum (DMEM; Gibco) media, 
supplemented with 10% Fetal Bovine Serum (FBS; Gibco) and 
maintained at 37°C, 5% CO2. Cell media was changed on average 
every 3 days and cells grown to 90% confluency before splitting. 
Cells were split by trypsinising to collect adherent cells and plating 
into T175 tissue culture flasks at a 1:5 ratio. 
 
Fibroblasts were cultured in DMEM media supplemented with 10% 
FBS and 200 µM uridine (Sigma) and maintained at 37°C, 5% CO2. 
The production of uridine is dependent upon the functioning of the 
respiratory chain, and since uridine is a precursor of nucleic acids, it 
is essential that uridine is supplemented in cells which may have a 
deficient respiratory chain. Mitochondrial DNA mutations can be lost 
in cells that are not supplemented with uridine. Cells were 
maintained in T75 tissue culture flasks and media changed on 
average twice a week. Cells were grown to 90% confluency before 
splitting by trypsinising and plating at a 1:2 ratio. 
 
Molecular Biology techniques 
Mitochondrial isolation 
 
In order to identify the presence of proteins in the mitochondria or to 
improve the signal of low-expressed mitochondrial proteins by 
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Western blot, isolation of mitochondria can be performed prior to 
immunoblotting. The method of mitochondrial isolation used in these 
experiments involved gentle disruption of the cell membrane 
followed by centrifugal fractionation. 
 
Cells were plated onto 10 cm tissue culture plates and incubated 
overnight to reach full confluency. After treatments, if relevant, 
media was aspirated and cells were washed briefly with ice-cold 
phosphate-buffered saline (PBS; Sigma). PBS was completely 
removed before cells were harvested in mitochondrial isolation 
buffer (10 mM Tris-HCl (pH 7.4), 1 mM sodium EDTA 
(Ethylenediaminetetraacetic acid), 250 mM sucrose, supplemented 
with protease and phosphatase inhibitors (Roche)).  
 
Tris-HCl is present in the buffer to maintain a pH of 7.4, under which 
our target proteins are most stable. EDTA is a chelator of divalent 
cations and since many DNases and proteases require magnesium 
ions (Mg2+) to function, EDTA along with additional protease and 
phosphatase inhibitors are present in the buffer to protect extracted 
proteins. Sucrose is added to the buffer to stabilise lysosomal 
membranes and reduce protease release into the lysate. 
 
To each 10 cm plate, 400 µl of mitochondrial isolation buffer was 
added and then frozen at -80°C overnight. The following day the 
plates were thawed on ice and cells collected into eppendorf tubes 
using plastic cell scrappers. The plates were washed with another 
400 µl of isolation buffer and added to the eppendorf to ensure 
complete collection. Next, the eppendorfs were frozen at -80°C for 1 
hour then thawed again on ice. Ice crystals are formed during 
freeze-thawing, which rupture cell membranes and cause cell lysis.  
 
Cell lysates were centrifuged at 1,500 g for 20 minutes at 4°C to 
pellet cell debris. The supernatant was transferred to a clean 
eppendorf and centrifuged at 12,500 g for 20 minutes (4°C) to pellet 
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the mitochondria. The cytoplasmic fraction was collected in a 
different eppendorf and the mitochondrial pellet washed twice in 
mitochondrial isolation buffer (centrifugation at 16,100 g for 10 
minutes at 4°C) to remove any contaminating cytoplasmic proteins.  
 
Protein levels of the cytoplasmic fraction were measured using the 
DC protein assay (Bio-Rad), and these measurements used to infer 
relative differences between mitochondria enriched samples. The 
cytoplasmic fraction was diluted in 4X LDS buffer (10 mM 
Dithiothreitol; DTT; Sigma), and the mitochondrial pellet 
resuspended in 1X LDS buffer (10 mM DTT). DTT is used to reduce 
protein disulfide bonds prior to SDS-PAGE, and is less toxic than 2-
mercaptoethanol. Mitochondria enriched samples were sonicated 
for 20 seconds at a power amplitude of 10 microns. 
 
Cell lysate preparation 
 
For analysis of proteins in whole cell lysates, cells were plated in 
one well of a 6-well plate and incubated overnight at 37°C. The 
following day cells were treated if applicable (16 or 24 hours for 
mitophagy experiments, 1.5 hours for PINK1 accumulation) then 
harvested. To harvest cells, on ice, the media was aspirated and 
cells washed briefly in cold PBS, then once all the residual PBS had 
been removed, 100 µl of lysis buffer was added to each well. The 
lysis buffer used in these experiments was NP-40 buffer, containing 
150 mM NaCl, 50 mM Tris-Cl (pH8.0) and 1% NP-40 (abcam cat# 
ab142227). NP-40 is a non-ionic detergent comprising a water-
soluble hydrophilic head and a hydrophobic tail, which allows it to 
enter and disrupt membranes. In addition, protease and 
phosphatase inhibitors were added to the NP-40 lysis buffer to 
protect extracted proteins. To ensure complete lysis, the samples 
were frozen to -80°C for at least 1 hour. Once thawed on ice, cells 
were collected into clean eppendorfs using cell scrappers and 
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centrifuged at 12,000 g for 10 minutes at 4°C to pellet cell debris 
and the supernatant collected in a new eppendorf. Protein 
quantification was performed using DC protein assay and samples 
were diluted to approximately 1 µg/µl in 4 x LDS buffer (10 mM 
DTT). When analysing proteins extracted from SH-SY5Y cells, 
approximately 10 µg of protein would be loaded onto a gel for 
Western blotting. When analysing proteins extracted from 
fibroblasts, approximately 20 µg of protein would be loaded onto a 
gel for Western blotting. 
 
Western blotting 
 
After sample preparation, proteins are separated using gel 
electrophoresis. This separation technique utilises the mobility of 
charged proteins through a porous matrix when a voltage is applied. 
The speed at which a molecule will move through the matrix 
depends upon the size and shape of the protein. In these 
experiments, precast polyacrylamide gels were used for protein 
separation (NuPAGE® 4-12% Bis-Tris gel; Novex). Polyacrylamide 
gels contain pores similar in size to many proteins, formed by 
crosslinked structures of bisacrylamide between acrylamide polymer 
strands.  
 
Proteins can be positively or negatively charged; therefore in order 
to separate proteins only by size and not charge, gels are run in the 
presence of the detergent SDS. As described above, SDS was 
added to the sample proteins, and this coats proteins in a negative 
charge, as well as being present in the buffer. In these experiments, 
a continuous buffer system was used, which means that the same 
buffer is in the gel and tanks, which are generally less susceptible to 
problems than discontinuous systems. Due to the size of proteins 
being detected, the NuPAGE® MES SDS running buffer 
(ThermoFisher) was used, since it is recommended for separating 
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small to medium protein sizes. The buffer was diluted in deionized 
water before adding to the electrophoresis tank. 
 
In the electrophoresis unit, the gel is placed within a buffer chamber 
so that movement from the cathode to anode can only occur 
through the porous gel. Once voltage is applied, samples loaded in 
the wells of the gel (formed using a gel comb) will first enter a lower 
density stacking gel, which is approximately twice the length of the 
sample wells. The purpose of this is to concentrate the proteins 
before reaching the higher density area of the gel, known as the 
resolving gel (created using a higher concentration solution of 
bisacrylamide and acrylamide), so proteins separate dependent on 
size.  
 
Alongside the samples, a molecular weight marker was loaded on 
the gel (Novex Sharp Pre-stained Protein Standard; Life 
Technologies) to enable size estimation of the proteins. On 
average, samples were run through the stacking gel at 100 V, and 
then resolved at a voltage of 180V for 1.5 hours.  
 
Following separation by size, proteins must be immobilised onto an 
inert membrane to enable detection using antibodies. The process 
used in these experiments was electrotransfer onto PVDF 
Immobilon-P membrane (Merck Millipore). The most common 
membranes used in Western blotting are nitrocellulose and PVDF 
membranes, which are both porous materials. The pore size of the 
material affects the binding capacity; many small pores increases 
the binding surface compared to fewer bigger pores. PVDF 
membranes have a higher binding capacity, however this also 
means that the background signal is greater compared to 
nitrocellulose membranes. PVDF membranes are hydrophobic, so 
before use membranes were cut to size and soaked in methanol for 
1 minute, then rinsed in distilled water and soaked for 20 minutes in 
transfer buffer. 
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The transfer buffer used in electrotransfer contains Tris/glycine 
diluted in distilled water and 20% methanol (V/V). This buffer 
enables movement of the negatively charged proteins towards the 
anode, and the methanol is required for efficient binding to the 
PVDF membrane.  
 
In these experiments a ‘wet transfer’ method was used, which 
means that the gel containing separated proteins and membrane 
are positioned in an electrotransfer tank submerged in transfer 
buffer. As in polyacrylamide gel electrophoresis (PAGE), 
electrotransfer utilises current to move charged proteins, in this 
case from the gel to the membrane, perpendicular to the direction of 
movement in PAGE so that the migration positions remain intact.  
 
Within the tank, the ‘transfer sandwich’ is assembled as follows, 
starting from the cathode side of the tank: 
Sponge 
Filter paper 
Gel 
PVDF membrane 
Filter paper 
Sponge 
 
Sponges are added as required outside of the sandwich to enable a 
close fit in the tank. This avoids movement or bubbles to form 
between the layers. Since the buffer can become hot during 
transfer, this process is run at a low voltage (35 V) over a long 
period of 2-3 hours. 
 
In these experiments, the transfer of proteins was checked before 
membranes were blocked and incubated with antibody. For this, 
Ponceau S (Sigma) was used, as it is quick and gentle on the 
membrane. To do this, the transfer sandwich was removed from the 
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tank and, using forceps, the membrane was placed in distilled water 
(keeping the proteins facing up, i.e. the side that was in contact with 
the gel). The membrane was then transferred to Ponceau S for 1 
minute and back into distilled water so the excess Ponceau S was 
removed and protein bands clearly visible. If membranes were to be 
cut (for detection of multiple proteins) this was done after 
visualisation with Ponceau S. Membranes were then washed with 
PBS 2% Tween-20 (Sigma) (PBST) to remove Ponceau S before 
blocking. 
 
Membranes were blocked in 5% milk in PBST for 1 hour at RT, 
placed in 50 ml falcons on a laboratory roller. Primary antibodies 
were diluted in 1% milk PBST and membranes incubated overnight 
at 4 °C. The following day, at RT, membranes were washed 3 times 
in PBST (10 minutes for each wash) then incubated for 1 hour with 
secondary antibody diluted in 1% milk PBST. Finally, the 
membranes were washed again 3 times in PBST and visualised 
using chemiluminescence.  
 
Primary antibodies bind to the protein target and secondary 
antibodies conjugated to horseradish peroxidase (HRP) will bind to 
primary antibody. Enhanced chemiluminescence (ECL) reagent 
added to HRP causes the HRP enzyme to catalyse the oxidation of 
luminol, which generates the emission of light (enhanced by the 
ECL). The intensity of light emission is proportional to the amount of 
antibody, and therefore the amount of protein. The light emission 
signal was detected using X-ray film and developed using a Konica 
Minolta SRX-101A processor.  
 
The densitometry of the bands obtained from Western blotting were 
analysed using ImageJ software. The densitometry of the protein of 
interest was always normalised to a loading control, such as β-actin 
or GAPDH. All Western blots were performed at least 3 times. 
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Immunocytochemistry 
 
Cells were plated on 13 mm glass coverslips at a confluency of 50-
60% if experiments involved long treatment times, or 70-80% for 
characterisation or short treatment times. Cells were incubated 
overnight at 37°C. 
 
If applicable, treatments were added with fresh media to the cells 
the following day. Once timepoints had been reached or cells were 
suitably confluent, the coverslips were fixed using 4% 
paraformaldehyde (PFA; Sigma). Cells are fixed to stabilise cell 
morphology and enable cellular processes to be ‘frozen’ in time for 
analysis these processes, since proteolytic enzymes will be 
inactivated. Furthermore, fixation of cells strengthens the layer of 
cells so they are not damaged by further processing and protected 
from contamination. PFA is a chemical fixative which reacts with 
primary amines, forming methylene bridges. 
 
To fix cells, media was aspirated from the coverslips and cells were 
washed briefly in PBS. Coverslips were just covered in fresh 4% 
PFA (diluted in PBS), around 150 µl in a 24-well plate, and 
incubated at RT, covered, for 20 minutes. 
 
Fixed cells were then permeabilised with 0.5% Triton X-100 (Sigma) 
in PBS for 30 minutes at RT. Triton X-100 is a detergent that 
dissolves lipids from cell membranes, enabling improved 
penetration of antibody if target proteins are intracellular.  
 
Following permeabilisation, cells were blocked to reduce 
background fluorescence of staining. Blocking buffer comprised of 
10% fetal bovine serum (FBS) in PBS + 0.5% Triton X-100. Serum 
contains antibodies which will bind to non-specific sites so that there 
is less non-specific binding to antibody, causing background 
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fluorescence. Coverslips were incubated with blocking buffer for 40 
minutes at RT.  
 
Primary antibodies were diluted in blocking buffer and well mixed. 
Coverslips were washed three times in PBS then incubated with 
primary antibody for 2 hours at RT. Primary antibody will bind to the 
antigen of interest and the signal is then amplified by the use of a 
fluorophore-conjugated secondary antibody. The secondary 
antibody needs to be raised against the species in which the 
primary was raised. 
 
Following primary antibody incubation, coverslips were washed 3 
times in fresh PBS to remove excess primary antibody. Secondary 
antibody was diluted in blocking buffer and protected from light 
exposure. Cells were then incubated with secondary antibody for 1 
hour at RT, also protected from light exposure. After incubation, 
coverslips were washed three times with PBS to remove excess 
antibody and then mounted on microscope slides using ProLong 
Gold antifade reagent with DAPI (ThermoFisher). DAPI is a blue-
fluorescent DNA stain, used for identifying cell nuclei. Microscope 
slides were dried at RT overnight to enable mountant to hard-set. 
 
Images were collected using a Zeiss LSM 700 upright confocal 
microscope, 63x oil-immersion lens and 1.4 numerical aperture; and 
digitally captured using ZEN 2009 software. Laser power was 
adjusted to prevent saturation and reduce background signal for 
each fluorescent channel. Settings were kept the same throughout 
image capture for each experiment. DAPI nuclei staining was used 
for cell counting and ImageJ FIJI software was used for all image 
analysis. 
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Antibodies 
 
Primary antibodies for Western blotting: 
 
Mouse anti-β-Actin (1:10,000; Sigma-Aldrich A2228 cat# 
123m4887v) 
Rabbit anti-FLAG (1:5000; Sigma-Aldrich F7425) 
Mouse anti-Mitofusin 1 (1:1000; Abcam cat# ab57602) 
Mouse anti-Mitofusin 2 (1:1000; Abcam cat# ab50838) 
Mouse anti-ATPβ (1:5000; Abcam cat# ab14730) 
Mouse anti-PINK1 (1:1000; University of Dundee; Novis) 
Rabbit anti-PINK1 (1:1000; Takeda) 
Mouse anti-Parkin (Prk8) (1:700; Cell Signaling Technology #4211) 
Rabbit anti-TOM20 (1:5000; Santa Cruz Biotechnology cat# G2304) 
Mouse anti-Tim23 (1:1000; BD Biosciences cat# 611223) 
Goat anti-Hsp60 (N-20) (1:1000; Santa Cruz Biotechnology 
cat#SC1052) 
Mouse anti-GAPDH (6C5) (1:5000; Abcam cat# ab8245) 
Primary antibodies for immunocytochemistry: 
 
Rabbit anti-FLAG (1:2000; Sigma-Aldrich F7425) 
Mouse anti-ATPβ (1:2000; Abcam cat# ab14730) 
Rabbit anti-TOM20 (1:500; Santa Cruz Biotechnology cat# G2304) 
Mouse anti-SQSTM1/p62 (1:2000; Abcam cat# ab56416) 
Mouse anti-Tim23 (1:100; BD Biosciences cat# 611223) 
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Goat anti-Hsp60 (N-20) (1:100; Santa Cruz Biotechnology 
cat#SC1052) 
Goat anti-hNanog (1:100; R&D Systems AF1997-SP) 
Goat anti-hSox2 (1:200; R&D Systems AF2018-SP) 
Mouse anti-Oct4 (1:500; Abcam cat# ab59545) 
Rabbit anti-TBR1 (1:300; Abcam cat# ab31940) 
Rat anti-Ctip2 (25B6) (1:300; Abcam cat# ab18465) 
Mouse anti-Satb2 (1:100; Abcam cat# ab51502) 
Mouse anti-MF20 MYH1 (MlgG2b) (1:100; DSHB) 
Rabbit anti-MyoD (C-20) (1:100; Santa Cruz) 
 
Secondary antibodies for Western blotting: 
 
Goat anti-rabbit IgG-HRP (1:5000; Santa Cruz Biotechnology cat# 
K1010) 
Goat anti-mouse IgG-HRP (1:5000; Santa Cruz Biotechnology cat# 
K1710) 
Secondary antibodies for immunocytochemistry: 
 
Alexa Fluor 568 goat anti-mouse (1:2000; Invitrogen cat# A11004) 
Alexa Fluor 488 goat anti-rabbit (1:2000; Invitrogen cat# A11008) 
Alexa Fluor 488 donkey anti-goat (1:2000; Invitrogen cat# A11055) 
Alexa Fluor 488 goat anti-rat (1:2000; Invitrogen cat# A11006) 
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DNA extraction 
 
DNA was extracted from cells using the Wizard® Genomic DNA 
Purification Kit (Promega, cat# A1125). Cells were plated in 10cm 
tissue culture plates and incubated at 37°C overnight. The following 
day, cells were treated if applicable, then media was aspirated, cells 
washed in PBS and trypsinised to collect a cell pellet. Cell pellets 
were lysed in Nuclei Lysis Solution and mixed with RNase Solution 
for RNase digestion. This mixture was incubated for 15-30 minutes 
at 37°C, then the sample was left to cool at room temperature for 5 
minutes before proceeding. The cellular proteins were removed by 
salt precipitation, by adding the kit’s protein precipitation solution 
and vortexing vigorously at high speed for at least 20 seconds. The 
sample was chilled on ice for 5 minutes and then centrifuged for 4 
minutes at 16,000 g. The precipitated protein forms a tight pellet 
and the supernatant containing the high molecular weight genomic 
DNA was then transferred to a new eppendorf containing room 
temperature isopropanol. The genomic DNA was desalted by 
isopropanol precipitation and DNA pelleted by centrifugation. The 
DNA was then rehydrated in DNA Rehydration Solution overnight at 
4°C. 
 
DNA was quantified on the Nanodrop Spectrophotometer 
(ThermoFisher Scientific). To identify the ‘purity’ of DNA, the ratio of 
absorbance at 260 nm and 280 nm is used, and a 260/280 ratio of 
~1.8 is expected. 
 
Long-range PCR and quantification 
 
DNA was extracted using the Wizard® Genomic DNA Purification kit 
(Promega) and two large PCR products covering the mitochondrial 
genome generated using the ExpandTM Long Template PCR kit 
(Roche) according to manufacturer’s instructions using the primer 
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sequences: L16331 (5’-
ACATAGCACATTACAGTCAAATCCCTTCTCGTCCC-3’) and 
H9068 (5’-ATTGCTAGGGTGGCGCTTCCAATTAGGTGC-3’); and 
L8753 (5’-TCATTTTTATTGCCACAACTAACCTCCTCGGACTC-3’) 
and H16566 (5’-
CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT-3’). The 
amplified products were quantified using the Qubit dsDNA BR 
Quantification Kit and pooled to a final working stock of 0.2 ng/µl. 
Libraries were prepared according to manufacturer’s instructions 
using the Nextera XT DNA Sample Preparation Kit and sequencing 
reactions carried out using the MiSeq or HiSeq platforms. 
 
Nextera library preparation 
 
Sequencing of the mitochondrial genome was performed on the 
Illumina MiSeq platform, and samples were prepared using the 
Nextera XT DNA Sample Preparation Kit.  
 
The Nextera XT transposome simultaneously fragments and adds 
adapter sequences to the ends of template DNA. Tagment DNA 
buffer and Amplicon Tagment mix buffer were added to 1 µg of 
template DNA and heated to 55°C for 5 minutes. Once cooled to 
10°C, Neutralise Tagment buffer was added.  
 
The tagmented samples were then indexed with oligos to allow 
pooling of the samples, using index primers and full adapter 
sequences. The Nextera PCR Mastermix and primers (making a 
note of which indexes were used for each sample, as this is 
required for cluster formation) were added to the tagmented 
samples, then cycled as follows: 72°C for 3 minutes, 95°C for 30 s, 
then 12 cycles of 95°C for 10 s, 55°C for 10 s and 72°C for 10 s. 
Finally the plate was held at 72°C for a further 5 minutes before 
cooled to 10°C.  
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The samples underwent PCR clean up using Agencourt AMPure XP 
beads. In this process, the PCR products bind to the magnetic 
beads and can therefore be separated from contaminants using a 
magnetic stand. The contaminants can then be removed and whilst 
still in the magnetic stand, washed with 80% freshly prepared 
ethanol. Finally the PCR amplicons can be eluted from the magnetic 
particles and transferred to a clean plate for library normalisation. 
For clean up, AMPure XP beads were added to each well of PCR 
product and incubated with shaking (1800 rpm) for 2 minutes, then 
incubated without shaking for 5 minutes. The plate was then placed 
on a magnetic stand and once the supernatant was clear 
(approximately 2 minutes after placing on stand), the supernatant 
was discarded. The beads were washed twice with 80% EtOH, 
using the magnetic stand to collect the beads before discarding the 
supernatant. The beads were air-dried on the magnetic stand for 15 
minutes before adding resuspension buffer, shaking for 2 minutes 
then incubating without shaking for a further 2 minutes. The plate 
was then put back on the magnetic stand and the clear supernatant 
transferred to a new plate. 
 
Library normalisation aims to ensure equal representation in the 
final pooled sample, using magnetic beads. The Nextera beads can 
only ‘hold’ a limited about of material; therefore excess sample can 
be easily removed by discarding the supernatant when the plate is 
on the magnet. The Nextera beads were added to the cleaned PCR 
products and once thoroughly mixed and then separated using a 
magnetic stand, the supernatant containing excess product was 
removed, and the beads then washed twice with wash buffer. The 
bound PCR products were eluted from the beads for library pooling 
before loading onto the MiSeq by taking 5 µl of each library.  
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The MiSeq run was conducted by Deborah Hughes and Cathy 
Woodward (UCL), and data analysed by Dr A. Pittman and Dr M. 
Athanasopoulou (UCL). 
 
Sanger Sequencing  
 
DNA was extracted using the Wizard® Genomic DNA Purification Kit 
and quantified as described above. Sanger Sequencing utilises 
DNA polymerase enzymes, which copy single-stranded DNA 
templates.  
 
After DNA extraction, polymerase chain reaction (PCR) was used to 
amplify the gene of interest for the sequencing reaction, using 
primers designed to flank the region of interest. DNA is separated 
into single strands by exposure to high temperature on a PCR 
cycler, then the temperature is lowered, which enables the single-
stranded primers to find and anneal to their complementary 
sequences. The Taq polymerase, a heat stable catalyst isolated 
from Thermis aquaticus bacterium, can withstand the high 
denaturing temperature and then begin DNA synthesis once the 
primers are annealed and the temperature has reached the 
optimum activity temperature for the particular enzyme 
(approximately 72°C). The Taq polymerase uses deoxynucleotide 
triphosphates (dNTPs) to synthesise the new DNA strand 
complementary to the DNA template strand in the 5’ to 3’ direction. 
In these experiments, the FastStartTM High Fidelity PCR System 
(Roche) was used for the PCR reaction at a total volume of 25 µl 
and a reaction of 35 cycles.  
 
PCR products were cleaned to remove the reagents from the PCR 
reaction before sequencing, such as excess primers and 
unincorporated nucleotides. In these experiments enzymatic 
purification was used by incubation of 5 µl PCR product with 2 µl 
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ExoSAP-ITTM (Affymetrix USB) for 15 minutes at 37°C followed by 
15 minutes at 80°C. The PCR product was run on a 1% agarose gel 
to ensure a single band was present, indicating specific 
amplification of target by the primers. 
 
The sequencing reaction requires the cleaned PCR product, 
primers, DNA polymerase, four nucleotides (A, T, C, G) and four 
dideoxynucleotides containing fluorescent tags. The sequencing 
reaction works similarly to a PCR reaction, whereby the sample is 
heated to separate the double strands of the template DNA, then 
the temperature lowered for the primers to anneal at the 
complementary sequences on the template DNA. The temperature 
is then raised again so the enzyme can bind to the DNA, from which 
new nucleotides are used to extend the chain, complementary to 
the template strand. When a fluorescently tagged dideoxynucleotide 
is incorporated however, the reaction is terminated, as these lack a 
3’-hydroxyl group with which another nucleotide can join. The 
random incorporation of dideoxynucleotides results in a mixture 
containing thousands of differing length strands.  
 
For these experiments, the BigDyeTM Terminator Cycle Sequencing 
Kit (Applied Biosystems) was used to a total volume of 20 µl: 
 
 
Table 1: BigDye Terminator Cycle Sequencing reaction 
Component Volume/reaction (µL) RT conditions 
BigDyeTM Terminator 
Ready Reaction Mix 
8 
96°C – 1 min 
25 cycles of: 
96°C – 10 s 
50°C – 5 s 
60°C – 4 mins 
Forward Primer (3.2 
µM)  
1 
Reverse Primer (3.2 
µM) 
Deionized water 9 
Template 2 
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The reaction was then purified using the BigDye XTerminator® 
Purification Kit (Applied Biosystems) by adding the SAMTM Solution 
and XTerminator TM Solution directly to the plate, sealing the plate 
and vortexing for 30 minutes. The plate was then centrifuged briefly 
and loaded onto the 3730 DNA Analyser (Applied Biosystems) for 
capillary electrophoresis. 
 
The capillaries in DNA analysers are filled with polymer and a 
voltage is applied, so that the negatively charged DNA products of 
the sequencing reaction move through the polymer, separating by 
size, towards the anode. A laser beam is applied near the anode 
that causes the DNA fragments to fluoresce in the correct order of 
sequence due to the separation by size.  
 
Mitochondrial membrane potential 
 
Cells were plated on 25 mm glass coverslips at a confluency of 60-
70% and incubated overnight at 37°C. For each treatment or cell 
line, at least 2 coverslips were prepared per experiment, and 
experiments were performed on 3 independent occasions. The 
following day the cells were loaded with dye 40 minutes prior to 
imaging.  
 
The dye most commonly used for mitochondrial membrane potential 
is tetramethylrhodamine methyl ester (TMRM), which is a cell-
permeant cationic dye. TMRM is a single-wavelength indicator or 
membrane potential (ΔΨm) and accumulates electrophoretically in 
cells in proportion to ΔΨm without inhibiting mitochondrial function 
(Chazotte 2011; Scaduto & Grotyohann 1999). In cells with intact 
membrane potentials, TMRM loaded at low concentrations will 
accumulate in the negatively charged mitochondrial matrix, due to 
the charge properties of the compound, without inducing 
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aggregation and fluorescence quenching. Upon loss of membrane 
potential, the TMRM dye will disperse throughout the cell cytosol, 
causing a substantial reduction in fluorescence.  
 
TMRM (Life Technologies T-668) was diluted to 25 nM in Hank’s 
Balanced Salt Solution (HBSS) (156 mM NaCl, 3 mM KCl, 2 mM 
MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM 
HEPES, pH 7.35), a buffer used to maintain physiological pH when 
imaging. Cell media was aspirated then cells were washed once in 
HBSS, before 1 ml of 25 nM TMRM in HBSS was added to each 
coverslip. The cells were left to load for 40 minutes at RT, covered 
from light. Attofluor cell chambers (ThermoFisher Scientific A-7816) 
were used to hold the coverslips whilst imaging, which were 
thoroughly cleaned with ethanol and distilled water before use to 
remove any toxins from previous experiments. After 40 minutes of 
loading, one coverslip at a time was secured in a chamber and 500 
µl of fresh diluted TMRM was added.  
 
Images were taken using a Zeiss LSM 700 upright confocal, 63 x 
oil-immersion lens, 1.4 numerical aperture and captured using Zen 
2009 software. In order to assess ΔΨm, we used untreated healthy 
controls to determine the laser power settings, which were to be 
kept the same throughout all data collection on that day. It is of vital 
importance to not image using a high laser power, as the heat of the 
laser can cause stress in the live cells and give misleading results. 
Furthermore, saturation of images causes unusable data, since the 
correlation between fluorescence and ΔΨm will not be linear, so it is 
important to determine settings so that hyperpolarised cells can be 
accurately quantified.  
 
Once TMRM settings were determined, Z-stacks images of the cells 
were captured and approximately 5 images were taken per 
coverslip. If several lines (for example in the patient fibroblast 
experiments) were being imaged, addition of TMRM was staggered 
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so cells were always loaded for 40 minutes before imaging. Addition 
of compounds was recorded using the ZEN time-lapse feature, 
whereby basal TMRM signal was recorded, then recording paused 
whilst compound was added into the 500 µl of solution in the 
chamber as quickly and carefully as possible before starting 
recording again. It is important when adding small volumes to mix 
the solution well in order to be able to identify the given effect when 
visualising only a small subset of cells. 
 
In cases where use of TMRM was not appropriate, e.g. when 
pretreating with Rhodamine 6G, Rhodamine 123 was used to 
measure ΔΨm using the same protocol as above, but loaded with 1 
mM Rhodamine 123. For large numbers of cell lines, TMRM data 
was acquired using the ImageXpress® (Molecular Devices) for 
which cells were plated in BD Falcon 96 well clear bottom tissue 
culture imaging plates (SLS). Cells were loaded with 25 nM TMRM 
as described above. 
 
Images were analysed using FIJI software, where the maximal 
intensity projection was used to threshold the red channel (in order 
to eliminate background) and measure mean intensity across the 
field using ROI (region of interest) manager. In each experiment the 
mean for each treatment or cell line was calculated, and the means 
were then averaged across three independent experiments.  
 
Mitochondrial network analysis 
 
Cells were plated on 25 mm glass coverslips at a confluency of 60-
70% and incubated overnight at 37°C. For each treatment or cell 
line, at least 2 coverslips were prepared per experiment, and 
experiments were performed on 3 independent occasions.  
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The following day, cells were loaded with 200 nM MitoTracker® 
Green FM (ThermoFisher) in HBSS for 40 minutes at RT. 
MitoTracker® Green FM is a carbocyanide-based probe which is 
fluorescent in lipid environments and therefore exhibits minimal 
background fluorescence. Unlike other MitoTracker® probes, 
MitoTracker® Green FM accumulates in mitochondria independently 
of membrane potential, making it suitable for mitochondrial 
quantification and network analysis.  
 
Cells were imaged by taking z-stacks at several sites on each 
coverslip, in order to analyse the entire depth of cells on the 
coverslips. Images were analysed using ImageJ FIJI software, 
where mitochondrial staining was thresholded to remove 
background signal and enabled quantification. Mitochondrial content 
was quantified per field: on each Z-stack slice, the area of 
MitoTracker signal was calculated, then summed across all Z-stacks 
(i.e. the depth of the cell) and divided by the number of cells in that 
field (obtained by counting nuclei). This gave a measurement 
referred to in these experiments as mitochondrial volume per cell. 
Ideally, a volume of the cell would be used to obtain mitochondrial 
volume per cell volume, however it was found during experimental 
optimisation that Calcein Blue (Thermofisher) (a commonly used 
dye for cell volume measurements) was not retained by the 
fibroblasts for the duration of the experiment. Therefore, the cell 
volume would appear to reduce over time and consequently was 
deemed unreliable for these experiments. Several fields of view 
were obtained and the mean mitochondrial volume per cell was 
calculated across three independent experiments. 
 
For analysis of mitochondrial network, images taken from cells 
loaded with MitoTracker® Green FM were used. ImageJ FIJI 
software was used to threshold the MitoTracker® Green FM signal 
and the mitochondrial network was convolved using the following 
kernel: 
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-10 -5 -2 -1 -2 -5 -10 
-5 0 3 4 3 0 -5 
-2 3 6 7 6 3 -2 
-5 0 3 4 3 0 -5 
-10 -5 -2 -1 -2 -5 -10 
 
A kernel is a matrix whereby the center represents the source pixel 
and the outer numbers correspond to pixels neighbouring the 
source pixel. This enables the analysis software to interpret the 
network and allow measurement of area, perimeter and aspect 
ratio. Form factor could be determined using the following formula: 
(perimeter)2/(area x 4π). These data were collected for images from 
each cell line and the mean value calculated. Data across three 
independent experiments were then averaged and the standard 
error or mean calculated. 
 
GSH levels by live imaging 
 
Intracellular reduced glutathione (GSH) is detected using 
monochlorobimane (MCB), a lipophilic GSH specific probe. MCB 
can passively diffuse across cellular membranes and is only 
fluorescent upon conjugation to low molecular weight thiols, due to 
quenching by its chorine group when unbound. GSH levels were 
assessed in live cells, which had been incubated on 25 mm glass 
coverslips overnight at 37°C. Cells were loaded with 1 mM MCB in 
HBSS for 40 minutes at RT and Z-stack images captured. Images 
were analysed using ImageJ FIJI software. The MCB fluorescent 
signal was thresholded and mean intensity across the field 
analysed. The data was averaged across all coverslips imaged, and 
then this was averaged across three independent experiments. 
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EM imaging 
 
Fibroblasts were cultured in T75 flasks and fixed overnight in 0.1 M 
sodium cacodylate buffer (pH 7.4) containing 2% paraformaldehyde 
and 2.5% glutaraldehyde. Samples were post-fixed for 1 h at room 
temperature in a solution containing 1% osmium tetroxide and 1% 
potassium ferrocyanide.  
 
After fixation, samples were stained en bloc with 5% aqueous uranyl 
acetate overnight at 4oC; the samples were then dehydrated via a 
series of ethanol washes and embedded in TAAB epoxy resin 
(TAAB Laboratories Equipment Ltd., Aldermaston, UK). Semi-thin 
sections were stained with toluidine blue, and areas of the sections 
were selected for ultramicrotomy. Ultrathin sections were stained 
with lead citrate and imaged using a MegaView 3 digital camera and 
iTEM software (Olympus Soft Imaging Solutions GmbH, Münster, 
Germany) in a Jeol JEM-1400 electron microscope (Jeol UK Ltd., 
Welwyn Garden City, UK) at an accelerating voltage of 100kV.  
Sample preparation, electron microscopy and image analysis was 
performed by Dr Samantha Loh at the University of Leicester. The 
fibroblasts send for preparation and analysis had each been 
allocated a code, so Dr Loh was unaware of the genotype of each 
fibroblast line. Using the images obtained, two parameters were 
analysed: mitochondrial-ER contacts and mitochondrial length. 
Mitochondrial-ER contact was counted by eye, and only a physical 
contact between organelles was considered as contact. If any 
distance between organelles could be measured, then these were 
considered not in contact. A minimum of 120 mitochondria were 
identified for each sample, and the number of those in contact with 
ER was counted. The data was then presented as the percentage of 
mitochondria in contact with ER. Mitochondrial length was 
measured as the longest straight length for each mitochondria, and 
each data point (measured in micrometers) was plotted on a scatter 
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graph for each sample. The mean mitochondrial length was 
calculated and analysed using a Bonferroni’s multiple comparison 
test. 
 
RNA extraction 
 
RNA was extracted from either one confluent well of a 6-well plate 
or a 10 cm plate. Cells were plated, incubated overnight and, if 
applicable, treated the following day. Cells were pelleted and 
disrupted using lysis buffer from the RNeasy® Mini Kit (Qiagen cat# 
74104). The RNeasy® Mini Kit enables the purification of RNA 
molecules longer than 200 nucleotides, consequently enriching for 
mRNA molecules. Cells were lysed and homogenised to disrupt the 
cell walls and plasma membranes then reduce the viscosity of the 
resulting lysates. Before loading sample to the RNeasy Mini spin 
column, ethanol was added to promote selective binding of the RNA 
to the column membrane. Once lysates had been passed through 
the column using centrifugation (16,000 g), wash buffer was applied 
to remove contaminants from the membrane-bound RNA. To 
ensure complete removal of remaining DNA, which is essential for 
RT-PCR analysis, on-column DNase digestion was subsequently 
performed (Qiagen cat# 79254). RNA was treated with DNase 
incubation mix directly onto the membrane and incubated at RT for 
15 min. Finally the membrane was washed again with the provided 
buffers and eluted in RNase-free water.  
 
RNA was quantified on the Nanodrop Spectrophotometer 
(ThermoFisher Scientific). Absorbance measurements include the 
absorbance of all molecules present in the sample, including RNA, 
ssDNA and dsDNA, therefore the ratio of absorbance at 260 nm 
and 280 nm is used to identify the purity of the extracted RNA 
sample. For ‘pure’ RNA, a 260/280 ratio of ~2.0 is expected.  
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cDNA synthesis 
 
An RNA template can be used to produce complementary DNA 
(cDNA) using a process known as reverse transcription. Random 
primers anneal to the RNA template, providing a starting point for 
the reverse transcriptase enzyme. This ensures first strand 
synthesis occurs efficiently with all RNA molecules in the sample. 
Reverse transcriptases are RNA-dependent DNA polymerases, 
isolated from retroviral sources, such as the Moloney murine 
leukemia virus.  
 
Total RNA was reverse transcribed to single-stranded cDNA using 
the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) and the following reaction (prepared on ice): 
 
 
Table 2: High Capacity cDNA Reverse Transcriptase reaction 
 
Q-PCR reaction 
 
Quantitative-PCR, or real-time PCR, is used to quantify gene 
expression whereby amplified DNA is detected by fluorescence 
during each cycle of PCR. SYBRgreen is an intercalating 
Component Volume/reaction (µL) RT conditions 
10X RT Buffer 2.0 
25°C - 10 mins 
37°C - 120 mins 
85°C - 5 mins 
4°C - ∞ 
25X dNTP Mix (100 
mM) 
0.8 
10X RT Random 
Primers 
2.0 
MultiScribe™ Reverse 
Transcriptase 
1.0 
Nuclease-free H2O 4.2 
RNA sample 10 
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fluorescent dye, which fluoresces more greatly when intercalated 
within the DNA double helix as this alters the structure of the dye. 
Therefore, as the PCR cycles amplify more DNA, SYBRgreen can 
intercalate with more DNA and more fluorescence is generated. 
This can be quantified and used to identify relative gene expression 
to controls. 
 
Forward and reverse primers approximately 20 nucleotides in length 
were designed for each gene of interest and housekeeping gene, 
and ordered from Sigma at a concentration of 100 µM.  
 
To identify the fold change in mRNA expression between patients 
and controls or untreated and treated cells, the Ct value needs to be 
used. This is the PCR cycle at which the fluorescent signal crosses 
a threshold within the exponential phase of amplification. The lower 
the Ct the greater the amount of amplicon, since fewer rounds of 
PCR cycle would be required to generate the same amount of 
amplicon. Therefore, to ensure that the exponential phase is 
reached within the total number of cycles, the amount of starting 
template needs to be determined for each primer set, as these will 
have differing efficiencies. To do this, a standard curve needs to be 
generated for each primer set. In order to represent the expression 
of the gene of interest across all samples, 4 µl of neat cDNA from 5 
reactions were combined to make the dilutions for the standard 
curve. Serial dilutions 1:5, 1:50, 1:500, 1:5000 and 1:50000 were 
made (thoroughly mixing between dilutions) and a blank prepared 
with RNase-free water. These were used with each primer pair 
(diluted to 3.3 µM in RNase-free water) in triplicate using the 
following reaction: 
 
Component Volume/reaction 
(µL) 
qPCR 
conditions 
2X Fast SYBR green 10 95°C – 20 s 
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Master Mix 45 cycles of: 
95°C – 3 s 
60°C – 20 s 
Forward primer (3.3 µM) 1 
Reverse primer (3.3 µM) 1 
H2O 3 
cDNA 5 
 
Table 3: Fast SYBR green QPCR reaction 
 
Reactions were prepared on ice and the 384-well plate sealed and 
loaded onto the QuantStudio 7 Flex Real-Time PCR System 
(Applied Biosystems®). At the end of the run, triplicates were 
checked and wells with errors attached were removed and re-
analysed. The dissociation curves were checked for each primer 
set, for which all products should appear at the same temperature, 
without any ‘shoulders’ indicating a second product, which would 
require redesigning of primers. To identify the suitable amount of 
template to use with each primer set, the lowest dilution for which 
the exponential phase occurred within the 45 cycles was selected.  
 
With this information, the experiment was performed as above but 
with the 5 µl cDNA from single reactions at the appropriate dilution 
for each primer set. After removal of unsuccessful reactions, the 
average Ct from the triplicate (or duplicate if one removed) was 
obtained for the gene of interest and housekeeping gene, for each 
sample. Then, for each sample the Ct from the housekeeping gene 
was subtracted from the Ct for the gene of interest, to normalise for 
starting amounts of amplicon across the samples. The fold change 
in mRNA expression between patients and controls was calculated 
using the formula:  
 
2 - ((Ct gene of interest – Ct housekeeping gene) patient – (Ct gene of interest- Ct housekeeping 
gene) control) 
 
 77 
Each experiment was performed three times and the average fold 
change in expression calculated.  
 
MtDNA copy number 
 
Mitochondrial DNA copy number was determined using quantitative 
real-time PCR. As described above, quantitative-PCR is used to 
quantify gene expression whereby amplified DNA is detected by 
fluorescence during each cycle of PCR. To identify the relative 
amount of mitochondrial DNA present in cells from different 
patients, genomic DNA is used as a control from which the number 
of mitochondrial DNA copies can be normalised.  
 
DNA was extracted from fibroblast cell pellets as described above, 
and primers designed to a house-keeping genomic DNA gene and a 
mitochondrial gene (one which did not contain a mutation in any of 
the patient lines). Primers used were for the quantification of the 
ND1 gene in mtDNA and for the amplification of the single-copy 
nuclear gene human globulin (HGB). 
 
ND1-F: 5’-CCCTAAAACCCGCCACATCT-3’  
ND1-R: 5’-GAGCGATGGTGAGAGCTAAGGT-3’  
 
 
HGB-F: 5’-GCTTCTGACACAACTGTGTTCACTAGC-3’  
HGB-R: 5’-CACCAACTTCATCCACGTTCACC-3’  
 
DNA was diluted to 3 ng/µl in TE buffer. TE buffer consists of Tris, a 
pH buffer, and EDTA, a cation chelator, and is used to solubilise 
DNA, preventing it from degradation.  
 
Preparation for the PCR reaction was performed on ice, as follows: 
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Component Volume/reaction 
(µL) 
qPCR 
conditions 
SYBR Green PCR 
Mastermix 
12.5 
95°C – 10 mins 
40 cycles of: 
95°C – 5 s 
60°C –60 s 
Forward primer (0.4 µM) 2 
Reverse primer (0.4 µM) 2 
H2O 2 
Template DNA 8.5 
 
Table 4: SYBR Green PCR reaction 
 
For each cell line, a PCR reaction was performed using the ND1 
primers and another using the HGB primers. On the plate, each 
reaction was performed in triplicate and overall the experiment was 
performed on 3 independent occasions from new cell pellets. 
 
Using the triplicate reactions, the mean Ct was found for each cell 
line for ND1 and HGB. The delta Ct (ΔCt ) was calculated: gDNA Ct 
– mtDNA Ct , and relative mtDNA content calculated: 2-ΔCt 
 
The mean 2-ΔCt was calculated from the three independent 
experiments and SEM determined. 
 
Primer Sequences 
 
PGC1α -F: 5’-GTCACCACCCAAATCCTTAT-3’  
PGC1α-R: 5’-ATCTACTGCCTGGAGACCTT-3’  
 
PINK1-F: 5’-GCCTCATCGAGGAAAAACAGG-3’  
PINK1-R: 5’-GTCTCGTGTCCAACGGGTC-3’  
 
GAPDH-F: 5’-GGAGCGAGATCCCTCCAAAAT-3’  
GAPDH-R: 5’-GGCTGTTGTCATACTTCTCATGG-3’  
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ND1-F: 5’-CCCTAAAACCCGCCACATCT-3’  
ND1-R: 5’-GAGCGATGGTGAGAGCTAAGGT-3’  
 
HGB-F: 5’-GCTTCTGACACAACTGTGTTCACTAGC-3’  
HGB-R: 5’-CACCAACTTCATCCACGTTCACC-3’  
 
DNMT3B-F: 5’-ATAAGTCGAAGGTGCGTCGC-3’ 
DNMT3B-R: 5’-GGCAACATCTGAAGCCATTT-3’ 
 
KLF4-F: 5’-GGTCGGACCACCTCGCCTTACAC-3’ 
KLF4-R: 5’-CTCAGTTGGGAACTTGACCA-3’ 
 
Rex-F: 5’-CCGAGACCACGTCTGTGCGG-3’ 
Rex-R: 5’-AGCGCTTTCCGCACCCTTCA-3’ 
 
Myc-F: 5’-CTGAAGAGGACTTGTTGCGGAAAC-3’ 
Myc-R: 5’-TCTCAAGACTCAGCCAAGGTTGTG-3’ 
 
Complex I activity assay 
 
The enzyme activity of mitochondrial OXPHOS Complex I was 
analysed using the Complex I Enzyme Activity Microplate Assay Kit 
from Abcam (ab109721). This assay measures the NADH-
dependent activity of Complex I and is not dependent on the 
presence of ubiquinone. The microplate wells are pre-coated with 
capture antibodies specific for Complex I and the samples are 
immobilised in the wells. As NADH is oxidised to NAD+, 
simultaneously the dye in the well (ε = 25.9/mM/well) is reduced 
which causes an increase in absorbance at OD 450 nm. 
 
Fibroblasts plated in a 10 cm tissue culture plate were harvested 
and the cell pellet washed twice with PBS. The cell pellet was 
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resuspended in PBS to a concentration of 5.5 mg/ml and the 
proteins extracted by adding detergent and incubating on ice for 30 
minutes to allow solubilisation. The samples were then centrifuged 
at 16,000 g for 20 minutes at 4°C and the supernatants collected in 
a new eppendorf. For the assay, 200 µg of sample was loaded onto 
the plate in duplicate with background wells (containing only buffer) 
and background control sample wells (containing sample but no 
assay solution to be added after incubation), and the microplate was 
incubated for 3 hours at room temperature. The wells were then 
emptied, washed twice with buffer (all wells except the background 
control sample wells) and emptied again. The assay solution, 
containing buffer, NADH and dye, was then added to all wells 
except the background control sample wells, avoiding bubbles, and 
loaded onto the plate reader with the following program: 
 
 
 
 
 
 
 
 
Table 5: Complex I activity assay program settings 
 
Complex I activity is proportional to the increase in absorbance at 
OD 450 nm. To analyse the data, the duplicates of each sample 
were averaged and the background control was subtracted from the 
sample reading. Then the linear rate of increase calculated for each 
sample and expressed as mOD/min. This experiment was repeated 
three times. 
 
Mode Kinetic 
Wavelength: 450 nm 
Time: 30 minutes 
Interval: 20 sec – 1 min 
Shaking: Shake between readings 
Temperature: Room temperature 
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IPSC and Differentiation techniques 
Stemgent microRNA-Enhanced mRNA Reprogramming 
System 
 
Reprogramming of human fibroblasts to induced pluripotent stem 
cells (iPS) was achieved using the Stemgent mRNA 
Reprogramming Kit, the Stemgent microRNA Booster Kit and 
Stemgent Stemfect RNA Transfection Kit. This method of 
reprogramming has a high efficiency, is fast and avoids the use of 
genome-integrating viruses. This process utilises the daily 
transfection of synthetic mRNAs, together with interferon inhibitor 
B18R, as first described by Warren et al. (Warren et al. 2010). In 
total, the protocol takes 16 days to produce iPS cell cultures, in 
which there are 2 microRNA transfections and 11 mRNA 
transfections. 
 
Before beginning reprogramming, NuFF-Conditioned Pluriton 
Medium must be prepared, which is used to supplement cultures 
when reprogramming in feeder-free conditions. The generation and 
maintenance of culture systems traditionally uses animal product-
based components (e.g. ‘feeder cells’), however these can cause 
problems with contamination of the culture, limiting their use in 
many important applications, such as drug development. In this 
protocol inactivated newborn human foreskin fibroblasts (NuFF 
cells) are incubated with Pluriton Medium (Stemgent) for 24 hours. 
This medium becomes ‘conditioned’ and can be frozen (for up to 3 
months) before use in the reprogramming experiment. In addition, 
before reprogramming, single-use aliquots were prepared of the 
Pluriton supplement and B18R Recombinant protein (stored at -
80°C), and the mRNA and microRNA cocktails prepared.   
 
The mRNA Reprogramming cocktail consisted of: 
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Table 6: mRNA reprogramming cocktail components 
 
The cocktail was mixed thoroughly, aliquoted into single-use 
volumes and stored at -80°C.  
 
The tissue-culture plates used in these experiments were coated 
with Corning® Matrigel® Matrix (hESC-qualified) a day before use. 
Matrigel is a solubilised basement membrane preparation used to 
improve attachment and differentiation of iPSCs. 
 
On day 0, Fibroblasts were plated by removing culture medium, 
washing cells briefly with PBS and adding 0.05% Trypsin/EDTA to 
the culture surface of the flask. The flask was incubated for at least 
3 minutes at 37°C until detached. Conditioned Pluriton medium was 
added to the flask to neutralise the trypsin/EDTA and transferred to 
a 15ml falcon. Cells were centrifuged at 200 g for 5 minutes, 
supernatant removed and cell pellet resuspended in 5 ml media. 
Cells were counted using a counting chamber and 5 x 104 cells 
were plated per well into the Matrigel® coated 6-well tissue culture 
plates. Plates were incubated at 37°C and 5% CO2 overnight. 
 
On day 1, cells were to be pre-treated with B18R protein and then 
transfected with microRNA cocktail. Conditioned media was 
warmed to 37°C in the incubator and Pluriton supplement and B18R 
protein thawed on ice; these were then combined and mixed well. 
Oct4 mRNA 400.0 µl 
Sox2 mRNA 123.8 µl 
Klf4 mRNA 162.0 µl 
c-Myc mRNA 153.5 µl 
Lin28 mRNA 85.7 µl 
nGFP mRNA 115.0 µl 
Total cocktail 1040 µl 
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The media was aspirated from the cell culture plate and the freshly 
made media containing B18R added to the cells for 2 hours at 37°C 
and 5% CO2. The microRNA cocktail aliquot was thawed on ice, 
and the Stemfect Buffer and Stemfect Transfection Reagent allowed 
to equilibriate to RT for 30 minutes. The Stemfect Buffer was 
combined with the microRNA cocktail in one tube (tube 1), and the 
Stemfect Buffer combined with the Stemfect Transfection Reagent 
in another tube (tube 2). The contents from tube 2 was combined 
with tube 1 and pipetted gently 3-5 times. This complex was 
incubated at RT for 15 minutes, then aliquoted into the wells of the 
cell culture plate in a dropwise fashion. The plate was gently rocked 
from side to side, front to back, and incubated at 37°C and 5% CO2 
overnight. 
 
On days 2-4, cells were again pre-treated with B18R, as described 
above, then transfected with the mRNA cocktail. Where possible, 
transfections was performed at the same time each day in order to 
maintain sufficient levels of factors. As described previously, the 
Stemfect Buffer and Stemfect Transfection Reagent were allowed to 
equilibriate to RT for 30 minutes, and the mRNA reprogramming 
cocktail was thawed on ice. The Stemfect Buffer and mRNA cocktail 
was combined in tube 1 and the Stemfect Buffer and Stemfect 
Transfection Reagent combined in tube 2. The contents of tube 2 
was then transferred to tube 1, gently mixed 3-5 times and 
incubated at RT for 15 minutes. The complex was added to the 
wells of the cell culture plate in a dropwise fashion and gently 
mixed, then the plate was incubated at 37°C and 5% CO2 overnight. 
 
On day 5, the cell culture was co-transfected with both the mRNA 
reprogramming cocktail and the microRNA cocktail. As described 
previously, the cells were pre-treated with B18R protein, and the 
mRNA and microRNA complexes prepared as before. The two 
complexes were added to the wells in a dropwise fashion, mRNA 
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just before the microRNA, and the plate was incubated at 37°C and 
5% CO2 overnight. 
 
On days 6-12, cells were pre-treated with B18R protein and 
transfected with mRNA reprogramming cocktail (same method as 
on days 2-4). 
 
After completion of RNA transfections, the cells were maintained 
using conditioned Pluriton media for 1-3 extra days until the iPS 
colonies were large enough to be picked. The media was changed 
daily with NuFF-conditioned Pluriton media and Pluriton 
supplement, and cells maintained at 37°C and 5% CO2. 
 
On approximately day 15, the iPC colonies were picked, with each 
individual colony being transferred to a separate well (maintaining 
clonal lines). 12-well tissue culture plates were pre-coated with 
Matrigel® before starting. The iPS colonies were identified by 
morphology under the microscope and the position in the well 
marked. NuFF-conditioned Pluriton media with Pluriton supplement 
was added to the prepared 12-well plate, and cell media was 
replaced with fresh media. On the pre-marked colony, a sterile 10 µl 
pipette tip was used to gently separate the colony from the 
fibroblasts surrounding it, then the colony was broken into smaller 
pieces (most often into quarters, but depended on colony size). The 
colony pieces were removed with a sterile pipette tip and transferred 
to a single well of the prepared 12-well plate. The colonies were 
maintained at 37°C and 5% CO2. 
 
The colonies were maintained according to standard iPS cell culture 
protocol (described below) and immunocytochemistry and Sanger 
sequencing used to confirm the pluripotency and presence/absence 
of mtDNA mutations. 
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Karotyping iPSC 
 
IPSC karotyping was carried out by TDL Genetics (London, W1T 
4EU). The iPSCs were cultured on Geltrex® (ThermoFisher) coated 
T25 flasks and then prepared by TDL Genetics for analysis, 
beginning with a pretreatment of colcemid overnight before harvest 
and analysis. A 20 cell analysis was performed on all lines and all 
were found to have a normal karyotype and banding pattern. 
Culturing IPSC 
 
IPSC were maintained using Essential 8TM Medium (Gibco Life 
Technologies) on Geltrex® (ThermoFisher) coated 6-well tissue 
culture plates at 37°C and 5% CO2. Media was changed everyday, 
except the day after a split.  
 
The Essential 8TM Media (E8) was prepared by thawing the E8 
supplement overnight at 4°C and adding to 500 mL E8 media which 
had been warmed to RT (not using a waterbath). To prevent 
degradation by repeated warming, the supplemented media was 
aliquoted into 50 ml falcons and stored at 4°C. For experiments 
involving mtDNA mutant cells, media was supplemented with 200 
µM uridine (Sigma). Before use, an E8 aliquot was warmed (not 
artificially) to RT.  
 
Stocks of Geltrex® were prepared by aliquoting 240 µl into sterile 15 
mL falcons and storing at -20°C. When ready to use, 12 ml of 
DMEM media (Gibco) was added to a single 15 ml falcon aliquot, 
mixed well and 1 ml added to each well of two 6-well tissue culture 
plates. Plates were incubated for at least 1 hour at 37°C, and all 
excess Geltrex® removed before adding media or cells to the well.  
 
IPSC grown to full confluency are likely to spontaneously 
differentiate, normally to fibroblasts, therefore it is important to 
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maintain cultures at no more than 70% confluency. At this point, 
cells were split using EDTA, most commonly at a ratio of 1:6. 
 
To split cells, 6-well tissue culture plates were pre-coated with 
Geltrex® and media warmed to RT. The cell media was aspirated 
and cells washed briefly with 1 ml EDTA (Invitrogen). This EDTA 
was discarded, and 1 ml of fresh EDTA was added to the well for 
cell detachment. The plate was incubated with EDTA for 5 minutes 
at 37°C. Whilst incubating, the Geltrex® was aspirated from the new 
tissue culture plate and fresh E8 media added. Under the 
microscope, the appearance of small holes in the colonies was 
checked to indicate that the EDTA was ready to be removed. The 
EDTA was discarded and 1 ml of fresh media was added to the 
colonies, relatively harshly, to cause complete detachment from the 
plate surface, but not to break colonies up too much. Colonies will 
not attach well if in single cell suspension so it is important to break 
large colonies into smaller clumps, but not into single cells. The 
cells were then collected and distributed in a dropwise fashion to the 
new tissue culture plate. The plate was gently moved side to side 
and back and forth, to ensure even distribution of the colonies. The 
media was not changed the day after splitting. 
 
 
Cortical neuron differentiation 
 
Differentiation of iPSCs into cortical neurons was conducted using 
the protocol written by Shi et al., IPSCs were cultured as described 
above for 2 weeks to establish a healthy culture before starting 
induction.(Shi et al. 2012). All media used in the protocol was 
supplemented with 200 µM uridine for maintenance of mtDNA 
mutations.  
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Differentiation took place in a 6-well tissue culture plate coated with 
Matrigel® on 100% confluent iPSCs. Therefore cells were first 
passaged 2:1 using EDTA, as described above, and plated into the 
Matrigel® coated wells in E8 media supplemented with 10 µM 
ROCK inhibitor (Sigma) to aid cell survival.  
 
The following day (day 1), if the cells were 100% confluent, media 
was aspirated and cells washed briefly with PBS, then 2 ml of 
neural induction medium was added per well. Induction media was 
made by supplementing neural maintenance media with SB431542 
(Tocris), a small-molecule inhibitor of TGF-β signalling, and 
Dorsomorphin (Tocris), a small-molecule SMAD inhibitor. By 
inhibiting TGF-β signalling, the activation of SMAD proteins 
mediated by TGF-β is inhibited, providing a ‘dual SMAD inhibition’ 
with these two compounds, which enables differentiation towards 
the anterior neuroectodermal lineage. 
 
Neural maintenance media (referred to as N2B27 media) was 
prepared by adding supplemented Neurobasal media (Life 
Technologies) and supplemented DMEM F12 Glutamax media (Life 
Technologies) at a 1:1 ratio, which was stored at 4°C and used 
within 3 weeks. The components of N2B27 media were prepared as 
follows: 
 
Reagent Supplier Volume 
DMEM F12 
+Glutamax 
Gibco Life 
Technologies 
500 ml 
Insulin (10 mg/ml) Sigma 0.25 ml 
2-mercaptoethanol 
(50 mM) 
Life Technologies 1 ml 
Non essential amino 
acids (100x) 
Life Technologies 5 ml 
N2 supplement Life Technologies 5 ml 
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Pen/Strep Life Technologies 5 ml 
 
Neurobasal Gibco Life 
Technologies 
500 ml 
B27 supplement Life Technologies 10 ml 
L-Glutamine (200 
mM) 
Life Technologies 5 ml 
Pen/Strep Life Technologies 5 ml 
 
Table 7 Neural maintenance media components 
 
Neural induction media was prepared as follows: 
 
Reagent Supplier Volume 
N2B27 media Prepared as 
above 
10 ml 
SB431542 (resuspended in DMSO 
to 10 mM stocks, stored at -20°C) 
Tocris 10 µM 
Dorsomorphin (resuspended in 
DMSO to 10 mM stocks, then 
diluted to 1 mM stock in H2O, stored 
at -20°C) 
Tocris 10 µM 
 
Table 8 Neural induction media components 
 
Neural induction media was changed daily for 10 days, by which 
point a neuroepithelial sheet should have appeared. The 
neuroepithelial cells were collected using dispase as follows: 200 µl 
dispase (Life Technologies) was added directly to the well (media 
was not removed) and incubated at 37°C for 10-15 minutes. Using a 
Gilson P1000 pipette, the cells were collected and added to 7 ml 
PBS in a sterile 15 ml falcon. The cells were left to settle to the 
bottom of the falcon, then the PBS was removed and replaced with 
fresh PBS, and this was repeated 3 times. Finally the cells were 
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resuspended in N2B27 media and plated at a 1:2 ratio onto laminin 
(Sigma) coated wells (plates were previously prepared by 
incubating with laminin overnight at 37°C). The cells were incubated 
overnight at 37°C and the following day the media changed to 
N2B27 supplemented with 20 ng/ml fibroblast growth factor 2 
(FGF2, PeproTech), which promotes the expansion of neural stem 
cells. The media was then changed every other day.  
 
After four days of N2B27 + FGF2, media was changed to just 
N2B27, again refreshing every other day for neural expansion and 
differentiation. Cells were split at a 1:2 ratio with dispase (as 
described above) when neural rosette structures began to expand 
and meet at the edges. Between days 20-30, cells were dissociated 
using accutase (Innovative Cell Technologies) at a ratio of 1:1. The 
cell media was aspirated and cells washed briefly with PBS, then 
0.5 ml accutase was added per well and incubated for 5 minutes at 
37°C. The cells were triturated with a Gilson P1000 pipette and 
returned to the incubator for a further 3 minutes. The cells were then 
collected in N2B27 media, centrifuged at 400 g for 5 minutes, 
resuspended in N2B27 media and plated in a pre-prepared laminin 
coated plate. The media was changed the day after plating and from 
then every other day. Accutase splitting was repeated at a 1:2 ratio 
when the cells reached 90% confluency. On days 27-31, the cells 
were split to a 1:4 ratio with accutase, and then passaged for the 
final time around day 35, as the cell the survival rate after this point 
has been found to be relatively low. The plates and coverslips for 
final experiments were prepared by coating first with poly-L-
ornithine (Sigma) for at least 4 hours at 37°C, then with laminin as 
described previously. Cells were cultured for another 50-60 days 
after the last passage; using N2B27 media changed every other 
day.  
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Myogenic differentiation 
 
Myogenic differentiation of iPSCs should take place on healthy, 
regularly passaged iPSCs and utilise fresh, non-freeze-thawed 
reagents. DMEM media was supplemented with 200 µM uridine 
throughout the myogenic differentiation protocol.  
 
IPSCs were seeded onto Matrigel® coated plates (prepared at least 
1 hour before seeding), by washing cells with PBS and adding 
0.05% Trypsin/EDTA to detach the cells. To aid detachment, cells 
were incubated with Trypsin/EDTA at 37°C for 2-6 minutes, until the 
cells had separated into clumps of 3-4 cells (not single cells). The 
cell clumps were removed from the plate with DMEM 10% FBS and 
collected in a 15 ml sterile falcon. The falcon was centrifuged at 800 
rpm for 4 minutes and the pellet resuspended in approximately 2 ml 
of media for cell counting, using a counting chamber. For each IPS 
line, 3 wells (of a Matrigel® coated 6-well tissue culture plate) of 1 x 
105 cells were plated and another 3 wells at double density. The 
media used for cell plating was: 
 
Reagent Supplier Conc Volume  
DMEM F12 
Gibco Life 
Technologies 
1X 50 ml 
F12 stands for 
Ham’s Nutrient 
Mixture F12, which 
was developed for 
serum-free cell 
culture 
CHIR Tocris 3 µM 7.5 µl 
Inhibitor of 
glycogen synthase 
kinase 3 (GSK-3). 
GSK3 is a negative 
modulator of 
myogenic 
differentiation 
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Table 9 Myogenic differentiation media 
 
 
The plated cells were incubated at 37°C and 5% CO2 overnight. The 
following day (day 2), if cells had attached, the media was replaced 
with no ROCK inhibitor and half the concentration of CHIR (1.5 µM). 
On day 3, if enough cells were still attached, the media was 
aspirated off the cells and replaced with differentiation media: 
 
 
 
 
 
 
Table 10 Day 3 Myogenic differentiation media 
LDN 
StemMACS 
Miltenyi 
Biotec 
0.5 µM 5 µl 
Inhibitor of bone 
morphogenetic 
protein (BMP) 
signalling. BMPs 
have a profound 
repressive effect on 
myogenic 
differentiation  
Insulin-
Transferrin-
Selenium 
supplement 
(ITS) 
Gibco Life 
Technologies 
1X 
500 µl 
(stock is 
100X) 
Aids cell culture in 
serum-free media 
Rho-
associated 
protein 
kinase 
(ROCK) 
inhibitor 
Sigma 10 µM 50 µl Boosts cell survival 
DMEM F12 1X 
CHIR 1.5 µM 
LDN 0.5 µM 
ITS 1X 
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On day 4-6, cells underwent a full media change daily, with 
fibroblast growth factor-2 (FGF-2, R&D Systems), a key regulator of 
embryonic myogenesis (Świerczek et al. 2015): 
 
 
 
 
 
 
 
Table 11 Day 4-6 Myogenic differentiation media 
 
On day 7 and 8, cell media was changed to media containing 
human hepatocyte growth factor (HGF, R&D Systems) and human 
insulin-like growth factor I (IGF, R&D Systems), which plays an 
important role in muscle regeneration (Philippou et al. 2007). HGF 
has been shown to increase proliferation of quiescent satellite cells 
but also suppress the expression of late myogenic differentiation 
factors, thereby essentially delaying the process to enable 
proliferation of more cells for differentiation with the aim of 
generating a greater number of fibres at the end (Gal-Levi et al. 
1998).  
 
 
 
 
 
 
Table 12 Day 7 Myogenic differentiation media 
 
DMEM F12 1X 
CHIR 3 µM 
LDN 0.5 µM 
ITS 1X 
FGF-2 10 ng/ml 
DMEM F12 1X 
HGF 10 ng/ml 
IGF 2 ng/ml 
LDN 0.5 µM 
FGF-2 20 ng/ml 
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On day 9-12, cell media was changed daily to just DMEM-12, IGF-I 
(2 ng/ml) and 15% KnockOutTM Serum Replacement (KSR, Gibco 
Life Technologies). KSR is an FBS-free medium supplement used 
to support the growth of stem cells during in vitro differentiation; 
during this stage a lot of proliferation was expected so the KSR 
percentage could be reduced to 7.5% if necessary. From day 13, 
the media was changed every other day, this time containing the 
addition of 10 ng/ml HGF. 
 
On day 35, the cells were plated for terminal differentiation. New 6-
well tissue culture plates were prepared with Matrigel® coating prior 
to splitting. The media was aspirated from the well, cells washed 
briefly with PBS, and 1ml of collagenase (Life Technologies) and 
100 µl of dispase (Life Technologies) added per well, then 
incubated at 37°C for approximately 30 minutes until cells had lifted 
in one clump. The cells were transferred to a 15 ml sterile falcon 
with DMEM F12 media and left to settle to the bottom 
(approximately 5 minutes), then the supernatant media was 
removed as close to the cells as possible with disturbing, discarded, 
and 5 ml of fresh DMEM F12 added. This was repeated twice more 
to thoroughly wash the cells, then finally 2 ml of plating media was 
added to the cell suspension: 
 
 
 
 
 
 
 
 
Table 13 Terminal Myogenic differentiation media 
 
 
DMEM F12 1X 
KSR 15% 
HGF 10 ng/ml 
IGF 2 ng/ml 
ROCK 
inhibitor 
10 µM 
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The cells in plating media were triturated gently using a 5 ml 
stripette and then again with a p1000 pipette before seeding at a 1:6 
ratio onto the pre-prepared culture plates. The cells were incubated 
at 37°C and 5% CO2 overnight and the following day, the media 
was changed to remove the ROCK inhibitor. 
 
For each line, cells in half the wells were matured using ITS media 
and the other half using KSR, since some lines mature better with 
one than the other but this is difficult to predict so both were used in 
parallel: 
 
 
 
 
 
 
 
Table 14 Myogenic maturation media 
 
The media was then changed 3-4 times per week until day 45 when 
experiments were then performed. 
 
Assessing mitophagy in differentiated cell types  
 
To induce mitophagy, cells were depolarised with 10 µM carbonyl 
cyanide 4-(trifluoromthoxy)phenylhydrazone (CCCP, Sigma). In SH-
SY5Y cell lines and fibroblasts, cells were exposed to CCCP for 12-
24 hours, however in cortical neurons and myotubes the treatment 
was longer so CCCP was ‘refreshed’. This worked as follows: the 
cell media was changed 2 hours before inducing depolarisation, 
when 10 µM CCCP was added to the cell media. For myotubes, 
after 12 hours the media was discarded and fresh media containing 
10 µM CCCP was added. This was repeated every 12 hours until a 
ITS maturation KSR maturation 
DMEM F12 1X DMEM F12 1X 
ITS 1X KSR 3% 
HGF 10 ng/ml HGF 10 ng/ml 
IGF 2 ng/ml IGF 2 ng/ml 
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total treatment time of 48 hours was reached. For cortical neurons, 
which are more prone to detachment, the same protocol applies 
however only half the media was removed at a time so as not to 
disturb the cells.  
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Chapter 1 
Mechanistic insights into the 
mitophagy pathway 
1.1 Introduction 
 
1.1.1 Methods to induce mitophagy 
 
To study the process of mitophagy, compounds can be used to 
cause global disruption to the mitochondrial network, or alternatively 
a more targeted approach can be taken. There are advantages and 
disadvantages to both, but since mitophagy in mammalian cells is a 
relatively infrequent process, artificial induction is required to study 
the pathway. 
 
The mitochondrial stressor carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP) causes uncoupling of the proton gradient and 
subsequent mitochondrial membrane depolarisation. As well as 
causing an increase in proton conductance, CCCP has many 
nonspecific effects. These include targeting autophagosome and 
lysosome degradation, and the stimulation of apoptotic processes 
(Kasianowicz et al. 1984; Padman et al. 2013; Cai et al. 2012).  In 
addition to CCCP, the potassium ionophore valinomycin and the 
combination of oligomycin, an ATP synthase inhibitor, and antimycin 
A, a Complex III inhibitor, can be used to stimulate the mitophagy 
process. The use of these compounds enables simple and fast 
initiation of mitophagy that can be measured in numerous ways.  
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The global loss of membrane potential across the entire 
mitochondrial network is convenient for biochemical experiments, 
which often require a large mitophagy induction to detect the 
proteins involved in the process. However, this large area of 
mitochondrial damage is not particularly representative of 
physiological mitophagy in which subsets of mitochondria are more 
likely to be affected (Ashrafi & Schwarz 2013). 
 
A technique that applies a more focused area of damage is the use 
of photobleaching, which has been demonstrated in neurons. This 
involves the use of neurons containing mitochondrial KillerRed and 
eliciting spatiotemporally controlled ROS-mediated damage 
(Ghazaleh Ashrafi et al. 2014). Whilst this technique is 
physiologically more relevant and fewer off-target effects will be 
produced, the analysis involves lower n numbers and therefore 
many more experiments would be required to identify significant 
effects. Furthermore, experimental approaches to analyse the effect 
of damage to sub-sets of mitochondria, through the use of 
microfluidics for example, will be mainly limited to imaging 
techniques.  
 
1.1.2 Methods to study mitophagy 
 
1.1.2.1 Detecting the autophagosome 
 
A common technique used to confirm the induction of mitophagy is 
the engulfment of damaged mitochondria by autophagic machinery. 
However this timepoint of mitochondrion-autophagosome interaction 
is relatively short so for accurate assessment of mitophagy, 
lysosomal degradation is often inhibited (Klionsky et al. 2012). 
 
The colocalisation of mitochondria and autophagosomes can be 
assessed in fixed cells by immunocytochemistry or in live cells 
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loaded with fluorescent dyes. For immunocytochemistry, mitophagy 
is induced in cells adhered to glass coverslips then after a certain 
timepoint of stimulation with a mitochondrial stressor, cells are fixed, 
for example with paraformaldehyde. After permeabilisation and 
blocking (described in detail in the methods section), cells are 
incubated with primary antibodies for a mitochondrial protein and an 
autophagic protein. Images of the prepared cells can be used to 
calculate colocalisation, whereby areas of overlap between the 
mitochondria channel and the autophagic channel are deduced. 
This requires comparable grey-level dynamics in each channel 
during image capture, and is highly sensitive to poor set-up of the 
image acquisition software. The benefit of immunocytochemistry is 
that if slides are properly stored, imaging can be repeated should it 
be required. Live cells loaded with dye however can only be imaged 
in one session and it is vitally important to be careful when 
preparing the settings. Cells used in these experiments are 
commonly transfected with GFP-LC3 and loaded with a membrane 
potential-independent mitochondrial dye, such as some MitoTracker 
dyes. However, the reported aggregation of LC3, which occurs 
separately from induced mitophagy, can result in false positives 
(Kuma et al. 2007).  
 
1.1.2.2 Lysosomal delivery 
 
Since the autophagosome-mitochondria interaction during 
mitophagy is transient and measurement of GFP-LC3 can be 
misleading, visualising the delivery of mitochondria to the lysosome 
provides an alternative method of mitophagy assessment. 
 
The colocalisation of mitochondria and lysosomes can be performed 
using similar methods to that of the mitochondria and autophagic 
proteins. Lysosomal-associated membrane protein 1 (LAMP1) can 
be used in immunocytochemistry as a late endosome/lysosome 
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marker and colocalisation quantified between LAMP1 and a 
mitochondrial protein marker. For analysis of mitochondrial delivery 
to lysosomes in live cells, cells can be loaded with LysoTracker, 
which accumulates in the acidic environment of lysosomes. 
However this dye has been known to cause an increase in 
intracellular pH if cells are imaged over large timeframes, which can 
consequently quench the LysoTracker signal (Chen et al. 2015). 
 
The acidic environment of lysosomes has been utilised in an 
alternative method of mitophagy assessment. The expression of a 
mitochondrial-targeted tandem mCherry-GFP tag enables a change 
in colour of fluorescence upon delivery of mitochondria to 
lysosomes (Allen et al. 2013). As described in the introduction, this 
has been used to detect mitophagy in systems not involving the 
overexpression of Parkin. Under basal conditions both tags will 
fluoresce, however in a low pH environment, protonation of the GFP 
fluorophore will occur and the signal will be quenched. This does 
not happen to the mCherry tag, since it has a lower pKa, which is 
the pH at which fluorescence is at 50% of its maximal signal. To 
determine mitophagy in this assay, the number of red mCherry 
puncta were counted, compared to yellow, which would be caused 
by the combined mCherry and GFP fluorescence. 
 
Another lysosomal assay, which relies on its acidic environment, 
involves the use of a mitochondrial matrix-targeted mt-Keima. Mt-
keima is a molecule that has a bimodal excitation spectrum, which 
represents neutral and acidic environments with a shift in excitation 
spectrum peak. This assay has been used in MEFs derived from a 
mt-Keima reporter mouse, using fluorescence-activated cell sorting 
(FAC) to distinguish the distribution of cells positive or negative for 
mitophagy (Sun, Yun, Liu, Malide, Liu, I. Rovira, et al. 2015). 
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1.1.2.3 Elimination of mitochondrial proteins 
 
The measurement of mitochondrial proteins after mitophagy is 
stimulated enables quantification of the successful completion of the 
process. This is a convenient method which denotes the actual 
degradation of mitochondria. Most often this is achieved by 
immunoblotting and immunocytochemistry to quantify the amount of 
mitochondrial protein in control-treated cells compared to uncoupler-
treated cells. In these experiments, the amount of protein is typically 
normalised to the expression of a housekeeping gene in Western 
blotting or by cell counting in imaging experiments.  
 
A significant disadvantage of this method however is that the net 
change of mitochondrial mass is quantified, and not the amount of 
mitochondria degraded by mitophagy alone. This method therefore 
may falsely overestimate the amount of mitophagy by including, for 
example, proteasomal degradation, or falsely underestimate the 
amount of mitophagy by any stimulation of mitochondrial 
biogenesis, which may in fact be significantly upregulated in cases 
of widespread mitochondrial uncoupling. 
 
1.1.3 Aims and hypothesis 
 
In this chapter the aims were to investigate the triggers and 
methods of measuring mitophagy in different cell types. In 
particular, these experiments made use of the compound 
Rhodamine 6G in an attempt to study the mitophagy pathway 
without the use of the CCCP, which may be limiting our 
understanding of the ways mitophagy can be stimulated by simply 
causing loss of membrane potential. 
 
Rhodamine 6G is a cationic dye, and therefore contains positively 
charged dye molecules which bind to the negatively charged region 
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of the mitochondrial membrane (Yaginuma et al. 1973). It was first 
proposed that Rhodamine 6G inhibited energy transduction in 
oxidative phosphorylation (OxPhos) by blocking adenine nucleotide 
translocase (ANT) (Gear & Gear 1974). The function of ANT is to 
export the ATP generated from the OxPhos mechanism to the 
cytosol. However, this proposed mechanism of inhibition by 
Rhodamine 6G was found to be incorrect and it is now believed that 
Rhodamine 6G targets two sites in the OxPhos mechanism (Higuti 
et al. 1980). The F1F0-ATPase comprises the F1 head group, which 
combines Pi and ADP to form ATP, and the inner mitochondrial 
membrane embedded F0 base which functions as a proton channel. 
The oligomycin-sensitivity conferring protein (OSCP) is required for 
the correct binding of F1 to F0. The ATPase activity of the purified F1 
region is not inhibited by oligomycin, nor by Rhodamine 6G, 
however Rhodamine 6G does inhibit ATP hydrolysis by purified 
oligomycin-sensitive ATPase, which suggests an inhibition site on 
F0 (Higuti et al. 1980). In addition, unlike oligomycin and other 
uncoupling agents, Rhodamine 6G inhibition also occurs at sites 
related to H+-ejection by redox components (Higuti et al. 1980). 
 
As a consequence of inhibiting mitochondrial oxidative 
phosphorylation, Rhodamine 6G causes a profound reduction in the 
number of intact mitochondria in the cell. Rhodamine 6G has been 
used in the study of mitochondrial DNA diseases, through the 
generation of cytoplasmic hybrid cells, cybrids. A cybrid is produced 
by the fusion cell with a cytoplast, an enucleated cell generated by 
centrifugation and disruption of the cytoskeleton. Treatment of 
primary patient fibroblasts with Rhodamine 6G to eliminate 
mitochondria enables endogenous mtDNA to be replaced with an 
alternative mitochondrial genome through cytoplast fusion (Trounce 
& Pinkert 2007; Williams et al. 1999),(Ziegler & Davidson 1981). 
However, short term culture of human skin fibroblasts with 
Rhodamine 6G showed that whilst mtDNA remained present, 
mtDNA-encoded polypeptides were not synthesised or were 
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unstable, suggesting that mtDNA damage precedes mitochondrial 
elimination (Williams et al. 1999).  The hypothesis for chapter one 
therefore was that Rhodamine 6G would trigger mitophagy using an 
alternative mechanism to CCCP, which would provide insight to the 
requirements of mitophagy. Understanding what is required to 
trigger mitophagy will contribute the main objective of this thesis, 
which is to identify whether the initiation of mitophagy is impaired in 
mtDNA disease. 
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1.2 Results 
1.2.1 Rhodamine 6G causes PINK1 stabilisation, Parkin 
translocation, and triggers mitophagy 
 
Using FLAG-Parkin overexpressing SH-SY5Y cells, Rhodamine 6G 
was found to cause significant PINK1 stabilisation in cell lysates at a 
dose of 2 µM for 1.5 hours (Figure 12 A,B). This was confirmed to 
occur at the mitochondria by the significant increase in PINK1 
detected at the same dose in enriched mitochondrial fractions by 
immunoblot analysis (Figure 12 C, D). Translocation of FLAG-
Parkin was identified by immunoblot analysis of enriched 
mitochondrial fractions and immunocytochemistry (Figure 13 A, B, 
E, G). Immunoblot analysis revealed striking degradation of 
mitofusin 1 occurring in Rhodamine 6G treated cells, to a similar 
extent as that seen in positive-control CCCP treated cells (Figure 13 
C, D). Colocalisation was found to occur between FLAG-Parkin and 
mitochondrial respiratory chain protein Complex V after 3 hours of 
Rhodamine 6G treatment when assessed by immunocytochemistry 
(Figure 13 E, G). After 6 hours of Rhodamine 6G exposure, 
significant p62 colocalisation with mitochondria was observed and 
subsequent reduction in mitochondrial proteins was quantified 
(Figure 13 F, H; Figure 14 A, B). Analysis of outer and inner 
mitochondrial membrane proteins confirmed a significant loss of 
mitochondria by both immunocytochemistry and immunoblotting 
(Figure 14). Between 6 and 16 hours, there was an increased loss 
of mitochondria in CCCP treated cells, however in Rhodamine 6G 
treated cells the mitochondria were depleted to a greater extent at 6 
hours compared to 16 hours. This finding suggests a different 
mechanism of action, by which Rhodamine 6G potentially 
possesses a shorter active timeframe or that the damage it exerts is 
more readily reversible compared to CCCP.  
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Figure 12: Rhodamine 6G induces PINK1 accumulation 
A Representative immunoblot showing PINK1 protein levels in FLAG-
Parkin-overexpressing SH-SY5Y cells. Cells were exposed to 2 µM, 1.5 µM 
or 1 µM Rhodamine 6G, or positive control 10 µM CCCP or negative control 
DMSO. B Histograms represent mean PINK1 protein levels, normalized to 
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loading control. Error bars represent SEM, two-tailed Student’s t-test * p < 
0.05, ** p < 0.01, n = 3. C Representative immunoblot showing the levels of 
PINK1 protein in enriched mitochondria from FLAG-Parkin-overexpressing 
SH-SY5Y cells. D Histogram to show quantification of PINK1 accumulation 
in enriched mitochondria. Error bars represent SEM, two-tailed Student t-
test ** p < 0.01, n = 3.  
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Figure 13: Rhodamine 6G stimulates Parkin translocation, p62 recruitment 
and the degradation of mitofusin 1 
A Representative immunoblot of Parkin protein levels obtained from 
enriched mitochondria from FLAG-Parkin overexpressing SH-SY5Y cells 
treated with DMSO, 10 µM CCCP or 2 µM R6G. B Quantification of Parkin 
protein levels obtained by Western blotting, histograms represent mean 
protein levels normalized to loading control and error bars represent SEM; 
two-tailed Student’s t-test * p < 0.05, n = 3. C Representative immunoblot 
showing mitofusin 1 levels in enriched mitochondria from FLAG-Parkin 
overexpressing SH-SY5Y cells treated with DMSO, 10 µM CCCP or 2 µM 
R6G. D Histogram indicates the mean protein levels of mitofusin 1, 
normalized to loading control. Error bars represent SEM, two-tailed 
Student’s t-test * p < 0.05, n = 3. E Representative images of FLAG-Parkin 
translocation to mitochondria in FLAG-Parkin overexpressing SH-SY5Y 
cells, indicated by white arrows. Green: FLAG, red: Complex V, blue: DAPI. 
F Representative images of p62 translocation to mitochondria in FLAG-
Parkin overexpressing SH-SY5Y cells, indicated by white arrows. Green: 
Tom20, red: p62, blue: DAPI. G Histogram represents the percentage of 
cells in which Parkin colocalises with mitochondria as determined by 
immunocytochemistry. Error bars represent SEM; two-tailed Student’s t-test 
** p < 0.01, n = 3 H Histogram represents the percentage of cells in which 
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p62 colocalises with mitochondria as determined by immunocytochemistry. 
Error bars represent SEM; two-tailed Student’s t-test ** p < 0.01, n = 3. 
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Figure 14: Rhodamine 6G induces mitophagy 
A Representative images of Tom20 protein expression in FLAG-Parkin 
overexpressing SH-SY5Y cells, showing a reduction in protein levels after 
stimulation with CCCP or Rhodamine 6G for 6 H. Green: Tom20, blue: DAPI; 
scale bar represents 20 µm. B Quantification of the mean Tom20 area per 
cell as assessed by immunofluorescence. Error bars represent SEM; two-
tailed Student’s t-test ** p < 0.01, *** p < 0.001, n = 3. C Representative 
immunoblot showing the levels of Tim23 protein in FLAG-Parkin 
overexpressing SH-SY5Y cells after 16 hours of treatment with 10 µM CCCP 
or 2 µM R6G. D Quantification of Tim23 protein levels, normalized to loading 
controls after 16 hours of treatment with 10 µM CCCP or 2 µM R6G. Error 
bars represent SEM; two-tailed Student’s t-test ** p < 0.01, **** p < 0.0001, n 
= 4. 
 
1.2.2 Ubiquitination of mitofusin 1 is PINK1/Parkin 
dependent 
 
Using human fibroblasts derived from Parkinson’s disease patients, 
it was possible to assess the dependency upon PINK1 and Parkin 
for mitofusin 1 ubiquitination. The mutations in these fibroblasts 
were PINK1 c.261_276del16; p.T90LfsX12 (homozygous) and 
Parkin R275W. PINK1 and Parkin mutation fibroblasts have been 
used previously to demonstrate the requirement of these proteins 
0.0 
20.0 
40.0 
60.0 
80.0 
100.0 
120.0 
Control CCCP Rhodamine 6G 
M
ea
n 
To
m
20
 a
re
a 
pe
r c
el
l, 
no
rm
al
is
ed
 to
 u
nt
re
at
ed
 
ce
lls
, a
fte
r 6
 H
 tr
ea
tm
en
t 
** 
*** 
B C 
Tim23 20 
40 β - Actin 
-         CCCP       R6G       
0 
20 
40 
60 
80 
100 
120 
Control CCCP Rhodamine 6G 
Ti
m
23
 d
en
si
to
m
et
ry
, a
rb
 u
ni
ts
 
** 
**** 
D 
 110 
for mitofusin 1 ubiquitination when treated with mitochondrial 
uncouplers (Rakovic et al. 2011). The data here confirm those 
findings and also show that mitofusin 1 ubiquitination induced by 
Rhodamine 6G is also dependent upon the presence of PINK1 and 
Parkin (Figure 15). 
 
 
 
Figure 15: Mitofusin 1 ubiquitination stimulated by Rhodamine 6G is 
dependent upon PINK1 and Parkin 
A Representative immunoblot showing mitofusin 1 protein and 
ubiquitinated mitofusin 1 protein in control and PINK1 homozygous mutant 
human fibroblasts (c.261_276del16) treated with DMSO, 10 µM CCCP or 2 
µM R6G, for 1.5 or 3 hours. B Representative immunoblot showing 
mitofusin 1 protein and ubiquitinated mitofusin 1 protein in control and 
Parkin homozygous mutant human fibroblasts (R275W) treated with DMSO, 
10 µM CCCP or 2 µM R6G, for 1.5 or 3 hours.  
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1.2.3 Rhodamine 6G does not induce membrane 
depolarisation, but PINK1 stabilisation is caused by 
oxidative stress 
 
Since Rhodamine 6G is a red dye, to assess membrane 
depolarisation Rhodamine 123 (a green dye) was used instead of 
the commonly used TMRM dye. After 1.5 hours incubation of 
Parkin-overexpressing SH-SY5Y cells with Rhodamine 6G, the 
mitochondrial membrane potential was found to be hyperpolarised 
and could be subsequently depolarised with CCCP (Figure 16 A, B). 
This finding suggests that PINK1 accumulation in Rhodamine 6G 
treated cells is independent on membrane depolarisation.  
 
Oxidative stress in cells is a balance between the production of 
reactive oxygen species and the presence of antioxidants. Reduced 
glutathione (GSH) is an abundant antioxidant, and levels can be 
measured using the dye monochlorobrimane (MCB). Using live cell 
imaging, Rhodamine 6G treated cells had a significantly lower MCB 
fluorescence, indication high oxidative stress, which could be 
restored by treatment in combination with N-acetyl-L-cysteine (NAC) 
(Figure 16 C). NAC is a precursor of GSH and therefore increases 
cellular levels of the antioxidant. Using the dose of NAC that 
restored MCB fluorescence, Western blot analysis showed that 
PINK1 accumulation induced by Rhodamine 6G was inhibited in the 
presence of NAC, suggesting that oxidative stress is the mechanism 
by which Rhodamine 6G stabilises PINK1 (Figure 16 D, E). 
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Figure 16: Rhodamine 6G does not depolarise the mitochondrial membrane 
but induces oxidative stress to cause PINK1 stabilisation 
A Histogram represents mean basal mitochondrial membrane potential, 
measured in FLAG-Parkin overexpressing SH-SY5Y cells loaded with 
Rhodamine 123. Cells were pre-treated for 1.5 hours with vehicle or 2 µM 
Rhodamine 6G. Error bars represent SEM; two-tailed Student’s t-test * p < 
0.05, n = 3. B Representative images of FLAG-Parkin overexpressing SH-
SY5Y cells loaded with Rhodamine 123 and treated as in A, then 10 µM 
CCCP was added to induce depolarization. Scale bars represent 20 µm. C 
Histogram to show the mean MCB fluorescence levels in live FLAG-Parkin 
overexpressing SH-SY5Y cells. Cells were pre-treated for 1.5 hours with 
vehicle or 2 µM Rhodamine 6G or 2 µM Rhodamine 6G with 20 mM NAC. 
Error bars represent SEM; two-tailed Student’s t-test *** p < 0.001, **** p < 
0.0001, n = 3. D Representative immunoblot of PINK1 protein levels in 
FLAG-Parkin overexpressing SH-SY5Y cells treated with just Rhodamine 6G 
for 1.5 or 24 hours, or in combination with 20 mM NAC. E Histogram to 
show quantification of PINK1 protein levels, normalized to loading control, 
in FLAG-Parkin overexpressing SH-SY5Y cells treated with just Rhodamine 
6G for 1.5 or 24 hours, or in combination with 20 mM NAC. Error bars 
represent SEM; two-tailed Student’s t-test * p < 0.05, n = 3. 
 
1.2.4 Deep-sequencing reveals mitochondrial DNA 
mutations are caused by Rhodamine 6G 
 
In order to identify whether Rhodamine 6G affected the 
mitochondrial genome, NGS was used to detect mutations caused 
by exposure to the compound. Parkin-overexpressing SH-SY5Y 
cells and human fibroblasts were treated with Rhodamine 6G, then 
the DNA extracted and sequenced to identify any changes in the 
mitochondrial genome. The sequences were aligned against the 
Cambridge Reference Sequence. Read-depth of the sequences 
varied between 200 and 10,000. After removing low quality reads, 
the variants were listed for each condition and the percentage of 
reads these variants occurred in calculated. After removing 
haplotype specific variants, homoplasmic variants that were present 
across cell types, the remaining variants were further sorted to 
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identify those that were not present in the untreated controls from 
each cell type. Figure 17 shows the gene in which a transition or 
deletion occurred under each condition caused by treatment with 
Rhodamine 6G (i.e. not showing those that occurred in control and 
Rhodamine-treated cells). The mutation frequency, i.e. the 
percentage of reads in which the mutation occurred, is represented 
by colour. 
 
Deep-sequencing of the mitochondrial genome showed that variants 
were present in the DNA of cells treated with Rhodamine 6G. Of the 
SH-SY5Y cells, 80% of variants occurring within the D-loop were 
transitions, and the remaining 20 % were deletions. Variants that 
occurred elsewhere in SH-SY5Y cells were all deletions. Although 
these mutations occurred at a low frequency, the time scale at 
which these are found suggests that treatment with Rhodamine 6G 
increases the susceptibility of mtDNA to damage. The mechanism 
by which this occurs remains unknown. 
 
Cell type 
Parkin-o/e 
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Parkin-o/e 
SH-SY5Y 
Fibroblast Fibroblast 
Length of 
treatment with 
Rhodamine 
6G 
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RNR2 ND2 DLOOP5 DLOOP5 
 
COX1 COX1 DLOOP5 ND2 
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DLOOP3 ND3 ND4 
< 2 % 
 
DLOOP3 DLOOP5 DLOOP3 
< 3 % 
 
DLOOP3 DLOOP5 
 
< 4 % 
 
DLOOP3 
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Figure 17: Rhodamine 6G induces mutations in the mitochondrial genome 
2 µM Rhodamine 6G was added to FLAG-Parkin overexpressing SH-SY5Y 
cells and control human fibroblasts for 1.5 H, 14 H or 24 H as stated. The 
DNA of cells was extracted and sequenced using NGS on the Illumina 
MiSeq. Here shows the position of mutations detected that were not present 
in control cells and the colour represents the mutation frequency in all the 
reads obtained (approximately 10,000 reads per base). Each lane 
corresponds to a different mutation, which are specified in the appendix. 
 
 
 
 
1.2.5 PINK1-dependent mitofusin 1 ubiquitination can be 
detected in human fibroblasts, but not PINK1-dependent 
mitophagy 
 
Treatment of healthy control fibroblasts for 16 hours with 10 µM 
CCCP revealed a striking loss of complex V signal, suggestive of 
mitophagy (Figure 18 A). However, performing this experiment in 
parallel with PINK1 mutant fibroblasts showed that this effect is not 
PINK1-dependent (Figure 18 A). This data suggests that PINK1-
dependent mitophagy cannot be induced by 16 hours of 10 µM 
CCCP treatment. After 1.5 hours of 10 µM CCCP treatment 
however, PINK1-dependent mitofusin 1 ubiquitination can be 
identified (Figure 18 B). Whether the loss of mitochondria observed 
at 16 hours by immunocytochemistry is mitophagy or an artefact 
remains to be determined. 
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Figure 18: PINK1-dependent mitophagy cannot be detected in fibroblasts 
A Representative images of fixed control and PINK1 mutant fibroblasts 
stained with Complex V and treated with DMSO or 10 µM CCCP for 16 H. 
Red: Complex V, blue: DAPI. B Representative immunoblot showing 
mitofusin 1 in control and PINK1 mutant fibroblasts treated with DMSO or 
10 µM CCCP for 1.5 H. 
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1.2.6 Complex V mitochondrial staining is loss first upon 
induction of mitophagy in non Parkin-overexpressing cell 
systems 
 
Identification of the loss of complex V signal in fibroblasts seen in 
figure 18 was particularly interesting since it has been reported that 
mitophagy cannot be detected in fibroblasts (Rakovic et al. 2013). 
This experiment was repeated in control fibroblasts but using 
several mitochondrial protein markers to measure mitophagy. It was 
found using analysis of Tom20 (OMM protein), Tim23 (IMM protein) 
and Hsp60 (matrix protein) that the loss of signal was limited to 
Complex V (Figure 19 A, B). Furthermore, the same effect was seen 
in control and PINK1 mutant fibroblasts (Figure 19 B). Immunoblot 
analysis revealed no loss of any mitochondrial proteins in the 
presence of CCCP, revealing discrepancies between results 
obtained from immunocytochemistry and Western blotting.  
 
The fibroblasts used in these experiments contain only endogenous 
Parkin; therefore SH-SY5Y cells were employed to investigate any 
differences between systems containing endogenous and 
overexpressed Parkin. Treatment of Parkin-overexpressing SH-
SY5Y cells with DMSO or 10 µM CCCP for 12 and 24 hours showed 
a decrease in both Complex V and Tom20 mitochondrial markers 
(as detected by immunocytochemistry) at a similar rate and at the 
24 hour timepoint both were nearly completely lost (Figure 19 E). 
However, analysis by immunocytochemistry of wild-type SH-SY5Y 
cells treated with DMSO or 10 µM CCCP for 12 hours showed a 
loss of complex V signal but not Tom20, as had been observed in 
the fibroblasts (Figure 19 F). 
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Figure 19: Differences in the loss of mitochondrial proteins in non over-
expressing Parkin systems 
A Representative images of fixed control fibroblasts treated with DMSO or 
10 µM CCCP for 16 H. Red: Complex V, green: Tom20, blue: DAPI. B 
Quantification of mitochondrial protein area as determined by different 
mitochondrial markers (Tom20, Complex V, Tim23 and HSP60) in control 
and PINK1 mutant fibroblasts. Histograms represent the mean % change in 
area per cell between untreated control fibroblasts and control fibroblasts 
treated with 10 µM CCCP for 16 H. Dotted line indicates no change, error 
bars represent SEM, n = 3. C Representative immunoblots showing protein 
levels of mitochondrial proteins (Complex V, Tim23 and Tom20) of control 
or PINK1 mutant fibroblasts with and without 16 H of 10 µM CCCP. D 
Quantification of Western blots from E, normalised to loading control. 
Histograms represent mean densitometry, error bars represent SEM and 
dotted line indicates no change, n = 3. E Representative images of FLAG-
Parkin overexpressing SH-SY5Y cells treated with DMSO, 12 H 10 µM CCCP 
or 24 H 10 µM CCCP. Fixed cells were stained with Tom 20 (green) or 
Tom 20 Complex V 
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Complex V (red). F Representative images of wild type SH-SY5Y cells (not 
Parkin overexpressing) treated with DMSO or 10 µM CCCP for 12 H. Fixed 
cells were stained with Tom20 (green) or Complex V (red). 
 
1.3 Discussion 
 
1.3.1 Key findings in the mitophagy pathway 
 
As previously described, the short-term treatment of human 
fibroblasts with Rhodamine 6G causes inhibition of mtDNA-encoded 
polypeptides synthesis and reduces their stability (Williams et al. 
1999). Treatment of Parkin-overexpressing SH-SY5Y cells, a 
commonly used system for the study of mitophagy, with Rhodamine 
6G was found to cause the stabilisation of PINK1 and translocation 
of Parkin from the cytosol to the mitochondria. Downstream of this, 
p62 was found to colocalise with mitochondria indicating the 
recruitment of autophagic machinery and in line with this, a 
reduction in the area of mitochondria was observed.  
 
Human fibroblasts obtained from patients with inherited Parkinson’s 
disease caused by PINK1 and Parkin mutations were used in an 
assay to identify whether the effect of Rhodamine 6G is 
PINK1/Parkin-dependent. In the current model of the mitophagy 
pathway, the ubiquitination of outer mitochondrial proteins is 
understood to be caused by PINK1 and Parkin phosphorylation, 
therefore the presence of mitofusin 1 ubiquitination in PINK1 and 
Parkin mutant cells would indicate a PINK1/Parkin independent 
pathway (Lazarou et al. 2015). Here it was shown that Rhodamine 
6G did not stimulate mitofusin ubiquitination in the PINK1 or Parkin 
mutant cells, suggesting that these proteins are necessary for 
Rhodamine 6G to exert it’s effect.  
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The finding that Rhodamine 6G, like CCCP, required the presence 
of PINK1 and Parkin, suggested a similar mechanism of action 
between the two compounds. However, further investigation 
demonstrated that unlike CCCP, Rhodamine 6G did not induce the 
loss of mitochondrial membrane potential. Instead, the membrane 
was found to be hyperpolarised following treatment of Parkin-
overexpressing cells with Rhodamine 6G.  
 
Two subsequent findings suggested potential triggers of the 
mitophagy process caused by Rhodamine 6G. Firstly, Rhodamine 
6G appeared to cause an increase in oxidative stress, which when 
inhibited with a precursor of reduced glutathione, did not cause 
long-term PINK1 stabilisation. In these experiments, the blue 
fluorescent dye monochlorobrimane was used to assess the cellular 
levels of GSH, and it was found that after the same dose of 
Rhodamine 6G that triggered the mitophagy process, levels of GSH 
were significantly reduced. Secondly, deep sequencing of the 
mitochondrial genome revealed that at this same timepoint low level 
mitochondrial DNA mutations were present in the Rhodamine 6G 
treated cells. With longer exposure these mutations increased in 
both location and frequency, and as expected, the D-loop was the 
most commonly affected area. The same effect was seen in two 
healthy control fibroblast lines treated with Rhodamine 6G. 
 
These experiments using Rhodamine 6G demonstrate that PINK1-
dependent mitophagy can be induced by oxidative stress 
independently of mitochondrial depolarisation. The mechanism of 
PINK1 stabilisation without loss of mitochondrial membrane 
potential is unknown but importantly it challenges the current model 
of mitophagy induction.  
 
In addition to this, experiments using the known mitochondrial 
uncoupler CCCP in numerous cell lines, highlighted important 
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differences in the loss of mitochondrial proteins for the 
measurement of mitophagy. These experiments among others have 
shown that fibroblasts do not undergo complete mitophagy, 
however PINK1/Parkin-dependent ubiquitination of mitofusins can 
be induced (Rakovic et al. 2011; Rakovic, Shurkewitsch, Seibler, 
Grunewald, et al. 2013). Nevertheless, stimulation using CCCP 
caused the loss of mitochondrial protein Complex V (antibody 
against ATP-β) when assessed by immunocytochemistry. This 
effect appeared to be independent of PINK1, occurring in fibroblasts 
and wild-type SH-SY5Y cells, but not detectable in Parkin-
overexpressing SH-SY5Y cells presumably because loss of other 
mitochondrial proteins also happens rapidly. Interestingly, the effect 
was only detectable by immunocytochemistry but not by Western 
blotting, which may suggest that the signal is lost due to a 
conformational change as opposed to the loss of mitochondrial 
protein. The effect was not seen in Tim23, another inner 
mitochondrial membrane protein, or the matrix protein HSP60. 
 
1.3.2 Mitochondrial membrane depolarisation-independent 
mitophagy 
 
As described in the mitophagy section of the introduction, under 
basal conditions PINK1 is understood to be imported from the 
cytosol into the mitochondria via the translocase of the outer 
mitochondrial membrane. PINK1 is undetectable under these 
conditions since it undergoes degradation by Rhomboid-
7/Presenilin-associated rhomboid-like protein and Lon (Thomas et 
al. 2014; Whitworth et al. 2008; Jin et al. 2010). Loss of 
mitochondrial membrane potential has been shown to prevent the 
import of PINK1 through the translocase of the inner mitochondrial 
membrane, causing it to become stabilised on the outer membrane 
(Jin et al. 2010). Mitochondrial membrane potential is believed to be 
the critical element determining whether a daughter mitochondrion 
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re-joins the mitochondrial network or whether it is singularly left to 
be degraded by mitophagy (Twig, Elorza, Anthony J A Molina, et al. 
2008a; Horbay & Bilyy 2016). The significant accumulation of PINK1 
at the mitochondria, stimulated by Rhodamine 6G independently of 
membrane depolarisation, therefore suggests an alternative 
mechanism by which PINK1 import is prevented. 
 
This data is not the first to question the standard model of 
membrane depolarisation causing PINK1 accumulation, which 
subsequently triggers mitophagy. Both carbonyl cyanide m-
chlorophenyl hydrazine (CCCP) and carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) are known to cause 
uncoupling of the proton gradient established across the inner 
mitochondrial membrane and thereby cause membrane 
depolarisation (Heytler & Prichard 1962). Whilst a low concentration 
of FCCP can cause a complete loss of membrane potential, this 
does not cause the induction of mitophagy even in a Parkin-
overexpressing system (Berezhnov et al. 2016). A dose of ten times 
the amount required to cause membrane depolarisation was 
sufficient to induce PINK1 stabilisation, Parkin translocation and 
downstream mitophagy. In this study, it was suggested that 
intracellular pH was the regulator of mitophagy, stimulated by FCCP 
through acidification of the cytosol (Berezhnov et al. 2016). 
 
Alternatively to the use of CCCP, the combination of oligomycin and 
antimycin A has been shown to stimulate loss of membrane 
potential and trigger significant Parkin translocation from the cytosol 
to the mitochondria (Vives-Bauza, Zhou, Huang, Cui, Rosa L A de 
Vries, et al. 2010). However, whilst treatment with antimycin A alone 
causes inhibition of complex III and subsequent loss of membrane 
potential, it is unable to stimulate the mitophagy pathway (Rego et 
al. 2001; Vives-Bauza, Zhou, Huang, Cui, Rosa L A de Vries, et al. 
2010; Allen et al. 2013). This effect was studied in both a model of 
Parkin-independent mitophagy and Parkin-dependent mitophagy. 
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Interestingly, using the Parkin-independent system to study 
mitophagy, it was shown that treatment of cells with oligomycin 
alone caused a significant increase in the delivery of mitochondria 
to lysosomes, despite the absence of membrane potential 
depolarisation (Allen et al. 2013). However until the data produced 
here, mitophagy in the absence of membrane depolarisation had 
not been shown in a seemingly PINK1/Parkin-dependent system. 
Whilst it remains unknown whether PINK1 accumulates in the 
presence of Rhodamine 6G due to the prevention of PINK1 import 
across the IMM or if PINK1 is simply no longer degraded, these 
data raise the possibility of an alternative mechanism of PINK1-
dependent mitophagy induction. 
 
1.3.3 Oxidative stress and mitochondrial DNA mutations 
as an inducer of mitophagy 
 
Using fluorescent dye to measurement intracellular reduced 
glutathione levels and cotreatment with NAC to restore antioxidant 
levels, it was found that Rhodamine 6G causes oxidative stress to 
cells. This amount of oxidative stress was not sufficient to cause 
depolarisation of the mitochondrial membrane potential, however 
the use of NAC demonstrated that PINK1 accumulation was 
dependent upon depletion of reduced glutathione caused by 
Rhodamine 6G.  
 
Interestingly, it has been shown previously that mitophagy can be 
stimulated through exposure to mild oxidative stress to a greater 
extent than through exposure to transient oxidative stress. This was 
demonstrated by the use of H2O2 to cause mild oxidative stress and 
starvation to simulate transient oxidative stress (Frank et al. 2012). 
Moreover, mild stress has also been associated with the formation 
of mitochondrial-derived vesicles (MDVs), the mechanism by which 
impaired mitochondrial components are transported to endosomes 
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or peroxisomes for degradation (Soubannier, G.-L. McLelland, et al. 
2012). Study of the content of MDVs revealed a, enrichment of 
oxidised protein, suggesting a triggering of this quality control 
process upon exposure to oxidative stress. 
 
Mitochondrial DNA mutations have also been associated with 
mitophagy in a study whereby mtDNA mutations appeared to be 
selectively removed upon overexpression of Parkin in heteroplasmic 
cybrid cells, suggesting that mitochondrial DNA mutations 
stimulated the mitophagy process (Suen et al. 2010). It has been 
suggested that under mild oxidative stress, or indeed the presence 
of low level mtDNA mutations, mitophagy may be triggered as a 
mechanism of damage limitation to prevent unnecessary stimulation 
of autophagy (Scherz-Shouval & Elazar 2011). The data shown 
here through the use of Rhodamine 6G presents an example of 
mitochondrial damage caused by mild oxidative stress and mtDNA 
mutations, that is sufficient to cause PINK1 accumulation and 
downstream processes, but does not cause uncoupling of the IMM 
proton gradient. 
 
1.3.4 Detecting mitophagy: what causes loss of Complex 
V signal in immunocytochemistry? 
 
Finding reliable and sensitive methods to measure mitophagic 
levels are critically important for the understanding of mitophagy 
and also for use in drug screens. 
 
Mitophagy is commonly quantified by the loss of mitochondrial 
protein expression, either by immunocytochemistry or 
immunoblotting. Whilst this technique cannot distinguish between 
mitophagy and other degradation processes or the stimulation of 
biogenesis, it is often used in combination with the assessment of 
mitophagy-associated proteins such as PINK1 and Parkin. 
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Furthermore, in Parkin-overexpression systems, the complete loss 
of mitochondrial proteins can be detected within 24 hours of 
mitochondrial uncoupling; therefore it is believed that mitophagy 
occurs rapidly enough for the lack of distinction from other 
processes to not be a problem. Nevertheless, it is of particular 
importance that the levels of numerous mitochondrial proteins are 
measured as highlighted in the results shown in this chapter.  
 
It is known that different mitochondrial proteins, even proteins that 
make up the same respiratory complex, can be degraded at 
different rates (Hare & Hodges 1982). Furthermore, mitochondrial 
proteins in the intermembrane space have been shown to be 
released following permeability transition, and therefore should not 
be measured alone in assessment of mitophagy (Scarlett & Murphy 
1997). In these experiments it was found that Complex V signal was 
rapidly lost in CCCP-treated fibroblasts and SH-SY5Y cells 
independently of PINK1 as measured by immunocytochemistry.  
 
These experiments gave rise to four important findings: 1. Of the 
mitochondrial proteins measured, from four different compartments 
in the mitochondria, Complex V signal only was lost following 
mitochondrial uncoupling 2. This finding was not emulated in 
experiments using immunoblotting 3. The finding was the same in 
control and PINK1 mutant fibroblasts, suggesting it is a PINK1-
independent mechanism 4. The finding was undetectable in Parkin-
overexpressing cells. 
 
The discrepancies between immunostaining and immunoblotting are 
suggestive of a conformational change being the cause of signal 
loss, since this would not be detectable in the Western blot results. 
The antibody used was an Abcam monoclonal mouse antibody to 
the complex V beta subunit (ATPβ). If was of particular interest to 
find another antibody to this subunit at a different epitope to see 
whether the same effect was found, however upon contacting the 
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manufacturer, we were informed that the epitope had not been 
mapped. 
 
The observation that loss of Complex V staining was not detectable 
in Parkin-overexpressing cells adds to the growing hypothesis that 
Parkin acts as an amplifier of the mitophagy process (Lazarou et al. 
2015). It is likely that the substantial overexpression of Parkin in the 
SH-SY5Y cells caused rapid loss of all mitochondrial proteins, so all 
mitochondrial protein signals were lost together.  
 
1.3.5 Future perspectives 
 
The experiments in this chapter aimed to aid understanding of the 
requirements for mitophagy induction and to investigate the 
assessment of mitophagy in several cell types.  
 
It has been demonstrated here that PINK1-dependent mitophagy 
can be induced independently of membrane depolarisation, 
however the mechanism of this remains unknown. Of particular 
interest would be to identify whether PINK1 is imported across the 
inner mitochondrial membrane in Rhodamine 6G, as PINK1 was 
thought to accumulation due to lack of import through TIM after loss 
of membrane potential.  
 
These experiments have highlighted discrepancies in commonly 
performed experiments which can lead to false mitophagy data if 
not verified with more than one technique. For future experiments it 
would be particularly interesting to assess the timecourse of 
Complex V immunostaining to see when it is lost and also whether it 
returns after mitochondrial turnover. Further analysis is required to 
confirm whether this indeed is a conformational change. 
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Chapter 2  
Fibroblast models of mtDNA 
disease and novel phenotypic 
findings 
 
2.1 Introduction 
2.1.1 Models of primary mtDNA disease 
 
Creating suitable models of mtDNA disease is challenging, 
particularly due to the clinical variability a single mutation can 
cause.  
 
Cytoplasmic hybrid (cybrid) cell models have been used in 
mitochondrial disease research for the characterisation of 
unsequenced mtDNA mutations, studying different heteroplasmic 
burdens of known mtDNA mutations, or for studying bigenomic 
(nuclear and mitochondrial DNA) compatibility (Khan et al. 2007). 
The cybrid technique utilises ρ0 cell lines, which are generated by 
first causing termination of mtDNA replication (Wilkins et al. 2014). 
Through subsequent rounds of cell division, the mtDNA pool will 
become ‘diluted’ until some cells contain no mtDNA, termed ρ0 
cells. These cells can then be isolated and for use in creating ρ0 cell 
lines. To create a cybrid, ρ0 cells are fused with cytoplasts, which 
are enucleated cells derived from patient cell lines (King & Attardi 
1989). 
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Cybrids cell lines have been of valuable use for studies investigating 
interactions between the nucleus and mitochondria, as well as the 
effect of mutant load on cellular function (figure 20). However, 
cybrid models have limitations to their use; for example, the 
generation of cybrids most often involves tumour cells, which are 
known to be glycolytic (depend on glycolysis for ATP production) 
and therefore are not metabolically similar to those cell types most 
often affected in mtDNA disorders. This may account for 
discrepancies reported between cybrid models and clinical 
phenotypes; for example a homoplasmic MTTV mutation that 
causes fatal metabolic defects in cardiac and skeletal muscle lacked 
any respiratory defect in the cybrid model (Rorbach et al. 2008).  
 
 
Figure 20 Schematic of the generation and use of cybrids for modelling 
mtDNA disease 
A. Blue mitochondria represent mitochondria containing wild-type mtDNA, 
green mitochondria represent mitochondria containing mutant mtDNA, N = 
nucleus. B Blue mitochondria represent mitochondria belonging to patient 
N 
N 
N 
N 
N 
N 
N 
N 
+ 
+ 
+ 
Heteroplasmic mtDNA 
Patient 1 mtDNA 
Patient 2 mtDNA 
ρ0 cell 
ρ0 cell 
ρ0 cell 
A. Study of mtDNA mutation at different mutant loads 
B. Study of different mtDNA mutations in same nuclear background 
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1, green mitochondria represent mitochondria belonging to patient 2, N = 
nucleus. Adapted from Wilkins et al., 2014. 
 
 
A naturally occurring animal model was identified in golden retriever 
dogs, which presents as a sensory ataxic neuropathy and is 
maternally inherited (Baranowska et al. 2009). The causative 
mutation was found to be a single base pair deletion in the 
mitochondrial tRNA tyrosine gene at position 5304. Similarly to 
human pathology, affected dogs exhibited reduced ATP production 
and respiratory chain enzyme function, and muscle biopsy indicated 
lowered cytochrome c oxidase (COX) activity, although no ‘ragged 
red fibers’ were found. The corresponding mutation site in the 
human mtDNA genome has not currently been associated with a 
mitochondrial disorder in humans, nor have similar phenotypes to 
those reported in dogs been reported in other mutations occurring in 
the human tRNA tyrosine gene. Nevertheless, a naturally occurring 
animal model would enable the inheritance of the pathogenic 
mutation to be studied and therefore may be of use in the 
development of treatments for the disease.  
 
Patient fibroblasts as models of disease have many advantages. 
Fibroblasts are obtained by carrying out a simple skin biopsy, which 
is a safe procedure that does not require stitches. Experimentally, 
fibroblasts are simple to culture and have been extensively used for 
studying mitochondria, especially in the field of Parkinson’s disease 
(Burbulla & Krüger 2012). Fibroblasts can be used in biochemistry 
experiments, immunocytochemistry and live cell imaging, making 
them a suitable cell type for many experiments.  
 
However, fibroblasts do have some limitations; for example, 
experimentally fibroblasts are difficult to transfect using common 
transfection reagents, and their protein content is low, meaning 
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biochemistry experiments require large quantities of cells. 
Furthermore, unlike cell types most affected in mtDNA disease, 
fibroblasts are glycolytic, therefore the phenotypic effect of the 
mutation may not be detected (Ghesquière et al. 2014). 
Nevertheless, fibroblast models have been of use in 
pharmacological screens, as described in section 2.1.2. 
 
2.1.2 Examples of uses of mtDNA disease fibroblast 
models 
 
Mitochondrial encephalo-myopathy, lactic acidosis and stroke-like 
symptoms (MELAS) syndrome is a common mitochondrial disorder, 
most often associated with point mutations in tRNA genes. 
Fibroblasts derived from patients harbouring the m.3243A>G were 
previously characterised as having decreased mitochondrial 
membrane potential and significantly impaired coenzyme Q10 levels 
and respiratory chain enzyme activity (Cotán et al. 2011). These 
fibroblasts were subsequently used in a pharmacological screen to 
identify that supplementation with coenzyme Q10 or riboflavin could 
improve the phenotype of the MELAS fibroblasts (Garrido-Maraver 
et al. 2012). There have been reports of both these compounds 
being of benefit to some patients, though not all and rigorous 
conclusive trials have not been conducted, however coenzyme Q10 
is very commonly used due to its good safety report, even at high 
doses (DiMauro & Rustin 2009; Haack et al. 2010; Ghezzi et al. 
2010). 
 
Studies into the effect of dietary manipulations on mtDNA disease 
has been investigated using fibroblasts with complex I deficiency 
derived from patients harbouring NDUFS1 mutations. In this study, 
a high fat diet was found to increase respiratory chain activity in the 
patient fibroblasts, and subsequent experiments found that disease 
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progression was significantly slowed in the complex I deficient 
Harlequin mice (Schiff et al. 2011).  
 
These examples, among others, show that fibroblast models can be 
good indicators before use of in vivo models (Viscomi et al. 2015). 
 
2.1.3 Therapeutic strategies for mtDNA disease and 
targeting heteroplasmy 
 
One of the many challenges of mitochondrial disease is the 
significant variation in clinical phenotype. Patients can present with 
a vast range of features, involving different organs types with 
varying severity. From a treatment point of view, therapy is currently 
limited to addressing the various symptoms of the disease but there 
is no cure for the cause of the disease. Patient heterogeneity 
causes difficulty not just in treatment itself, but also the ability to 
conduct clinical trials (Pfeffer et al. 2012). Mitochondrial diseases 
are rare in general, but together finding sufficient numbers of 
available patients who present with similar phenotypes or genotypes 
can be difficult. As a result, approaches in developing treatments for 
these diseases are focused on more general interventions that may 
alleviate a range of symptoms as opposed to targeting a particular 
genotype/phenotype (Lightowlers et al. 2015).  
 
Among others, potential therapeutic avenues for mtDNA diseases 
include restoration of metabolic function, mitochondrial replacement, 
scavenging excessive reactive oxygen species, and eliminating 
pathogenic mtDNA (Lightowlers et al. 2015). MtDNA disease can 
cause mitochondrial dysfunction that may be relieved by increasing 
mitochondrial mass, i.e. a greater number of partially functioning 
mitochondria may be the equivalent of fewer functioning 
mitochondria. As a result, targeting mitochondrial biogenesis is a 
potential therapeutic strategy. Mitochondrial replacement 
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approaches aim to prevent the transmission of maternal 
transmission of mtDNA mutations to offspring. It has been shown in 
vitro that transferring patient zygote, with male and female 
pronuclei, into a donor fertilised oocyte, with male and female 
pronculei removed, can successfully develop into a blastocyte, 
enabling no transfer of disease from mother to child (Craven et al. 
2010). In an iPSC model of Leber’s hereditary optic neuropathy, 
cybrid technology was used to generate isogenic iPSC controls by 
replacing mutant mtDNA with wild-type mtDNA (Wong et al. 2017). 
However, replacement therapy is limited in its use for all mtDNA 
disease cases, and is not widely available.  
 
Common to all mtDNA diseases is the occurrence of heteroplasmy: 
the coexistence of mutated mtDNA with wild-type mtDNA. As the 
mutant load increases, so does the biogenetic defect, leading to 
more severe phenotypes. In cases of heteroplasmy, the mutation is 
most often recessive, meaning that below a certain threshold 
(normally around 60% mutant load) the patient will experience no 
apparent dysfunction. Whilst different tissues will have different 
thresholds and varying clinical impact, it stands to reason that 
lowering heteroplasmy to below the threshold level may be as 
effective as elimination of mutant mtDNA altogether. 
 
Numerous methods to reduce mutant load have been explored, 
such as engineered transcription activator-like effector nucleases 
(TALENs), which have been used to reduce the abundance of 
mtDNA containing a common deletion, by cleaving the breakpoint 
region of mutant mtDNA (Bacman et al. 2013). However, whilst 
targeting mutant mtDNA amongst the wild-type mtDNA to reduce 
mutant load appears a promising potential therapy, it remains 
unknown as to why high mutant loads can be maintained when the 
mitochondrial network constantly undergoes quality assurance 
processes such as mitochondrial dynamics (fission and fusion) and 
mitophagy.  
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Mitophagy selectively targets energetically compromised 
mitochondria for degradation, and it has been shown that Parkin is a 
modulator of heteroplasmy in models using heteroplasmic cybrid 
cells and C. elegans (Suen et al. 2010; Valenci et al. 2015). 
Consequently, in cases of heteroplasmic mtDNA disease, it remains 
unknown whether under physiological conditions, selective 
mitophagy is ineffective at controlling mutant load, or whether this 
process is impaired. Either way, correction or enhancement of this 
process presents as a potential therapeutic strategy for these 
diseases. 
 
2.1.4 Mitophagy in mtDNA disease 
 
MtDNA diseases are maternally inherited, and whilst the 
mechanism is not completely understood, studies in C. elegans 
have shown that the removal of paternal mtDNA is thought to occur 
via mitophagy in the early embryo (Al Rawi et al. 2011; Sato & Sato 
2011). A recent study in mouse fibroblasts showed that paternal 
mitochondria loses mitochondrial membrane potential and that 
when embryos were injected with lentivirus expressing shRNA 
against PINK1 there was a significant increase in the persistence of 
paternal mtDNA (Rojansky et al. 2016). This data suggests that 
mitochondrial membrane depolarisation triggers PINK1-dependent 
mitophagy to eliminate paternal mtDNA. When shRNA against 
Parkin alone was injected into the embryos, the increase in paternal 
mtDNA was modest and not found to be significant, which 
corresponds with more recent mitophagy research suggesting that 
Parkin is an amplifier of the process but not essential (Lazarou et al. 
2015; Rojansky et al. 2016).  
 
Elimination of paternal mtDNA is stable, and therefore utilising 
mitophagy for the removal of pathogenic mitochondria for therapy in 
several disease areas is an appealing target. As described briefly in 
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section 2.1.3, studies in heteroplasmic cybrid cells showed that 
overexpression of Parkin could stably maintain a favourable wild-
type to mutant mitochondrial genome ratio (Suen et al. 2010). In 
these experiments, a mutation in the cytochrome c oxidase subunit I 
gene (COXICA65) caused a reduction in mitochondrial membrane 
potential but interestingly, there was no significant difference in the 
percentage of cells with Parkin located on the mitochondria between 
the COXICA65 mutant and wild-type cell lines (Suen et al. 2010). 
Overexpression of Parkin for several weeks caused a reduction in 
the presence of mutant mtDNA, suggesting that those mitochondria 
containing high levels of COXI mutant were selectively eliminated 
via mitophagy. Together with a favourable change in mutant load, 
activity of cytochrome c oxidase which had been on average 4.6% 
of wild-type cell lines, was restored to 96.9% (Suen et al. 2010). 
 
Mitophagy in fibroblasts harbouring the m.3243A>G mutation has 
previously been studied using an IN Cell 1000 analyser (Diot et al. 
2015). This technique was used to report the colocalisation of LC3-II 
positive autophagosomes with mitochondria, which was found to be 
increased in the heteroplasmic m.3243A>G patient compared to 
control, suggesting increased basal mitophagy (Diot et al. 2015). 
However, it was not reported whether the colocalisation observed 
was specific to mutant mitochondria, i.e. whether this effect was 
caused by a recruitment of autophagic machinery or if PINK1/Parkin 
machinery is selectively stimulating mitophagy in these mutants. If 
the latter is true, it is surprising that the presence of pathogenic 
mitochondria is maintained in cells over-stimulating the selective 
process of mitophagy. Whilst mitophagy is of interest in mtDNA 
disease research, the selective nature of this process is seldom 
investigated in great depth, and it remains unknown whether in 
patient cells PINK1/Parkin machinery is capable of selectively 
removing the pathogenic mitochondria.  
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2.1.5 Aims and hypothesis 
 
In this chapter the aim was to investigate characteristics of patient 
fibroblasts harbouring several different mtDNA mutations, affecting 
respiratory complexes or tRNA genes. In particular, the objective 
was to investigate the mitophagic machinery in these patient lines, 
studying endogenous expression of PINK1 and Parkin, 
ubiquitination of mitofusins and biogenesis. The hypothesis was that 
for mtDNA mutants to persist at a pathogenic load, selective 
mitophagy might be impaired in these patient cells. The studies that 
demonstrate that Parkin can positively regulate heteroplasmy give 
evidence to suggest that selective mitophagy should be able to 
remove mitochondria when a high mutant load is causing a 
pathogenic phenotype (Suen et al. 2010; Valenci et al. 2015). 
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2.2 Results 
 
2.2.1 Clinical description of patients with primary 
mitochondrial disease 
Patient 1 (P1): ND5 mutation 
Patient 1 had an A>G missense mutation in the complex I ND5 
gene, which presented as a MELAS (mitochondrial encephalopathy, 
lactic acidosis, stroke-like episodes) phenotype.  
 
Patient 2 (P2): tRNA leucine mutation 
Patient 2 had a heteroplasmic A>G point mutation in the mt-tRNA 
leucine gene. This m.3243A>G substitution in a highly conserved 
region of the tRNA(Leu) gene is the most common pathogenic 
mitochondrial DNA mutation, and is invariably heteroplasmic (de 
Laat et al. 2013; (Ng et al. 2015). It has been shown that this 
mutation causes a severe impairment of 16S rRNA transcription 
termination, which results in highly variable phenotypic 
characteristics (Tuppen et al. 2010; Hess et al. 1991). In this case 
the patient presented with a mixed MELAS/MERFF (myoclonic 
epilepsy with ragged-red fibers). 
 
Patient 3 (P3): tRNA lysine mutation 
Another common pathogenic mitochondrial DNA mutation is the 
A>G missense mutation found in the mt-tRNA lysine gene. This 
patient had a reported mutant load of 82% and presented as a 
MERFF phenotype, which is atypical for this genotype (Mancuso et 
al. 2014). 
 
Patient 4 (P4): tRNA lysine mutation 
Patient 4 was a relative of patient 3, and also had the A>G 
missense mutation in the mt-tRNA lysine gene. Patient 4 had a 
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mutant load of 44% which did not appear to cause a pathogenic 
phenotype.  
 
Patient 5 (P5): tRNA serine mutation 
Patient 5 presented with a phenotype of ataxia, myoclonus and 
deafness, caused by an insertion in the mt-tRNA serine gene. This 
m.7472insC mutation has been reported in several families to be a 
significant cause of hearing loss, and in some individuals with high 
mutation load levels neurological features, such as ataxia and 
myoclonus, are also reported (Hutchin et al. 2001; Jaksch et al. 
1998; Tiranti et al. 1995) 
 
Patient 6 (P6): tRNA serine mutation 
Patient 6 was a relative of patient 5, who also harboured the 
m.7472insC and presented with a phenotype of ataxia, myoclonus 
and deafness. 
 
Patient 7 (P7): ATP6 mutation 
Patient 7 had a mutation affecting a specific respiratory chain 
complex, caused by a homoplasmic missense mutation in mt-ATP6 
encoding the ATP6 subunit of the mitochondrial ATP synthase 
(OXPHOS complex V). This patient is part of an extended family, 
which was published reporting mt-ATP6 mutations as a previously 
unrecognised cause of isolated Charcot-Marie-Tooth (CMT) disease 
and distal hereditary motor neuropathy (dHMN) (Pitceathly et al. 
2012).  
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Table 15 Clinical Information reported on mtDNA disease patients whose 
fibroblasts were used in this study.  
The information in the tables shows clinical data obtained at the National 
Hospital for Neurology and Neurosurgery UCL, and Queen Square Centre 
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for Neuromuscular Diseases. M = muscle, b = blood and u = urine. n/a 
indicates where data was not collected or not present in patient notes. 
* Mild reduction complex IV (0.013 n.v. 0.014-o.034) 
 
2.2.2 Maintenance of mitochondrial membrane potential in 
cultured mtDNA disease fibroblasts 
 
The charge across the inner mitochondrial membrane (IMM) is 
generated by the reductive transfer of electrons across the electron 
transport chain (ETC). This charge gradient provides the energy for 
protons to cross the IMM against their concentration gradient, 
causing a net accumulation of protons to occur on the outer side of 
the IMM. Both the electrical gradient and mitochondrial pH gradient 
that has been created can then then drive protons back across the 
IMM (into the mitochondrial cytoplasm) through the ATP synthase 
(complex V of the ETC) to generate ATP. Mitochondrial membrane 
potential (ΔΨm ) therefore relates to a cells’ ability to generate ATP 
by oxidative phosphorylation.  
 
Tetramethylrhodamine methyl ester (TMRM) is a fluorescent probe, 
which accumulates in mitochondria with intact membrane potentials. 
Here we show that under basal conditions, fibroblasts containing the 
ND5 mutation (P1) exhibited a reduced ΔΨm to approximately 90% 
of healthy controls, consistent with other reports of reduced ΔΨm in 
fibroblasts containing the m.13528A>G mutation (McKenzie et al. 
2007) (Figure 21). A decrease in ΔΨm was also observed in the 
common m.3243A>G mutation (P2) present in the tRNA leucine 
gene, as has been also reported previously in the literature 
(Garrido-Maraver et al. 2012) (Figure 21).  However, despite the 
impairments tRNA genes have on respiratory chain complexes, a 
significantly reduced ΔΨm was not observed in the tRNA lysine (P3, 
P4) or tRNA serine (P5, P6) mutated lines, which was consistent 
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between multiple patients containing the same mutation (Figure 21). 
Finally, also contradictory to reports in the literature, measurement 
at basal levels showed the ATP synthase mutant fibroblasts (P7) to 
have a significantly reduced ΔΨm (Figure 21).  In general it is 
thought that mutations in the tRNA genes and respiratory chain 
proteins causes a decrease in ΔΨm but cells with mutations for the 
ATP synthase subunits result in hyperpolarised ΔΨm (Lorenz et al. 
2017; Szczepanowska et al. 2012). Interestingly, this mutation 
presents as a CMT2 phenotype in the patient (previously described 
(Pitceathly et al. 2012)) and other CMT  causing mutations have 
also been associated with a reduced ΔΨm (Loiseau et al. 2007; 
Noack et al. 2012).  
 
To further investigate the maintenance of the ΔΨm, we applied two 
inhibitors of the respiratory chain complexes to cells loaded with 
TMRM. Firstly, oligomycin was applied to cells to block the ATP 
synthase. Any loss of ΔΨm would indicate that the gradient across 
the IMM was in part maintained by the movement of protons across 
the ATP synthase out of the mitochondrial cytoplasm. Secondly, 
rotenone was applied to cells to inhibit complex I, to identify how 
much of the ΔΨm is maintained by complex I. 
 
The reduced ΔΨm observed in the ND5 mutant fibroblasts (P1) was 
not reduced any further following the addition of oligomycin, 
suggesting no compensation from the ATP synthase to maintain a 
89.3% ΔΨm (Figure 22A). In addition, the decrease in ΔΨm upon 
addition of rotenone did not vary from control cells, suggesting that 
the functioning of complex I to maintain the ΔΨm is not affected by 
the mutation in these fibroblasts.  
 
In the tRNA leucine mutant fibroblasts (P2) an increase in ΔΨm 
occurred after inhibition of the ATP synthase (Figure 22B). Upon 
repeating this three times, the extent of the increase was found to 
vary from a modest increase to a very large increase (depicted in 
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the large error bars) therefore did not reach statistical significance. 
Considering the significantly lower ΔΨm under basal conditions, one 
possible hypothesis for seeing an increase at all in ΔΨm with 
oligomycin could be an overactive ATP synthase, causing a greater 
influx of protons which lowers the ΔΨm but causes it to polarize 
when the ATP synthase is inhibited. Moreover, an increase in ΔΨm 
after inhibition of the ATP synthase can also occur due to an 
increased efflux of protons across the respiratory chain. Application 
of rotenone to the patient cells had the same effect as seen in 
control cells. 
 
The ΔΨm of tRNA lysine mutant fibroblasts (P3, P4) showed a 
tendency to lower slightly upon inhibition of the ATP synthase 
(Figure 22C, 22D). Both lines containing the same mutation 
exhibited a rapid loss of ΔΨm compared to control upon addition of 
rotenone, which could suggest a greater dependency on complex I 
for maintenance of ΔΨm, however this data alone is not enough to 
confirm this. The tRNA serine mutants (P5, P6) showed no 
difference to control upon addition of oligomycin, or in the loss of 
ΔΨm in response to rotenone (Figure 22E, 22F). In these four tRNA 
mutants, it was encouraging to see similar responses to these 
compounds between different lines containing the same tRNA 
mutation.  
 
Upon addition of oligomycin to the ATP6 mutant fibroblast line (P7), 
the ΔΨm showed no increase, which suggests a small 
compensation from the movement of protons out of the 
mitochondrial matrix via the ATP synthase (Figure 22G). 
 
The data shown in Figures 21 and 22 is an indication of the 
heterogeneity of these patient cases, and it is particularly interesting 
that despite significantly a reduced membrane potential being 
observed in several of the patient lines, the mutant mtDNA is 
maintained. 
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Figure 21: Mitochondrial membrane potential basal measurement in mtDNA 
disease patient fibroblasts 
Histograms represent mean TMRM intensity measured by live cell imaging 
as an indicator of mitochondrial membrane potential. Data was averaged 
across three independent experiments and normalized to the average 
results from two healthy control fibroblasts. Error bars represent SEM, n = 
3, two-tailed Student t-test * p < 0.05, *** p < 0.005. 
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Figure 22: Maintenance of mitochondrial membrane potential 
A-G Mitochondrial membrane potential, depicted as % of basal TMRM, in 
patient (n=3; grey) and control (n=4; black) fibroblasts. The gene in which 
each patient has the mtDNA mutation is stated in the key for each figure, 
along with the patient number (corresponding to table 15) in brackets. Data 
points represent mean TMRM intensity ± SEM. 2 µM Oligomycin was added 
to fibroblasts at timepoint 6, 2 µM Rotenone added at timepoint 26 and 5 µM 
FCCP added at timepoint 46. 
 
2.2.3 Mitochondrial dynamics in cultured mtDNA disease 
patient fibroblasts 
 
Mitochondria are highly dynamic organelles, continuously joining 
and dividing by processes of fusion and fission, respectively. These 
processes regulate the quality of the mitochondrial pool by enabling 
segregation of damaged mitochondria to be eliminated by 
mitophagy (Twig, Elorza, Anthony J A Molina, et al. 2008b). 
Mitofusins 1 and 2 (MFN1 and MFN2) are outer mitochondrial 
0 
20 
40 
60 
80 
100 
120 
140 
0 10 20 30 40 50 60 
TM
R
M
, %
 o
f b
as
al
 
Timepoint 
Control 
ATP6 (7) 
G 
Oli 
Rot 
FCCP 
 151 
membrane proteins that facilitate the process of fusion, and are 
ubiquitinated in a PINK1/Parkin-dependent manner upon loss of 
membrane potential to enable isolation of damaged mitochondria 
(Ishihara et al. 2004; Matthew E. Gegg et al. 2010). 
 
On assessment of mitochondrial volume, it was found that the three 
patients which exhibited significantly lower ΔΨm (P1, P2 and P7) all 
also had significantly lower mitochondrial volume in comparison to 
control fibroblasts Figure 23). This may suggest that the lower ΔΨm 
is triggering more mitophagy in these cells. However, identification 
of mitophagy in fibroblasts is particularly challenging and it has been 
suggested previously that overexpression of Parkin is required 
(Rakovic, Shurkewitsch, Seibler, Grünewald, et al. 2013). The 
method for data analysis of mitochondrial volume per cell is 
explained in the methods section under ‘Mitochondrial network 
analysis’. 
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Figure 23: Mitochondrial volume and mtDNA copy number in mtDNA 
disease patient fibroblasts 
A Histograms represent mean mitochondrial volume per cell, compared to 
control (dotted line), measured by z-stack imaging in live cells. Cells were 
loaded with MitoTracker and the area of mitochondrial signal calculated and 
summed across the depth of the z-stack. Mitochondrial volume was 
normalized to cell number by counting cell nuclei. Error bars represent 
SEM, n=3; two-tailed Student t-test * p < 0.05, ***** p < 0.0005. B Histograms 
represent mean mtDNA copy number relative to an average of two healthy 
controls (dotted line), measured by qPCR. The ND1 gene was used for 
mtDNA and the Human globulin (HGB) was used for gDNA. Error bars 
represent SEM, n=3. 
 
A PINK1/Parkin-dependent process indicative of mitophagy is the 
ubiquitination of mitofusins which is completely inhibited in PINK1 
and Parkin mutant fibroblasts (Rakovic et al. 2011). MtDNA mutant 
fibroblasts were therefore stimulated with CCCP and ubiquitination 
of mitofusin 1 and mitofusin 2 quantified in order to identify 
impairments to this process. The most striking effect was found in 
the tRNA serine mutants (P5 and P6), whereby there was a highly 
significant reduction in the amount of ubiquitinated mitofusins found 
in both patients (Figure 24 A-D).  This was particularly interesting, 
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as this effect has not been reported in fibroblasts other than PINK1 
and Parkin mutants. These data suggest potential defects in the 
mitophagy process when stimulated with CCCP, but in this cell type 
do not appear to affect mitochondrial volume cell. However 
assessment of PINK1 homozygous mutant fibroblasts also did not 
have a significantly altered mitochondrial volume. Significant 
reductions in ubiquitinated mitofusins, compared to control 
fibroblasts, were found in all patient lines except for the ATP6 
mutant (P7), in which ubiquitination of mitofusin 1 and mitofusin 2 
was consistently no different to controls (Figure 24 A-D).  
 
Upon quantification of endogenous mitofusin protein levels, only the 
tRNA lysine mutants appeared to have any significantly lower levels 
compared to controls (Figure 24E). 
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Figure 24: Ubiquitination of mitofusins in stressed mtDNA patient 
fibroblasts 
A, B Representative immunoblots to show mitofusin1 and mitofusin2 
ubiquitination following treatment with 10 µM CCCP for 1.5 hours. Loading 
control shown using housekeeping gene β-Actin. C, D Quantification of 
ubiquitinated mitofusin 1 and mitofusin 2 in response to 1.5 hours 10 µM 
CCCP, normalised to loading control (β-Actin) and presented relative to 
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healthy control (dotted line). Error bars represent SEM; mitofusin 1 (C): n=3; 
mitofusin 2 (D): n=2; two-tailed Student t-test * p < 0.05, ** p < 0.01, *** p < 
0.005, **** p < 0.001. E Histograms represent the mean endogenous protein 
levels of mitofusin 1 and mitofusin 2 as assessed by immunoblot, 
normalised to loading control (β-Actin) and presented relative to healthy 
control. Error bars represent SEM, n = 3 (mitofusin 1), n = 2 (mitofusin 2). 
2.2.4 Similarities in EM imaging and Complex I activity in 
tRNA Serine mutants and PINK1 mutant fibroblasts 
 
The highly significant impairment of mitofusin ubiquitination in the 
tRNA serine mutants lead to further investigation into whether there 
were other similarities between these cells and PINK1 mutant 
fibroblasts. 
 
 Studies in PINK1 mutant drosophila have shown that defective 
mitochondria cause endoplasmic reticulum (ER) stress signalling 
and an increase in mitochondria-ER contact points is identified in 
PINK1 mutant flies and also PINK1 mutant fibroblasts (Celardo et 
al. 2016). Here it was found that mitochondrial-ER contact points 
were also increased in both tRNA serine mutant fibroblast lines, to 
the same significance as that seen in PINK1 mutant fibroblasts 
(Figure 25 A,B). Further analysis of mitochondrial morphology 
revealed a significant reduction in mitochondrial length, which was 
not observed in the PINK1 mutant fibroblasts but occurred in both 
tRNA serine mutant lines, suggesting greater fragmentation of the 
mitochondrial network (Figure 25C). 
 
As well as its involvement in mitophagy, PINK1 has been implicated 
in the functioning of complex I activity. Complex I deficiency is 
implicated in Parkinson’s Disease pathology and has been reported 
in PINK1 mutant models (Schapira et al. 1990; Morais et al. 2009; 
Deas et al. 2009). It is believed that the role of PINK1 in regulating 
complex I activity is independent of its role in the mitophagy 
pathway (Pogson et al. 2014). Using a complex I activity assay on 
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whole cell lysates, it was found that the tRNA serine mutant 
fibroblasts also exhibited a reduction in complex I activity, similar to 
PINK1 mutant fibroblasts (Figure 25D). 
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Figure 25: tRNA serine mutants and PINK1 homozygous mutant, 
comparison of morphology and function 
A Representative EM images showing mitochondrial length and 
mitochondrial-ER contact. M in yellow indicates identified mitochondria, ER 
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in red indicates identified endoplasmic reticulum, and yellow stars indicate 
points of contact between mitochondria and ER. B Histogram showing the 
amount of mitochondria in contact with ER, represented as % of total 
mitochondria. Respective numbers of mitochondria are displayed on the 
histogram. C Scattergraph to show the respective lengths of mitochondria 
counted from EM images. D Histogram representing the Complex I activity 
measured from 200 ug of cell lysate. Error bars represent SEM, n = 3; two-
tailed Student t-test * p < 0.05. 
 
2.2.5 PINK1, Parkin and mitochondrial biogenesis in 
mtDNA disease patient fibroblasts 
 
It has been suggested that activating mitophagy could have a 
therapeutic role in eliminating mitochondria containing the highest 
load of mutant mtDNA, especially in the modulation of heteroplasmy 
(Villanueva Paz et al. 2015). Overexpression of Parkin in a 
heteroplasmic cybrid model containing deleterious COXI mutations 
was found to stimulate the selective removal of mutant 
mitochondria, and functionally restore cytochrome c oxidase activity 
(Suen et al. 2010). Similarly, Parkin was identified as a modulator of 
heteroplasmy in vivo  also, which lead us to postulate whether 
endogenous levels of Parkin were lower in the mutant fibroblasts 
which exhibited reduced mitofusin ubiquitination (Valenci et al. 
2015). However, upon assessment of protein levels by 
immunoblotting, endogenous Parkin levels were found to be highly 
variable between mutant fibroblasts, as well as healthy controls 
(Figure 26). Significance of the patient data was not assessed due 
to the variation in the controls within the same experiment.  
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Figure 26: Endogenous Parkin levels in mtDNA patient fibroblasts and 
healthy controls 
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A Representative immunoblot showing endogenous Parkin protein 
expression. B Quantification of endogenous Parkin levels. Histograms 
represent mean Parkin normalised to β-Actin, error bars represent SEM, n = 
3. C Representative immunoblot showing the endogenous Parkin levels in 8 
control fibroblast lines 
  
Mitophagy has been suggested as a potential therapeutic target for 
mitochondrial disease, however whether or not the quality control 
process is impaired in these diseases remains unknown. Due to 
unavailability of working antibodies for Western blotting or 
immunocytochemistry, PINK1 expression was assessed by RT-PCR 
and found under basal conditions that there was significantly lower 
expression in in three of the tRNA mutant fibroblast lines (P3, P4 
and P5) (Figure 27A).  
 
Since the pool of mitochondria present in cells is regulated by 
mitochondrial biogenesis as well as mitophagy, the expression of 
PGC-1α, an important regulator of biogenesis was investigated, 
upon depolarisation of mitochondria. MRNA analysis revealed a 
consistent decrease in PGC-1α expression upon depolarisation in 
healthy control fibroblasts compared to untreated cells, suggesting a 
down-regulation of biogenesis when mitophagy is stimulated. A 
decrease was consistently observed in the ND5 (P1) and ATP6 (P7) 
mutants; however in all fibroblasts containing a mutation in a tRNA 
gene (P2, P3, P4, P5, P6), biogenesis appeared to be upregulated 
(Figure 27B).  
 
Whilst the extent of upregulation was variable, no decreases in 
PGC-1α expression were observed in the depolarised tRNA 
mutants (P2, P3, P4, P5, P6), suggesting an alternative response to 
depolarisation compared to healthy cells. Interestingly, significant 
upregulation of PGC-1α has been previously identified in PINK1-
mutant IPSCs stimulated by depolarisation, believed to be a 
compensatory response to impaired degradation of depolarised 
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mitochondria (Seibler et al. 2011). Combined with the reduced 
mitofusin ubiquitination identified in the tRNA mutant fibroblasts in 
particular, these data implicate an impairment of mitophagy that is 
compensated for by stimulation of biogenesis upon depolarisation. It 
has been reported previously in studies using muscle, that PGC-1α 
has a role in buffering of oxidative stress, which in its absence can 
induce transcription of PINK1 and LC3 genes, and consequently 
stimulate mitophagy (Baldelli et al. 2014). In vivo studies have 
suggested that PGC-1α may have a protective role against 
excessive mitophagy; it has been shown using a mouse hindlimb 
immobilization and remobilization model that PGC-1α attenuated 
ubiquitination and degradation of mitofusin 2 (Kang & Ji 2016).  
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Figure 27: mRNA expression of PINK1 and PGC1α in mtDNA disease patient 
fibroblasts 
A Histogram showing the mean fold change in mRNA expression of 
endogenous PINK1, compared to control. Dotted line represents control 
mRNA expression. Error bars represent SEM, n = 3; two-tailed Student t-test 
* p < 0.05, *** p < 0.005, ***** p < 0.0005. B Histogram showing the mean fold 
change in mRNA expression of PGC-1α after 12 hours 10 µM CCCP 
treatment, compared to DMSO treatment. Dotted line represents mRNA 
expression in untreated cells. Error bars represent SEM, n = 3; two-tailed 
Student t-test * p < 0.05, *** p < 0.005. 
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2.3 Discussion 
 
2.3.1 Mitochondrial dynamics in mtDNA disease patient 
fibroblasts 
 
Studying mitochondrial dynamics in fibroblasts derived from patients 
with primary mitochondrial diseases revealed only minor differences 
in some of the fibroblast lines, suggesting that under basal 
conditions mtDNA patient fibroblasts show only slight phenotype. 
Mitochondrial membrane potential was significantly reduced in three 
of the patient lines (Complex I mutant, tRNA leucine mutant and the 
ATP6 mutant) but, whilst consistent, to no less than 80% of the 
potential maintained in control fibroblasts. Furthermore the addition 
of oligomycin and rotenone did not reveal compensatory 
mechanisms being utilised by the cells to maintain membrane 
potential. In the same fibroblast lines that exhibited reduced 
mitochondrial membrane potential, a significant reduction in 
mitochondrial volume, as measured by live cell imaging, was 
observed. The tRNA lysine and tRNA serine mutants (of which there 
are two patients with each mutation) all displayed no significant loss 
of membrane potential, and the mitochondrial volume was found to 
be no different to control. Mitochondrial membrane potential and 
mitochondrial volume data was collected by confocal imaging and 
data analysed by taking an average measurement across the cells 
in the field of view when imaging. Therefore it could be speculated 
that the fibroblast lines with approximately 90% of the control 
membrane potential may contain some depolarised mitochondria, 
which would cause only a modest decrease in overall membrane 
potential in numerous cells, but those depolarised few would trigger 
mitophagy and cause the significantly lower mitochondrial volume. 
 
Inducing mitochondrial stress to the fibroblasts enabled 
identification of mitofusin ubiquitination, a phenomenon thought to 
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occur due to the E3 ubiquitin ligase activity of Parkin. Upon loss of 
mitochondrial membrane potential caused by uncoupler CCCP, a 
reduction in ubiquitinated mitofusins was observed compared to 
control in all patient lines, except for the ATP6 mutant. The loss of 
ubiquitination in PINK1 and Parkin mutant fibroblasts is well-known, 
however has not been reported in other cells containing different 
mutations (Rakovic et al. 2011). The tRNA serine mutation 
appeared to cause the most significant loss of ubiquitinated 
mitofusin, in both patient lines, and therefore these cells were used 
to identify other similarities between PD-associated mutants.  
 
In collaboration with the University of Leicester, EM imaging was 
used to identify an increase in mitochondria-endoplasmic reticulum 
contacts, believed to occur via mitofusin bridges activating 
enhanced ER stress (Celardo et al. 2016). Using PINK1 mutant 
fibroblasts as a positive control, it was found that tRNA serine 
mutant fibroblasts also contained increased mito-ER contacts 
suggesting activation of ER stress. Furthermore, tRNA serine 
mutants exhibited reduced complex I activity in a similar manner to 
PINK1 mutant fibroblasts. These experiments have revealed 
phenotypic similarities between tRNA serine mutants and PINK1 
mutants in three areas: complex I activity, ER stress signalling and 
ubiquitination of mitofusins. 
 
Although Parkin has been implicated as a modulator of 
heteroplasmy and therefore is of great interest in the mtDNA 
disease field, endogenous Parkin protein levels were found to be 
widely variable even in healthy controls. It was not possible to find 
specific Parkin primers to investigate mRNA expression by QPCR, 
however this technique was used to study the expression of PINK1 
and PGC-1α. PINK1 mRNA expression was found to be significantly 
lower compared to controls in the two tRNA lysine fibroblast lines 
and one of the tRNA serine fibroblast lines. Most interesting was the 
change in mRNA expression of biogenesis regulator PGC-1α in 
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response to 12 hours CCCP treatment. Mitophagy and 
mitochondrial biogenesis are two tightly coordinated processes to 
enable efficient regulation of mitochondrial quality. Whilst the 
mechanism of their interaction remains largely unknown, it is 
thought that under physiological conditions, biogenesis is stimulated 
in response to mitophagy in order to maintain mitochondrial 
quantity, as well as quality (Palikaras & Tavernarakis 2014). In 
these experiments 10 µM CCCP was used to completely depolarise 
the entire mitochondrial network, causing a much greater level of 
mitochondrial stress than normal under physiological conditions. 
Interestingly, after 12 hours of CCCP treatment, mRNA expression 
of PGC-1α in control cells revealed a suppression of biogenesis in 
response to widespread activation of mitophagy. Presumably, under 
this great amount of mitochondrial stress the priority of the cell is to 
degrade the damaged mitochondria instead of producing more to 
prevent newly synthesised mitochondria being damaged by the 
production of ROS from the existing stressed mitochondria. This 
same response was seen in the complex I mutant fibroblasts and 
the ATP6 mutant fibroblasts, however none of the tRNA mutants 
appeared to trigger suppression of biogenesis but largely cause an 
upregulation in mRNA expression. If mitophagy were to be 
compromised in these lines, promoting biogenesis would be a likely 
compensatory mechanism in response to widespread mitochondrial 
damage. However, as will be discussed further in section 2.3.2, 
directly assessing mitophagy has proven difficult in mammalian cell 
cultures and measurement of mitochondrial volume/mass is often 
inconclusive, as shown in this data with PINK1 mutant fibroblasts 
which do not display increased quantities of mitochondria (figure 
23A). 
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2.3.2 Assessing mitophagy in fibroblast models 
 
2.3.2.1 Basal mitophagy or stress-induced mitophagy? 
 
In these experiments, mtDNA disease patient derived fibroblasts 
displayed striking impairments to mitofusin ubiquitination upon 
exposure to mitochondrial uncoupler CCCP, but by comparison only 
modest variation in mitochondrial membrane potential or 
mitochondrial volume under basal conditions. A previous study, 
which utilised various mitochondrial disease cell lines, showed that 
contrary to reports in the literature, mitochondrial membrane 
potential was often not found to be reduced in mtDNA disease 
patient derived fibroblasts and that under basal conditions 
autophagy was increased in these lines but not mitophagy (Morán 
et al. 2014). However in another study by the same authors and 
same patients showed that OXPHOS deficiencies caused slower 
recovery of membrane potential compared to control cells upon 
induced mitochondrial depolarisation (Morán et al. 2010). These 
reports show that measurement of mitochondrial mass or detection 
of autophagic machinery is not sufficient to make conclusions about 
mitophagy, especially in unstressed cells.  
 
The use of mitochondrial uncouplers enables easier detection of the 
response to damaged mitochondria, and is compatible with the use 
of biochemistry techniques such as Western blotting. Furthermore, 
fibroblasts are an unaffected cell type in these diseases, therefore 
whilst the mutation is present, cell stress may be required to assess 
its effect.  
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2.3.2.2 Can decreases in mitochondrial volume be detected? 
 
In order to identify defects in selective PINK1/Parkin-mediated 
mitophagy, it is logical to look at PINK1 mutant and Parkin mutant 
fibroblasts derived from PD-patients as a positive control.  
 
Data shown here and reported in the literature has shown that 
despite the lack of PINK1, either by the presence of a homozygous 
PINK1 PD-causing mutation or the generation of PINK1-KO of 
mouse embryonic fibroblast (MEF) lines, an increase in 
mitochondrial mass is not observed (Heeman et al. 2011). 
Therefore quantification of the basal mitochondrial network is not 
indicative of PINK1-dependent mitophagy impairments. 
 
Studies in both mutant and control fibroblasts have shown however 
that cells containing endogenous protein levels of Parkin do not 
exhibit significant reductions in mitochondrial proteins upon 
depolarisation (Rakovic, Shurkewitsch, Seibler, Grünewald, et al. 
2013). Despite it being difficult to find good commercial Parkin 
antibodies for Western blotting, this study used the separation of 
mitochondrial and cytosolic fractions to show translocation of Parkin 
to the mitochondria but found that from 3 hours post depolarisation, 
the presence of Parkin was reduced. Further investigation showed 
that in fibroblasts, endogenous Parkin is self-ubiquitinated and 
degraded so the loss of mitochondrial proteins cannot be detected 
despite the loss of membrane potential. When Parkin was 
overexpressed in primary fibroblasts, PINK1-dependent loss of 
mitochondrial proteins could be detected (Rakovic, Shurkewitsch, 
Seibler, Grünewald, et al. 2013). 
 
Difficulties in identifying Parkin-mediated mitophagy in mammalian 
cell cultures is often blamed on the fact that most of our 
understanding of the mitophagy pathway comes from studies 
utilising potent mitochondrial uncouplers in Parkin overexpressed 
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non-neuronal immortalised cell lines. However, a study using both 
highly mitochondria-dependent cortical neurons and glycolytic HeLa 
cells, showed that overexpressing Parkin in neurons still does not 
cause translocation of Parkin to depolarised mitochondria, and that 
when normally glycolytic HeLa cells are forced to rely on 
mitochondrial respiration, Parkin translocation no longer occurs 
(Van Laar et al. 2011). These data show that manipulation of the 
mitophagy model may produce misleading and unhelpful data. 
Consequently, in these experiments, cells were not transfected with 
Parkin or cultured in galactose media to reduce their glycolytic 
nature. 
 
2.3.2.3 What does mitofusin ubiquitination tell us? 
 
In these experiments, a suitable Parkin antibody was obtained 
which was able to detect endogenous levels of protein in 30 µg 
protein lysates by Western blot. However this antibody was not 
sensitive enough to be able to detect translocation of Parkin to the 
mitochondria. Therefore to investigate PINK1/Parkin-dependent 
effects upon mitochondrial depolarisation in a non-over-expressed 
system, mitofusin ubiquitination was studied. Using PINK1 and 
Parkin mutant fibroblasts, both depolarisation of the mitochondrial 
membrane potential or exposure to H2O2 failed to induce 
ubiquitination of mitofusins in mutant fibroblasts unlike control 
fibroblasts (Rakovic et al. 2011). This provided a robust 
PINK1/Parkin-dependent assay to identify impairments in this 
process. Ubiquitination of outer mitochondrial membrane proteins 
mitofusins 1 and 2 is mediated by Parkin, which leads to enhanced 
turnover by proteasomal degradation (M. E. Gegg et al. 2010; 
Glauser et al. 2011). In addition to the use of fibroblasts with PINK1 
and Parkin mutations, silencing of PINK1 or Parkin in SH-SY5Y 
cells was also found to cause significant reduction in the 
ubiquitination of mitofusins (M. E. Gegg et al. 2010). Ubiquitination 
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of mitofusins enables recruitment of ubiquitin-binding proteins, such 
as p62, to mediate elimination of damaged mitochondria via the 
autophagosome, and also prevents fusion of damaged mitochondria 
to the healthy mitochondrial network (Gegg & Schapira 2011). 
 
The significant reduction of ubiquitinated mitofusins to almost 
completely absent in the tRNA serine mutant lines indicates 
impairment in an early event in the mitophagy process, and 
therefore is of interest as a previously undescribed phenotype in 
mtDNA diseases. Investigations into Parkinson’s disease 
pathogenesis have hypothesised that the lack of mitofusin 
ubiquitination prevents clearance of mitochondria by the 
autophagosome system and enables damaged mitochondria to 
rejoin the mitochondrial network, causing persisting damage and a 
decline in mitochondria function (Abramov et al. 2011). It has been 
suggested that activation of mitophagy may play a therapeutic role 
in tissues such as muscle and neurons, which rely on efficient 
mitochondrial function (Abramov et al. 2011).  
 
2.3.3 Similarities between tRNA serine mutants and PINK1 
mutants 
 
The observation of reduced mitofusin ubiquitination in several of the 
mtDNA disease patient fibroblast lines was unexpected, as this 
phenomenon has not been reported in mutations other than PINK1 
and Parkin. Therefore investigating other phenotypes associated 
with PD pathogenesis was of interest. PINK1 deficiency has been 
reported to cause reduced complex I activity in PINK1(-/-) mice and 
pink(B9)-null mutant Drosophila (Morais et al. 2014). Furthermore, 
loss of complex I activity is a property of some Parkinson’s disease 
model neurotoxins, e.g. rotenone (Dauer & Przedborski 2003). In 
addition to mtDNA disease caused by mutations in complex I, 
complex I deficiency has been associated with mutations in 
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ribosomal and transfer RNAs in the mitochondrial genome (Porcelli 
et al. 2016; Haack et al. 2012; Lax et al. 2013). The finding of 
reduced complex I activity, to similar levels seen in PINK1 mutants, 
in two fibroblast lines containing the same mutations that had a 
highly significant reduction in mitofusin ubiquitination, provides 
further evidence that PINK1 may not be functioning correctly in 
these lines. It has been reported that the complex I subunit NdufA10 
is phosphorylated at Ser250 in a PINK1-dependent manner, and 
that phosphomimetic NdufA10 can rescue complex I activity but not 
mitophagy, suggesting that this function of PINK1 is independent of 
mitophagy (Morais et al. 2014; Pogson et al. 2014). Together, this 
data has shown impaired PINK1 function both under basal 
conditions and under stressed conditions, and impairments in two 
reportedly independent functions both dependent on PINK1. 
 
In addition, the EM experiments in this chapter revealed similarities 
in the morphology of tRNA serine mutant cells to PINK1 mutant 
cells. Celardo et al., demonstrated by EM imaging that an increase 
in contact points between mitochondria and endoplasmic reticulum 
was a characteristic of PINK1 and Parkin mutant fibroblasts 
(Celardo et al. 2016). The contact between the endoplasmic 
reticulum and mitochondria is thought to be important for the 
function of the PINK1-Parkin pathway, with implications in 
neurodegeneration (Erpapazoglou & Corti 2015). Analysis of 
PARK2 mutations in fibroblasts derived from mice and PD patients 
revealed a closer mito-ER proximity compared to controls (Gautier 
et al. 2016). An increase in mito-ER contact was also identified by 
ultrastructural analysis of pink1 and parkin mutant fly brains, and 
inhibition of PERK signalling was found to the neuroprotective even 
in the presence of damaged mitochondria (Celardo et al. 2016). 
This suggests that pharmacological intervention of PERK signalling 
may provide an alternative therapeutic target in mtDNA disease in 
which PINK1 activity is defective. 
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2.3.4 mtDNA disease and PD pathogenesis 
 
The accumulation of deletions in the mitochondrial genome is a 
feature associated with aging, though studies in PD patients and 
age-matched controls found these to have a higher incidence in PD 
patients in various brain regions (Ikebe et al. 1990; Ozawa et al. 
1990). The presence of parkinsonian features in mitochondrial 
disease however has only occasionally been observed, for example 
caused by a novel 12SrRNA point mutation or a cytochrome b gene 
deletion (Rana et al. 2000; Thyagarajan et al. 2000).  
Parkinson’s disease is considered the second most common 
neurodegenerative disease, and in an aging population, causes 
considerable strain on the health service. A substantial amount of 
research in academia and the pharmaceutical industry is focused on 
developing effective therapeutics for this disease. In contrast, as 
discussed in section 2.1.3, the heterogeneous nature of already rare 
mitochondrial diseases is a limiting factor in the development of 
disease therapeutics. As a result, the common features identified 
here between tRNA serine mutants and PD-causing PINK1 mutants 
may prove particularly beneficial in finding effective treatment for a 
subset of mtDNA disease patients more readily. 
 
2.3.5 Biogenesis and mitophagy in mtDNA disease 
 
A particularly interesting finding was the segregation of tRNA 
mutations and mutations in genes encoding for a subunit of a 
respiratory complex in the effect on biogenesis in response to 
mitochondrial stress. At the timepoint observed, when cells had 
been stressed with 10 µM CCCP, control fibroblasts and those with 
a mutation in a gene encoding a subunit of a respiratory complex 
repressed the expression of PGC-1α, a master regulator of 
mitochondrial biogenesis. In fibroblasts harbouring mutations in 
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tRNA genes, repression did not occur, and a significant upregulation 
of PGC-1α mRNA expression was activated. 
 
A mouse model containing a proof-reading deficient form of 
mitochondrial DNA polymerase gamma, which causes mtDNA 
deletions in various tissues was found to exhibit activated 
mitochondrial biogenesis, thought to be a compensatory mechanism 
(Perier et al. 2013). More recently, mitochondrial biogenesis was 
found to be protective against neuronal degeneration through the 
overexpression of necdin, a stabiliser of endogenous PGC-1α 
(Hasegawa et al. 2016). As well as activating transcription for 
mitochondrial biogenesis, PGC-1α has been shown to promote the 
expression of antioxidant enzymes during differentiation to buffer 
oxidative stress, strengthening the hypothesis that activation of 
PGC-1α may be a compensatory mechanism utilised in stressed 
cells (Baldelli et al. 2014).  
 
Interestingly, a study performed in atrophied muscle, a tissue type 
most commonly affected in mitochondrial disorders, showed that 
PGC-1α overexpression attenuated the ubiquitination and 
degradation of mitofusin 2, inhibiting the activation of mitophagy 
(Kang & Ji 2016). Moreover, in PINK1-mutant IPSC, after 12 hours 
of valinomycin, mRNA expression of PGC-1α was found to be 
significantly increased compared to untreated cells, despite there 
being no difference observed in the wild-type cells before and after 
valinomycin treatment (Seibler et al. 2011). These studies suggest 
that the activation of biogenesis observed in the tRNA mutant 
fibroblasts could be a compensatory mechanism, in line with the 
reduced ubiquitination of mitofusins upon stimulation of mitophagy. 
In cells with damaged mitochondria but defective mitophagy, 
expression of PGC-1α appears beneficial in order to attempt to 
maintain mitochondrial function by producing newly synthesised 
mitochondria and also for buffering of oxidative stress. 
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This effect was found to occur in the tRNA mutants but not the ND5 
or ATP6 mutant fibroblasts, and it remains unknown as to why this 
occurred. A mutation in a mitochondrial tRNA gene is likely to affect 
the translation of all mitochondrial genes, and perhaps stimulation of 
PGC-1α is therefore more effective as a compensatory mechanism. 
The fibroblasts containing the ATP6 mutation showed no 
impairment to mitofusin ubiquitination and as a result it is 
unsurprising that repression of PGC-1α occurred in the same 
manner as control fibroblasts. The ND5 mutant fibroblasts showed 
significant reduction in mitofusin 1 to approximately 50% of control 
cells, but no significant reduction was observed in the ubiquitination 
of mitofusin 2. In contrast, two of the tRNA mutant lines showed 
significantly impaired ubiquitination of mitofusin 2, but not 
mitofusin1, and both of these displayed a highly significant increase 
in PGC-1α mRNA expression in response to CCCP, which could 
suggest a greater reliance of the ubiquitination of mitofusin 2 
compared to mitofusin 1 in the mitophagy pathway. However, 
further investigation is required to understand these results. 
 
 
2.3.6 Future perspectives 
 
The data presented in this chapter have demonstrated novel 
phenotypic findings in mitochondrial DNA disease patient 
fibroblasts, such as impairment of mitofusin ubiquitination and 
increased mitochondrial-endoplasmic reticulum contacts. Two 
fibroblast lines containing the tRNA serine mutation m.7472insC 
were investigated in parallel with PINK1 mutant fibroblasts to reveal 
similarities in their characteristics. However due to experimental 
practicalities it was not possible to use all the patient lines with 
numerous age-matched controls to determine whether this effect 
would be found in some of the other patient lines too. In particular, 
considering the responses identified when analysing the mRNA 
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expression of PGC-1α, it would be interesting to determine whether 
these findings were limited to the tRNA mutant lines.  
 
As well as repeating some of these experiments with all the patient 
lines available, it would be particularly interesting to further 
investigate the highly significant mitofusin ubiquitination defect. In 
order to test whether mitofusin ubiquitination was reduced due to 
the same mechanism as observed in the PINK1 and Parkin 
mutants, it would beneficial to attempt to overexpress these 
proteins. Whilst the facilities were not available at the time of these 
experiments, it would be particularly interesting to transfect these 
fibroblasts using electroporation to overexpress PINK1 or Parkin to 
see if ubiquitination could be rescued. In the literature it has been 
shown that ubiquitination of mitofusin 2 in PINK1 mutant fibroblasts 
could be rescued by overexpressing PINK1 but not Parkin, and 
Parkin mutant fibroblasts rescued by overexpressing Parkin but not 
PINK1 (Rakovic et al. 2011). If a rescue were to be obtained, it 
could suggest whether impairments in PINK1 or Parkin were the 
cause. 
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Chapter 3 
Neuronal and Myogenic models of 
tRNA serine m.7472insC 
pathogenic mutation 
3.1 Introduction 
 
3.1.1 Induced Pluripotent Stem Cell models of mtDNA 
disease 
 
Patients harbouring the same mtDNA mutation can often present 
with varying clinical phenotypes, affecting different tissues with 
differing severity. How the same mutation can have a different effect 
in separate tissues remains unknown. Furthermore, how mutant 
load is determined from tissue to tissue is also not understood. The 
generation of induced pluripotent stem cells (iPSCs) has enabled 
huge advancements in disease modelling across many disease 
areas. Cultured cells from patients, most commonly skin biopsies, 
enable the study of a pathogenic mutation within the nuclear 
background of the patient, which has been shown to be important in 
modulation of the mutation effect (D’Aurelio et al. 2010). However, 
cultured cells commonly do not exhibit a pathological phenotype or 
are limited in their experimental potential, as experienced in Chapter 
2.  
 
Generation of iPSCs is now a relatively simple process, with several 
techniques available that achieve good reprogramming efficiency, 
 177 
such as mRNA transfection or the use of non-integration viruses 
(Malik & Rao 2013). In the experiments in this chapter, iPSCs were 
derived from patient and control fibroblasts and created by 
reprogramming to an embryonic stem cell–like state (epiblast 
stage), i.e. possessing the ability to self-renew and differentiate into 
cell types of all three embryonic germ layers (pluripotency). Since 
the use of transgenic technologies to modify the mitochondrial 
genome has been largely unsuccessful, the potential to study the 
same patient-derived mutation in various cell types using iPSCs is 
particularly useful for mtDNA diseases. 
 
Previous studies have shown normal efficiency of reprogramming 
cells with point mutations, and subsequent differentiation towards all 
three embryonic germ layers (Cherry et al. 2013; Hamalainen et al. 
2013; Fujikura et al. 2012). The generation of iPSCs from patients 
with Pearson’s syndrome, a mtDNA disease caused by deletions, 
enabled differentiation to erythroid cells which possessed abnormal 
iron accumulation, a characteristic feature of the disease (Cherry et 
al. 2013). Differentiation of MELAS-iPSCs produced neurons with a 
significant Complex I deficiency, and in another study using 
MELAS-iPSC lines this deficiency was found only to occur when 
derived from iPSC with a high mutant load (Kodaira et al. 2015; 
Hamalainen et al. 2013). This indicates that these models produce a 
phenotype characteristic of the disease that presents in a load-
dependent manner, replicative of the human disease. 
 
In accordance with previous reports of Parkin modulating 
heteroplasmy in cybrid models and C. elegans, neuronal 
differentiated MELAS-iPSCs showed Parkin and Complex I 
colocalisation in neurons with high mutant load (Hamalainen et al. 
2013). It was noted by the authors of this study that Complex I 
appeared to be enriched to a subset of mitochondria, which were 
degraded by mitophagy. It remains unclear as to why a mutation in 
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a tRNA gene, which is required for translation of all mitochondrial 
genes, causes impairment to Complex I specifically. 
 
In these studies, variability in the degree of heteroplasmy was 
observed during reprogramming, extended culturing and 
differentiation (Folmes et al. 2013; Cherry et al. 2013; Hamalainen 
et al. 2013; Kodaira et al. 2015). Whilst this effect poses a problem 
for reliably generating iPSC models of mtDNA disease, it may also 
be a useful tool in the creation of isogenic controls and the study of 
disease in the same cell type with different mutant loads. During the 
process of reprogramming, the load of mtDNA mutation appears to 
segregate in a bimodal fashion, generating iPS clones with no 
mutant mtDNA or a load of over 50% (Folmes et al. 2013; Cherry et 
al. 2013; Hamalainen et al. 2013; Fujikura et al. 2012). This 
segregation pattern is reflective of a mitochondrial bottleneck, which 
is observed in germ cells (Cao et al. 2009). It is unknown whether 
the mutant load level in iPS clones is dependent on the mtDNA load 
in the parental fibroblasts. 
 
3.1.2 Reprogramming to iPSC – mtDNA bottleneck theory 
 
The bottleneck mechanism is poorly understood, however its effect 
causes wide variation in the proportion of two genotypes within 
oocytes, leading to dramatic changes in heteroplasmy levels 
between generations. A small bottleneck size results in greater 
variation of heteroplasmy between mother and child, enabling 
reduction of mutant load to non-pathogenic levels or facilitating a 
more severe effect in the child than the mother.  
 
The concept of the bottleneck was developed following early 
observations in cows of rapid switching in levels of heteroplasmy 
even within a single generation (Ashley et al. 1989). During 
germline development, the large number of mtDNA molecules from 
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the maternal mtDNA pool is segregated into relatively small units 
which are transferred to the developing oocyte (Figure 28) (Cao et 
al. 2007). It is unclear when the bottleneck occurs exactly during 
development, with several groups concluding different results (Wai 
et al. 2008; Cao et al. 2007; Samuels et al. 2010). A recent study 
utilising a large number of human pedigrees showed that different 
mtDNA mutations segregate at different rates, relating to different 
size bottlenecks (Wilson et al. 2016). 
 
The bimodal segregation reported in the reprogramming process of 
several studies suggests a similar mitochondrial bottleneck (Cherry 
et al. 2013; Folmes et al. 2013; Fujikura et al. 2012; Hamalainen et 
al. 2013). The study of mouse germ cells has shown that mtDNA 
nonsynonymous mutations were underrepresented compared to 
synonymous mutations in protein-coding genes, and interestingly a 
similar phenomenon has been reported in iPSC with the reduction 
of ND5 mutations that was not observed with tRNA-leucine 
mutations (Stewart et al. 2008; Folmes et al. 2013; Hamalainen et 
al. 2013).  
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 Figure 28: Mitochondrial DNA Germline Bottleneck 
Schematic of the segregated units caused by the bottleneck from the large 
pool of maternal mtDNA. Blue mitochondria represent wild-type mtDNA 
containing mitochondria; red mitochondria represent mutant mtDNA 
containing mitochondria. N = nucleus. Beneath the bottleneck shape, which 
represents the maternal mtDNA pool, are the relatively small units that are 
transferred to the developing oocyte, demonstrating the variability of 
transfer and how mutant load can drastically increase or decrease. 
 
 
3.1.3 Neuronal and muscle cell types in mtDNA disease 
 
It is well known that mitochondrial disease phenotypes can be 
widely heterogeneous, however the involvement of both muscle and 
nerve is particularly common. Being diseases characterised by 
N N N 
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impaired mitochondrial energy output, it stands to reason that 
tissues highly dependent on efficient energy production have more 
serious consequences due to the presence of the mutation. Even in 
healthy individuals, it has been shown that mitochondrial point 
heteroplasmy is most common in muscle, followed by liver and brain 
(Naue et al. 2015). For this reason, studying mitochondrial disease 
in patient fibroblasts may limit our understanding of 
pathomechanisms. The clinical phenotypes experienced in the 
patients involved in this study were MELAS, MERFF, ataxia, 
myoclonus, deafness and CMT2.  No patients therefore 
experienced dermatological complications but all patients had 
affected muscle tissue and four patients also had neurological 
symptoms. 
 
3.1.4 Aims and hypothesis 
 
In this chapter the first aim was to reprogram patient and control 
fibroblasts to induced pluripotent stem cells using mRNA 
transfection, in order to create lines from which various cell models 
could be obtained by differentiation. Processes such as 
reprogramming fibroblasts, maintenance of iPSC cultures and 
differentiation are incredibly expensive and time-consuming, 
therefore it was not expected that all patient lines would be able to 
be used in these experiments.  
 
From the iPSC cultures obtained, the second aim was to 
differentiate these towards cortical neurons using an established 
protocol (Shi et al. 2012). The objective was to characterise the 
neurons derived from patient cells in a more energy demanding cell 
type, compared to fibroblasts. In addition, since mitophagy was not 
detected in the fibroblasts, this process was to be triggered in the 
neurons in attempt to identify any defects in the patient cells. 
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In addition to neurons, the third aim was to differentiate the iPSC to 
myotubes, since this was the most commonly affected tissue in the 
patient cohort used in this study. Like in the neurons, the objective 
was to characterise the patient cells and to attempt to induce 
mitophagy. 
 
The objective of generating iPSC possessing mtDNA mutations was 
to enable the comparison of mitochondrial phenotypes between 
fibroblasts, cortical neurons and myotubes. The hypothesis of this 
chapter was that, similar to the disease characteristics, generation 
of different cell types containing mutant mitochondrial DNA would 
result in some cell types possessing a phenotype and others not. 
This would benefit the study of mitochondrial DNA diseases, since it 
is poorly understood why some tissues present with clinical defects 
and others remain functioning despite the presence of the mutation. 
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3.2 Results 
 
3.2.1 Characterisation of induced Pluripotent Stem Cells 
(iPSCs) 
 
The seven mtDNA disease patient fibroblast lines used in chapter 2 
underwent reprogramming to induced Pluripotent Stem cells 
(iPSCs) using the Stemgent mRNA Reprogramming Kit, the 
Stemgent microRNA Booster Kit and Stemgent Stemfect RNA 
Transfection Kit, as described in the methods section. Wild-type 
fibroblasts and one of the tRNA serine mutants (patient 6) 
underwent reprogramming first and iPSC colonies were obtained. 
Several clones for each line were picked but only two each were 
used in the following experiments. In the following experiments WT 
Clone 1 and Clone 2, and Mutant Clone 11 and Clone 12 are used 
(WT Cl.1, WT Cl.2, Mutant Cl.11 and Mutant Cl.12). DNA was 
extracted from these lines and the Illumina NexteraTM library 
preparation kit was used to prepare for Next Generation 
Sequencing (NGS). Mutant Clone 11 and Mutant Clone 12 were 
both found to contain the tRNA serine m.7472insC mutation at a 
mutant load of greater than 80% (NGS data not shown).  
 
Subsequent reprogramming attempts with the other mutant lines 
proved to be very difficult. It was found that either iPSC colonies did 
not form or that picked colonies no longer contained the 
mitochondrial DNA mutation. Repeating attempts at reprogramming 
is a very expensive and time-consuming, especially when it is 
unknown as to why it failed the first time, therefore experiments 
were pursued with wild-type and the tRNA serine mutant clones 
alone. 
 
The iPSCs were first characterised before differentiated into other 
cell types to confirm their pluripotency. Nanog is a homeobox 
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transcription factor expressed in embryonic stem (ES) cells and was 
found to be strongly expressed in both wild-type and m.7472insC 
mutant clones when analysed by immunocytochemistry (Figure 29). 
Similarly, expression of Octamer-binding transcription factor 4 
(Oct4) a transcription factor essential for maintenance of 
pluripotency and self-renewal of ES cells, was identified in all iPSC 
lines (Wu & Schöler 2014). Finally, SRY (sex determining region Y)-
box 2 (SOX2), is a transcription factor which together with OCT4 
forms a trimeric complex on DNA, controlling gene expression 
during embryogenesis and acting as a gene repressor of neuronal 
differentiation (Liu et al. 2014). Expression of hSOX2 was identified 
in both wild-type and m.7472insC mutant clones when analysed by 
immunocytochemistry (Figure 30). 
 
Analysis of mRNA expression from RNA extracted from the four 
iPSC lines and a wild-type and mutant fibroblast cell line revealed 
increased expression of DNMT3 in the iPSCs compared to 
negligible expression in the fibroblasts (Figure 31). DNMT3 is a 
DNA methyltransferase, which during development, is essential for 
de novo DNA methylation, and therefore indicates similarities of the 
iPSCs to embryonic stem cells. 
 
C-Myc and Kruppel-like factor 4 (KLF4) are transcription factors, 
and both present in the mRNA cocktail used during reprogramming. 
It is known that the endogenous loci of several reprogramming 
factors, including c-Myc and KLF4, are expressed in some somatic 
cells, and here it was found that the mRNA expression of c-Myc and 
KLF4 was greater in the fibroblasts than in the iPSCs (Figure 31). In 
the generation of iPSCs from fibroblasts via retroviral transduction 
with human reprogramming factors, it was found that gene 
expression of c-Myc and KLF4 were unexpressed in established 
iPSCs and that differentiation was more efficient from the colonies 
with transient acitivation of c-Myc expression (Takayama et al. 
2010).  
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Finally, Rex1 (zfp42) is a zinc finger protein expressed primarily in 
undifferentiated stem cells in the embryo and adults, and therefore 
as expected its mRNA expression was greatly increased from 
unexpressed to highly expressed in the iPSCs compared to 
fibroblasts (Figure 31) (Scotland et al. 2009). 
 
 
 
Figure 29: Characterisation of induced Pluripotent Stem cells 
Representative images of iPSCs prepared by immunocytochemistry for 
staining with pluripotency markers hNanog (green) and Oct4 (red). DAPI 
staining labels cell nuclei. 
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Figure 30: Characterisation of induced Pluripotent Stem cells 
Representative images of iPSCs prepared by immunocytochemistry for 
staining with pluripotency marker hSox2 (green). DAPI staining labels cell 
nuclei. 
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Figure 31: Characterisation of induced Pluripotent Stem cells by qPCR 
Histogram to show the relative mRNA expression of markers DNMT3, c-Myc, 
KLF4 and Rex-1, relative to housekeeping gene GAPDH, in fibroblasts and 
iPSCs derived from control and patient skin biopsies. 
 
3.2.2 Characterisation of iPSC-derived cortical neurons 
 
IPSCs were differentiated to cortical neurons using the protocol 
written by Shi et al, described in the methods section. This protocol 
took 95 days before cells were characterised, and unfortunately the 
m.7472insC mutant clone 12 did not survive the differentiation by 
around day 50. In the interest of time, it was decided to proceed 
with the WT Cl.1, WT Cl.2 and Mutant Cl.11. 
 
At day 95, cells were characterised by immunostaining and DNA 
extracted for Sanger sequencing to confirm the presence of the 
mutation in Mutant Cl.11. Whilst it is not possible to estimate mutant 
load when using Sanger Sequencing, this is a significantly cheaper 
and quicker way to confirm the presence of the mutation. An 
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inserted ‘C’ was identified at the correct position in the mutant line 
that was not present in the wild-type (Figure 32). 
 
Neocortical markers Ctip2 and Tbr1 were used to assess the 
cortical properties of differentiated iPSCs by immunostaining. 
Pyramidal neurons in the neocortex are classified as deep-layer or 
upper-layer neurons, of which deep-layer are the first to be made 
during neurogenesis. Tbr1, a transcription factor, is expressed 
mainly in the neocortex by postmitotic pyramidal neurons, and is 
involved in the postmitotic regulation of layer VI and subplate 
(Hevner et al. 2001). 
 
Ctip2 is a transcription factor expressed by postmitotic neocortical 
subtypes, and is involved in the directing of pyramidal neurons to a 
deep-layer fate, and the formation of the corticospinal tract. 
Immunostaining of WT Cl.1, WT Cl.2 and Mutant Cl.11 cells that 
were day 95 post neuronal induction, revealed Ctip2 and Tbr1 
positive staining, indicating neocortical neurons (Figure 33). As 
expected, colocalisation of Ctip2 and Tbr1 was identified. 
 
Satb2 is a marker of callosal projection neurons in layers II-V. Loss 
of Satb2 expression causes upper-layer neurons to lose their upper-
layer identity, suggesting that Satb2 is involved in the regulation of 
upper-layer specification (Britanova et al. 2008). As expected, since 
deep-layer are the first to be generated during neurogenesis, fewer 
Satb2 positive cells were identified in the iPSC-derived neurons 
(Figure 33). 
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Figure 32: Sanger sequencing chromatogram of the m.7472insC mutation in 
iPSC-derived cortical neurons 
Representative chromatogram showing the 7472bp position where the 
inserted C (blue) is found in the mutant neurons (Mutant Cl.11) and not the 
wild-type neurons (WT Cl. 1) obtained by Sanger sequencing. DNA was 
extracted from neurons at day 95. 
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Figure 33: Characterisation of iPSC-derived cortical neurons 
Representative images of iPSC-derived cortical neurons prepared by 
immunocytochemistry for staining with neuronal markers Ctip2 (green, left), 
Tbr1 (red, left), Tom20 (mitochondrial marker; green, right) and Satb2 (red, 
right). DAPI staining labels cell nuclei. Scale bar represents 20 µM distance. 
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3.2.3 Mitochondrial physiology and function in mtDNA 
disease derived cortical neurons 
 
Analysis of basal mitochondrial membrane potential in live cells 
revealed no significant differences between wild-type neuronal lines 
and neurons containing the m.7472insC mutation (Figure 34A). In 
the analysis of TMRM intensity, both wild-type lines (WT Cl.1 and 
WT Cl.2), which were derived from different iPS colonies from the 
same fibroblast control line, had similar mean values; however 
analysis of cell lysates for the complex I activity assay proved quite 
different.  
 
In untreated cell lysates, complex I activity was found to vary greatly 
between WT Cl.1 and WT Cl.2, although there was relatively little 
variation on subsequent repeats for each line suggesting that the 
differences between neuronal lines was real (Figure 34B). The 
complex I activity of the Mutant Cl. 11 line was found to be slightly 
lower than the WT Cl.2, however with the large variation between 
controls, statistical significance was not measured.  
 
Previous experiments using PINK1 KD neuroblastoma cells have 
shown that growing cells for 24 hours in 300 µM folic acid (FA) 
could restore mitochondrial dysfunction (Tufi et al. 2014). Therefore 
taking into consideration the previous reduction in complex I activity 
observed in the mutant fibroblasts, the complex I assay was 
performed in parallel with lysates from cells that had been grown 
with folic acid for 24 hours. However, no differences in complex I 
activity were observed in any of the lines between the control and 
folic acid lysates (Figure 34B). 
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Figure 34: Quantification of mitochondrial membrane potential and complex 
I activity in cortical neurons 
A Histogram represents mean TMRM intensity measured by live cell 
imaging as an indicator of mitochondrial membrane potential. Error bars 
represent SEM, n = 3. B Histogram representing the Complex I activity 
measured from 200 ug of cell lysate with and without 24 H pre-treatment 
with folic acid. Error bars represent SEM, n = 3. 
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Assessing mitophagy in neurons has been of great interest in the 
field of mitophagy and, in particular, Parkinson’s disease research, 
however there have been several hurdles identified in the literature 
into the practicalities of doing so (as discussed in section 2.3.2).  
 
Our lab has studying this in depth and it has been found that iPSC-
derived cortical neurons treated with 10 µM CCCP for 48 H, 
‘refreshing’ the CCCP every 12 H (as described in the methods 
section) caused loss of mitochondrial proteins (data unpublished). 
This protocol was applied to WT Cl.1, WT Cl.2 and Mutant Cl.11, 
however only degradation of mitofusin 1 and the accumulation of 
PINK1 in CCCP treated cells could be identified (Figure 35 A-C). No 
loss of inner mitochondrial membrane marker Tim23 or outer 
mitochondrial membrane marker Tom20 could be identified in any of 
the lines (Figure 35 A,D). Comparing the results in WT Cl.1 and WT 
Cl.2, both exhibited substantial degradation of mitofusin 1 after 48 H 
CCCP treatment, more PINK1 accumulation was identified in WT 
Cl.1 than WT Cl.2, but similarly in both lines, no loss of 
mitochondrial proteins was observed. The m.7472insC mutant 
neurons revealed no differences to controls in the change in protein 
levels upon exposure to CCCP. No ubiquitination of mitofusin 1 was 
observed after 48 hours CCCP treatment, so a shorter timepoint 
was next observed.  
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Figure 35: Stimulation of cortical neurons with CCCP and quantification of 
mitochondrial protein levels 
A Representative immunoblot of mitophagy-associated protein levels in two 
wild-type cortical neuron lines and an m.7472insC mutant cortical neuron 
line, with and without 48H 10 µM CCCP treatment. B-D Histogram 
represents quantification of mitofusin 1 (B), PINK1 (C) and Tom20 (D) 
protein levels (normalised to β-actin protein levels) in the three lines (two 
WT and one mutant) with and without 48H 10 µM CCCP treatment. Error 
bars represent SEM. 
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WT Cl.1, WT Cl.2 and Mutant Cl.11 cortical neurons were treated 
with or without 10 µM CCCP for 24 hours, refreshing CCCP once 
after 12 hours (as described in the methods section). This 
experiment was also performed with CCCP alone or pretreatment (1 
H) and co-treatment with 10 µM MG132 (proteasome inhibitor). At 
the 24 hour timepoint, degradation of mitofusin 1 was observed in 
all three lines, but no mitofusin 1 ubiquitination (Figure 36). In the 
cells treated with both CCCP and MG132, degradation of mitofusin 
1 did not appear to be reduced but the appearance of ubiquitinated 
bands could be seen. If more neurons were available, it would have 
been preferable to perform a dose-response of MG132 in control 
cells to know if the most effective dose and treatment time had been 
used, in order to better draw conclusions from this effect. 
 
Figure 36: Stimulation with CCCP in the presence of proteasome inhibitor 
MG132 in iPSC-derived cortical neurons 
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Representative immunoblot to show the levels of mitophagy-associated 
proteins in two wild-type cortical neuron lines and an m.7472insC mutant 
cortical neuron line, with and without 24H 10 µM CCCP treatment, with and 
without proteasome inhibitor MG132. 
 
3.2.4 Characterisation of iPSC-derived myotubes 
 
IPSCs underwent myogenic differentiation following the protocol 
described in the methods section. For the first differentiation, WT 
Cl.1, WT Cl.2, Mutant Cl.11 and Mutant Cl.12 iPSCs were used and 
plated at p10 at a density of 1.2 x105 per well (in a 6-well tissue 
culture plate). Cells were treated as per the protocol described and 
split on day 25, however on examination of the cells on day 26, they 
had developed a neuronal-like morphology and it was clear that 
spontaneous differentiation had occurred. It was suspected that the 
cells had become too confluent prior to this spilt.  
 
A new frozen vial of iPSC was thawed and cultured ready for a 
second attempt. Unfortunately the WT Cl.2 did not survive the 
thawing process so in the interest of time it was decided to continue 
just with WT Cl.1, Mutant Cl.11 and Mutant Cl.12. This time, cells 
were plated at p12 and at a density of 1 x105. As it had not been 
determined why the first attempt at myogenic differentiation had 
failed, for the second attempt all new reagents were used and 
freshly aliquoted stocks were made. The second attempt was 
successful in all three lines and twitching myotubes were observed 
around day 35. 
 
Sanger sequencing of WT Cl.1, Mutant Cl.11 and Mutant Cl.12 
confirmed the presence of the m.7472insC mutation in the two 
mutant lines but not in the wild-type (Figure 37A). 
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MyoD is a master regulator of skeletal muscle cell differentiation, 
and has a central role myogenesis (Tapscott 2005). Whilst 
immunostaining was not particularly strong, expression of MyoD 
was identified in all three lines and found to colocalise with DAPI 
nuclei stain (Figure 37B). Myosin heavy chain is a protein found in 
muscle thick filaments and positive fibres were identified by 
immunostaining in all three lines (Figure 37B). 
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Figure 37: Confirmation of presence of m.7472insC mutation and 
characterisation of iPSC-derived myotubes 
 
A Representative chromatogram of the 7472bp position where the inserted 
C (blue) is positioned in iPSC-derived myotubes. In the wild-type line (clone 
1) at the site shown, there is a row of 6 ‘C’s, but in the two mutant lines 
there are 7. B Representative images of iPSC-derived myotubes prepared by 
immunocytochemistry using MyoD and MYC1 myogenic markers. DAPI 
staining labels cell nuclei. Scale bars represent 100 µM. 
 
DAPI MyoD Myosin heavy chain (MYC1) 
WT 1 Mutant 11 Mutant 12 
B 
DAPI MyoD Myosin heavy chain (MYC1) 
WT 1 Mutant 11 Mutant 12 
B 
 200 
3.2.5 Mitochondrial physiology and function in mtDNA 
disease derived myotubes 
 
Basal mitochondrial membrane potential obtained from experiments 
in live cells revealed no significant loss of membrane potential in 
either Mutant Cl.11 or Mutant Cl.12 compared to WT Cl.1 (Figure 
38A). Although unfortunately only one wild-type myotube line was 
available for these experiments, the data here suggests a large 
reduction in complex I activity in the Mutant Cl.11 and Mutant Cl.12 
compare to wild-type (Figure 38B). This difference was found to be 
of statistical significance between Mutant Cl.12 and WT Cl.1. 
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Figure 38: Quantification of mitochondrial membrane potential and complex 
I activity in iPSC-derived myotubes 
A Histogram represents mean TMRM intensity measured by live cell 
imaging as an indicator of mitochondrial membrane potential. Error bars 
represent SEM, n = 3. B Histogram representing the Complex I activity 
measured from 200 ug of cell lysate with and without 24 H pre-treatment 
with folic acid. Error bars represent SEM, n = 3; two-tailed Student t-test * p 
< 0.05  
 
 
The same protocol was used in the muscle cells for mitophagy as 
that which was used in the neurons, involving 48 hours of 10 µM 
CCCP treatment that was refreshed every 12 hours. Interestingly in 
the WT Cl.1 line, similar to the observations in the neurons, after 48 
hours of CCCP treatment, significant PINK1 accumulation and 
mitofusin 1 degradation was seen (Figure 39 A-D).  
 
However, both PINK1 accumulation and mitofusin 1 degradation 
was not significant in both Mutant Cl.11 and Mutant Cl.12 (Figure 39 
A-D). When analysing PINK1 protein levels a modest increase was 
observed in the mutants but not enough to reach significance like in 
the wild-type line. For the mitofusin 1 levels, the degradation 
observed was more variable, as depicted in the large error bars of 
the histogram, which is likely the reason for a non-significant 
difference.  
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Figure 39: Quantification of PINK1 levels in myotubes stimulated with 
mitochondrial uncoupler CCCP 
A Representative immunoblot showing PINK1 protein levels in wild-type 
and m.7472insC mutant (two clones) iPSC-derived myotubes with and 
without 48 H of 10 µM CCCP treatment. B Histogram to show the 
quantification of PINK1 protein levels, normalised to β-Actin protein levels. 
Error bars represent SEM, n = 3; two-tailed Student t-test * p < 0.05 C 
Representative immunoblot showing mitofusin 1 protein levels in wild-type 
and m.7472insC mutant (two clones) iPSC-derived myotubes with and 
without 48 H of 10 µM CCCP treatment. D Histogram to show the 
quantification of mitofusin 1 protein levels, normalised to β-Actin protein 
levels. Error bars represent SEM, n = 3; two-tailed Student t-test *** p < 
0.005 
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Measurement of mitochondrial proteins by immunoblotting revealed 
that CCCP treatment after 48 hours stimulated biogenesis instead 
of mitophagy. Like in neurons, no loss of mitochondrial proteins was 
observed in wild-type muscle cells, however quantification of Tom20 
revealed a significant increase in protein levels after 48 hours of 
CCCP (Figure 40). This increase was found to be significant also in 
both Mutant Cl.11 and Mutant Cl.12 (Figure 40).  
 
On analysis of another mitochondrial protein, Tim23, no significant 
increase or decrease was observed in WT Cl.1 after 48 hours of 
CCCP, and there was little difference in the mean values between 
untreated and treated (Figure 40). However an increase in Tim23 
protein levels was identified in both the Mutant Cl.11 and Mutant 
Cl.12, the latter of which reached statistical significance (Figure 40). 
Interestingly, under basal conditions (i.e. in the untreated samples) 
the protein levels of Tim23 were found to be significantly lower in 
Mutant Cl.12 that WT Cl.1 (Figure 40). 
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Figure 40: Quantification of mitochondrial protein levels in myotubes 
stimulated with 48 H CCCP 
A Representative immunoblot showing the protein levels of mitochondrial 
markers Tim23 and Tom20 in iPSC-derived myotubes treated with and 
without 10 µM CCCP for 48 H. B Histogram shows the quantification of 
Tim23 (dark grey) and Tom20 (light grey) protein levels, normalised to β-
actin protein levels. Error bars represent SEM, n = 3; two-tailed Student t-
test * p < 0.05 
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3.3 Discussion 
 
3.3.1 Limitations of iPSC derived mitochondrial disease 
models 
 
The differentiation of iPSCs expressing multiple pluripotency 
markers towards neuronal or myogenic cell fates did not cause a 
loss of mutation; on successful attempts, a high mutant load was 
obtained.  
 
Unfortunately, two major limitations were experienced during the 
experiments in this chapter, which would have required a significant 
amount of time to overcome which was not available. First, each 
differentiation into myotubes and neurons was only carried out 
once. All experiments performed in neurons or myotubes were 
carried out in triplicate, however it would have been beneficial to 
repeat these experiments from a separate induction. The process of 
differentiation involves long term exposure to many growth factors 
and can result in mixed cell populations; therefore it would be 
unsurprising if slightly variable results were observed on different 
inductions. To ensure results deemed significant were dependent 
on the presence of the mutation, it would be best to show this 
occurring in cells derived from a separate induction. Furthermore, 
multiple reprogramming and differentiation experiments may have 
enabled the generation of an isogenic control, which would have 
been particularly advantageous for determining the mutation 
dependent phenotype. 
 
Secondly, iPSCs and differentiated cell types in culture are 
particularly sensitive especially compared to immortalised cell lines 
and fibroblasts, therefore experiments in muscle and neurons could 
only be conducted on three lines due to cell survival problems. In 
the differentiation of iPSCs towards cortical neurons, mutant clone 
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12 did not survive beyond day 50, at which point the cells had 
completely detached from the tissue culture plate. During the later 
stages of neuronal differentiation, half-media changes are 
performed so as not to disturb the extremely delicate neurons in 
culture, therefore cell detachment could have been caused by a 
disturbance during the differentiation protocol. However more likely 
this was due to iPSC culture itself since duplicate wells of the same 
line are cultured during a single induction and all of these were lost 
originating from only one iPS clone. It was hypothesised at the time 
that the death of neurons could have been a phenotypic effect of a 
high mutant load, however once the differentiation protocol was 
completed and the surviving mutant clone was sequenced, this 
appeared to have a high mutant load itself, therefore would have 
been unlikely to survive if this was the reason for the loss of clone 
12. It is well known that iPSC cultures are characteristically 
heterogeneous, even among those derived from healthy controls, 
and differentiation capacity has been found to be influenced by 
factors prior to the differentiation process, such as passage number 
of the iPSC (Koehler et al. 2011; Hu et al. 2010). Whilst it is 
impossible to identify the reason for the loss of mutant clone 12, the 
heterogeneous nature of iPSCs is likely to be a factor and it is 
probable that a different induction with a different population of 
mutant clone 12 iPSCs would result in a successful differentiation.  
 
For the differentiation of iPSCs towards myogenic cell fates, one of 
the wild-type iPSC clones did not survive the thawing process. The 
iPSCs should be thawed and maintained in culture for at least two 
weeks before switching to mTeSRTM media for a few days before 
plating to begin muscle differentiation. Since the first differentiation 
failed at 26 days after cell plating, believed to be due to the 
importance of cell density being not too high, it was decided in the 
interest of time to continue with one wild-type clone and two mutant 
clones.  
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It was unfortunate that in both the neuronal and muscle experiments 
that the same three clones weren’t utilised, in particular because of 
the noticeable differences observed between the two neuronal wild-
type clones in complex I activity and PINK1 accumulation – two 
characteristics that appeared to be affected in the myotubes 
containing the m.7472insC mutation. It is not unusual to obtain 
different results from various healthy controls, for example the 
endogenous Parkin levels measured in 8 fibroblasts derived from 
healthy subjects from chapter 2, however it is more surprising to see 
different results from two clones obtained from the same fibroblast 
line.  
 
3.3.2 Phenotypes in cortical neurons containing 
tRNAserine mtDNA mutation 
 
In the iPSC-derived cortical neurons, fewer Satb2 positive nuclei 
were identified than Ctip2 and Tbr1, suggesting fewer more mature 
neurons were present in the cell population and it is likely that these 
cells were relatively glycolytic at the time of experiments (Agostini et 
al. 2016). Analysis of mitochondrial membrane potential in live cells 
using the TMRM dye, showed no significant differences in the 
maintenance of membrane potential suggesting an energised inner 
membrane that can sufficiently balance the movement of protons in 
order to generate ATP.  
 
The assessment of complex I activity showed considerable variation 
between the two wild-type clones. The activity of complex I was 
measured in cell lysates from neurons and also neurons cultured in 
folic acid for 24 hours prior to cell lysis. This was in anticipation of 
any significant decreases in complex I activity, like the results seen 
in fibroblasts. It has been shown previously that enhancing 
nucleotide pools through the use of folic acid, which adds 1-carbon 
units in the biosynthesis of nucleotides can alleviate mitochondrial 
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dysfunction caused by PINK1 deficiency (Tufi et al. 2014). 
Therefore it was hypothesised that had there been a significant 
decrease in the mutant neurons compared to controls that if it could 
be alleviated in the presence of folic acid it might suggest that this 
phenotype was linked to PINK1 deficiency. However, for these 
experiments there was no positive control, such as iPSC-derived 
neurons containing the PINK1 mutation use in the fibroblast 
experiments, therefore it was not possible to perform a dose-
response of folic acid treatment beforehand. In reality however, it 
was found that discrepancies between wild-type clone 1 and clone 
2, with the complex I activity measured from clone 2 cell lysates 
being approximately 60% of that measured in clone 1 lysates, made 
it not possible to identify any reliable changes in the mutant cells. 
Compared to clone 1, the mutant cell complex I activity was 
approximately 46%; but compared to clone 2 the mutant activity was 
at approximately 73%. 
When stimulating cells with the mitochondrial uncoupler CCCP, 
cortical neurons responded with a decrease in protein level of 
mitofusin 1, suggesting protein degradation however no 
ubiquitination was detected after 48 H. This effect was consistent 
between wild-type clones and the mutant neurons. The 
accumulation of PINK1 was detected at the 48 H timepoint, with a 
greater amount of protein detected in the wild-type clone 1 treated 
with CCCP than clone 2, however the accumulation in the mutant 
neurons appeared to be close to an average of both wild-type 
clones. These data suggest that the upstream processes of 
mitophagy, such as the accumulation of full-length PINK1 and the 
degradation of outer mitochondrial proteins, such as mitofusin1, 
were as expected in both wild-type and mutant neurons.  
 
Nevertheless, quantification of mitochondrial proteins, such as 
Tom20, showed no activation of mitophagy at the same timepoint. 
In the current model of mitophagy, PINK1 accumulation on 
depolarised mitochondria occurs upstream of the ubiquitination of 
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outer mitochondrial membrane proteins by the E3 ubiquitin ligase 
Parkin, and this triggers the ubiquitin-binding adaptor p62 and 
autophagic machinery for elimination. Therefore it is unclear why 
one outer mitochondrial protein, mitofusin 1, is degraded but not 
another outer mitochondrial membrane protein, Tom20. There was 
no significant difference in the Tom20 levels in any of the cells 
treated with DMSO to those treated with CCCP for 48H, therefore it 
is not known whether mitophagy or even biogenesis had been 
stimulated. If biogenesis was stimulated in these cells as a result of 
the widespread loss of functioning mitochondria caused by CCCP, 
the levels of Tom20 may be maintained but so too would mitofusin 1 
which would be also present on the newly synthesised 
mitochondria. The increase in PINK1 protein at this timepoint 
suggests that damaged mitochondria remain in the cells, but the 
near complete loss of mitofusin 1 suggests widespread 
mitochondrial clearance. These data, together with the findings in 
depolarised myotubes are discussed further in section 3.3.6. 
 
3.3.3 Phenotypes in myogenic cells containing tRNAserine 
mtDNA mutation 
 
In the iPSCs differentiated towards a myogenic cell fate, a high 
mutant load was determined in the two mutant clones and no 
insertion was detected in the one wild-type line used in these 
experiments. On analysis of mitochondrial membrane potential in 
live cells, the two mutant lines appeared to be polarised similarly to 
the wild-type myotubes. On repeat experiments it was found that 
nearly no noticeable difference was measured in the mutant lines, 
suggesting good reproducibility even in live cell imaging. Although 
only one wild-type line of differentiated myotubes was used, a 
significant decrease was found in complex I activity in the lysates of 
mutant clone 12, again with high reproducibility. Whilst it did not 
reach statistical significance, the complex I activity in mutant clone 
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11 cell lysates was also noticeably reduced. Since Sanger 
sequencing of mtDNA cannot be used to accurately quantify mutant 
load, the significant decrease achieved in clone 12 could not be 
attributed to a greater mutant load than in clone 11.  
 
The wild-type and mutant myotubes were treated with mitochondrial 
uncoupler CCCP as was carried out in the cortical neurons. The 
accumulation of PINK1 was significant in wild-type myotubes at the 
48 H timepoint, similarly to that seen in neurons. However the same 
exposure to CCCP in the two mutant clones caused no significant 
increase in PINK1 protein levels. The CCCP did appear to stimulate 
the stabilisation of full-length PINK1 in the mutants, but to a much 
more modest effect at this timepoint. No other timepoints were 
observed, so it is not to say that PINK1 did not accumulate at a 
different rate to that in the wild-type but it is interesting that the 
same reduction was identified in the two different mutant clones. 
Similarly, the significant degradation of mitofusin 1 was again 
observed in the wild-type myotubes, but this did not reach statistical 
significance in the two mutant clones. It should be noted that this 
was not a case of entirely no degradation of mitofusin 1 being 
caused in the mutant lines, but in both lines this degradation 
appeared to be variable across the triplicate experiments, in 
contrast to the very consistent effect of CCCP in the wild-type cells.  
 
In myotubes differentiated from iPSC containing wild-type mtDNA, 
no change in the protein levels of inner mitochondrial membrane 
protein Tim23 was detected after 48 hours of CCCP. However, a 
significant increase in outer mitochondrial membrane protein Tom20 
was identified, suggesting stimulation of mitochondrial biogenesis. 
As with the observations in the neurons, it is unclear why mitofusin 
1 is degraded when Tom20 protein levels are higher, in the case of 
myotubes, significantly. Looking at the effect of the mutation, a 
significant increase in Tom20 was also identified in both mutant 
clone lines, and in mutant clone 12 there was also a significant 
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increase in Tim23 protein levels; suggesting that biogenesis is 
stimulated in the mutants, and to a greater extent in particular in 
mutant clone 12. Interestingly, the basal protein levels of Tim23 
were found to be significantly reduced in mutant clone 12 compared 
to wild-type. 
 
Encouragingly, despite not having more than one wild-type line, 
phenotypic characteristics seemed to be consistent in both mutant 
clones. These myotubes exhibited reduced basal complex I activity, 
and under depolarised conditions, reduced PINK1 accumulation, 
reduced mitofusin 1 degradation and increased mitochondrial 
biogenesis.  
 
3.3.4 Differences in the effect of the same mutation in 
different cell types – fibroblasts, cortical neurons and 
myotubes 
 
It is commonly found in heterogeneous mitochondrial DNA diseases 
that high-energy demanding tissues are most often affected and to 
a greater severity. The reasoning behind this is that high-energy 
demanding tissues require a greater output from mitochondria and 
therefore the consequences of dysfunctional mitochondria are more 
apparent. In the phenotypic information provided for the patients 
harbouring the m.7472insC mutation, the observations were ataxia, 
myoclonus and deafness. Myoclonus can originate from numerous 
areas, defined for example as cortical myoclonus, spinal myoclonus 
or peripheral myoclonus; whilst cortical myoclonus is the most 
common presentation, the predicted origin of the m.7472insC 
patient’s myoclonus was not stated (Kojovic et al. 2011).  
 
In the three cell types studied containing the m.7472insC mutation, 
no significant changes in mitochondrial membrane potential were 
detected. In fibroblasts obtained from patients harbouring the 
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m.7472insC mutation, a significant reduction in Complex I activity 
was identified, however no dermatological symptoms were reported 
in the patients. In iPSC-derived neurons, Complex I activity 
appeared to be no different to one of the controls and in iPSC-
derived myotubes a significant reduction was again identified. 
Interestingly, no phenotypes were detected in the iPSC-derived 
neurons but both the fibroblasts and iPSC-derived myotubes 
appeared to harbour defects in part of the mitophagy pathway in 
addition to Complex I activity impairment. In the fibroblasts, 
mitofusin ubiquitination was significantly reduced, a phenotype also 
associated with PINK1 and Parkin mutant patient-derived 
fibroblasts, and in the myotubes a reduction in PINK1 accumulation 
was observed and no significant mitofusin degradation. 
 
A Complex I defect caused by the m.7472insC mutation has been 
reported in many patients harbouring this mutation and presenting 
with sensorineural deafness (Tiranti et al. 1995; Toompuu et al. 
2002). It is unknown whether the absence of Complex I defect in the 
iPSC-derived neurons is a result of tissue-specific phenotypes 
commonly seen in mitochondrial diseases or whether the model is 
not effective in this cell type. If this occurred due to a tissue-specific 
phenotype, it is particularly interesting to have three cell types all 
expressing the m.7472insC mutation to what is believed to be a 
high mutant load, but with one cell type not displaying a phenotype 
and two cell types which do but one a high-energy demanding cell 
type and the other a low-energy demanding cell type. In this case, 
these models provide a great set-up for studying why the Complex I 
and mitophagy alterations occur in muscle and not cortical neurons, 
and also why fibroblasts in the patient appear to ‘cope’ with the 
molecular pathology but muscle is implicated in the presentation of 
the patient.  
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3.3.4.1 Why was a phenotype not detected in the iPSC-derived 
cortical neurons? 
 
Studies in numerous patients harbouring the m.7472insC mutation 
have shown that neurological features of ataxia and myoclonus 
occur when mutant loads reach over 95% (Hutchin et al. 2001; 
Tiranti et al. 1995; Jaksch et al. 1998). Since the mutant load was 
not determined by NGS and therefore could not be accurately 
quantified, the absence of phenotype could be a result of a mutant 
load less than 95%. The other cell types, fibroblasts and myotubes, 
may not have a mutant load threshold so high and therefore a 
phenotype could be identified. Generation of numerous cell lines 
with various mutant loads would be required to identify if this was 
the cause. Unlike if iPSC-derived cardiomyocytes were generated 
and found to have no phenotype, it was surprising that the cortical 
neurons did not show any defects since they are a cell type likely to 
be involved in the myoclonus observed in the patient.  
 
Alternatively, the isolated iPSC-derived cortical neurons may not be 
sufficient to emulate functional consequences of mitochondrial DNA 
mutations. A two-dimensional culture may not be adequate to model 
neural circuitry and functional output (Paşca et al. 2015). 
Furthermore, the differences in the two neuronal lines derived from 
two wild-type iPS clones may have prevented the detection of a 
significant phenotype if the result from one of the wild-type clones 
was due to an error. Moreover, without a positive control, such as 
an iPSC-derived PINK1 mutant, and an abundance of cells to 
confidently establish a mitophagy assay, it remains unknown 
whether the concentrations and timepoints used for investigating 
mitophagy in the neurons were correct. The occurrence of 
mitophagy in neurons is discussed further in section 3.3.6. 
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3.3.4.2 Why do patients not exhibit a phenotype in fibroblasts 
when the cell model shows impaired Complex I activity? 
 
The m.7472insC fibroblasts and myotubes in these experiments 
revealed impairments in Complex I activity, which is a known 
consequence of some mitochondrial mutations, providing validity to 
this model. Furthermore, the presence of mitophagy-associated 
impairments in the cell types also exhibiting Complex I deficiencies 
suggests an involvement of mitophagy in the pathomechanism of 
this disease.  
 
As shown in Chapter 2, m.7472insC fibroblasts also exhibited 
increased mitochondria-endoplasmic reticulum contacts, increased 
biogenesis upon depolarisation of the mitochondrial membrane, and 
decreased mitochondrial length; however patients had no 
dermatological symptoms. Although not all these effects could be 
assessed in muscle, similar phenotypes were observed in the iPSC-
derived myotubes in Complex I activity and mitophagy-associated 
proteins, but the patient’s muscle is implicated in their presentation. 
Fibroblasts grown under standard culture conditions are glycolytic, 
and therefore utilise mitochondrial oxidative phosphorylation to a 
lesser extent, meaning that defects in their mitochondria may not 
affect their function (Zheng 2012). It has been found too that 
cultured muscle cells can be highly glycolytic, however mature 
myotubes in the patient rely predominantly on oxidative 
phosphorylation (Aguer et al. 2011; Sin et al. 2016). 
 
3.3.5 Working hypothesis for the effect of m.7472insC 
mutation on mitochondria in myotubes 
 
The data obtained from experiments in iPSC-derived myotubes 
suggest that under stressed conditions, such as exposure to the 
mitochondrial uncoupler CCCP, the accumulation of full-length 
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PINK1 is triggered in wild-type cells. With this, degradation of outer 
mitochondrial membrane protein mitofusin 1 was observed, which 
based on the current model of mitophagy is likely to be caused by 
the recruitment of the E3 ubiquitin ligase Parkin. Furthermore, 
measurement of mitochondrial protein expression suggested a 
stimulation of biogenesis, since the total mitochondrial protein levels 
either remained the same or increased. The high respiratory 
demands of myogenic cell types for efficient function suggests that 
even under circumstances of widespread depolarisation of 
mitochondria, which is not particularly likely to occur under normal 
biological conditions, it would not be energetically worthwhile to 
solely remove all mitochondria (Moraes et al. 1992). Instead, 
proliferation is more likely to be stimulated in parallel with 
mitophagy.  
 
In the myotubes containing the m.7472insC, stressed conditions did 
not cause an accumulation of PINK1, nor significant degradation of 
mitofusin 1, suggesting that PINK1 did not stimulate the 
translocation of Parkin. On assessment of total mitochondrial 
protein levels, a large increase in mitochondrial proteins was 
observed, suggesting that biogenesis had been stimulated. 
Experiments investigating the mRNA expression of PGC-1α in 
patient fibroblasts showed a large stimulation of biogenesis upon 
stress induced by CCCP, which was hypothesised as being 
compensatory since PGC-1α has been shown to buffer reactive 
oxygen species (Baldelli et al. 2014). Here it remains unknown 
whether stimulation of biogenesis occurs to the a greater extent in 
patient cells than wild-type, or whether larger increases in 
mitochondrial proteins are only due to the lack of mitophagy 
stimulated. If under widespread depolarisation the stimulation of 
mitophagy is impaired, it stands to reason that under basal 
conditions the quality control process is unable to regulate defective 
mitochondria and this is shown functionally in the impaired activity 
of Complex I. 
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3.3.6 Does mitophagy occur in neurons and myotubes? 
 
As discussed previously, exposing cells to a mitochondrial 
uncoupler for 48 hours is energetically compromising in high-energy 
demanding tissues, and various studies in muscle have revealed 
the importance of repopulation of biogenesis with mitophagy, 
described as a ‘cross-talk’ between two contrasting processes (Sin 
et al. 2016; Vainshtein et al. 2015; Greene et al. 2015). Other 
studies in vivo have also shown that the pathway of mitophagy is 
likely to be cell-specific, therefore since our understanding of 
mitophagy so far has been largely dependent on artificial cell lines, 
we should be open to potential alternative mechanisms (McWilliams 
et al. 2016; Sun, Yun, Liu, Malide, Liu, I. I. Rovira, et al. 2015).  
 
Recent studies in neurons have revealed alternative mechanisms to 
the traditional mitophagy model. In particular, the emergence of 
mitochondrial transfer, shown both in a Parkin-overexpressed 
system and in vivo (G. Ashrafi et al. 2014; Davis et al. 2014). This 
process involves the extrusion of damaged mitochondria for 
degradation by the lysosomes of neighbouring glia. It has been 
shown also that healthy mitochondria can be acquired from 
neighbouring glia following neuronal damage via neuro-glial 
mitochondrial transfer (Hayakawa et al. 2016). 
 
These studies call into question further the validity of a two-
dimensional neuronal cell model for mitophagy, since if damaged 
mitochondria are cleared by the transfer to neighbouring glia, this 
will not occur in isolated cell models. This may be why in these 
experiments, PINK1 accumulation is observed but no loss of 
mitochondrial membrane proteins Tom20 and Tim23.  
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3.3.7 Future perspectives 
 
The next experiments to do in this section would be to repeat the 
differentiation into myotubes and neurons. Independent 
differentiation experiments would help validate the findings shown 
here. Furthermore it would enable the use of more controls and 
potentially generate mutant lines with different mutant loads, 
including an isogenic control.  
 
The m.7472insC mutation has a similar molecular effect to the 
mitochondrial mutation A7445G, therefore it would be interesting if it 
were possible to obtain fibroblasts from these patients to assess the 
specificity of the phenotypes observed to the m.7472insC mutation 
(Toompuu et al. 2002). 
 
The recent work on trans-mitophagy in neurons also suggests that 
neuronal three-dimensional cultures should be investigated for the 
study of mitophagy. This would be particularly effective in neurons 
as this cell-type is very network dependent and relies on 
connectivity for function.  
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Discussion 
 
The main aim of this thesis involved testing the hypothesis that the 
process of selective mitophagy is impaired in mitochondrial DNA 
disease such that mutant mitochondrial DNA can persist.  
 
To do this, the requirements for mitophagy induction were explored 
as well as the methods of detection in various cell types. In chapter 
one it was shown that PINK1-dependent mitophagy can be induced 
independently of mitochondrial membrane depolarisation. The study 
of the mitophagy pathway is largely limited by the repeated use of 
mitochondrial uncouplers to initiate the process. Using only this 
method restricts our understanding of the physiological role of 
mitophagy. Here, using an alternative compound Rhodamine 6G, it 
was shown that oxidative stress at an insufficient level to cause 
membrane depolarisation could however induce the accumulation of 
PINK1. It has been shown previously that loss of mitochondrial 
membrane potential prevents the import of PINK1 through the 
translocase of the inner mitochondrial membrane, causing it to 
become stabilised on the outer membrane, however these results 
suggest that there must be an alternative mechanism by which 
PINK1 accumulates (Jin et al. 2010). Using next generation 
sequencing, it was found that Rhodamine 6G also induced low 
levels mutations in SH-SY5Y cells and fibroblasts, indicating that 
damage to the mitochondrial genome may also contribute to the 
induction of mitophagy. This data contributes to other evidence in 
the literature, which show mitophagy occurring in polarised 
mitochondria, such as a reduction in activity of mitochondrial 
processing peptidase and the loss of mitochondrial protease 
LONP1, both causing the accumulation of PINK1 at the 
mitochondrial surface (Jin & Youle 2013; Greene et al. 2012). The 
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main hypothesis of this thesis is that mitophagy is not triggered in 
mtDNA disease patient cells containing high ratios of mutant 
mtDNA, therefore not only do the requirements of mitophagy 
induction need to be better understood, if the hypothesis is found to 
be true then therapies targeting stimulation of mitophagy would 
need to be explored.  
 
The experiments in chapter one also highlighted a significant flaw in 
the field of mitophagy research. Using non-Parkin-overexpressing 
systems to assess the clearance of mitochondrial proteins, it was 
found by immunocytochemistry that the signal from one particular 
mitochondrial marker, an antibody against Complex V, was lost in a 
PINK1-independent manner, at a much earlier timepoint than other 
mitochondrial protein markers. This however was not found to be 
the case by Western blotting, and this phenomenon has not been 
reported in the literature. As discussed in section 1.1.2, there are 
several different methods that can be used to assess mitophagy 
and unfortunately each have their limitations. Without an approved 
and consensually agreed experimental method of defining 
mitophagy, the research in this field is hindered by non-comparable 
methods of assessing mitophagy between publications. The loss of 
mitochondrial proteins as assessed by immunocytochemistry is a 
common mitophagy indicator, however had Complex V been used 
to measure this in certain cell systems, the results would be 
misleading and false. In my opinion, it should be standard practice 
to show mitophagy by providing evidence of colocalisation of 
mitochondria with lysosomes in the presence of autophagy 
inhibitors, which would indicate ‘end-stage’ mitophagy, and not 
measuring ‘net’ change in mitochondria, which is heavily influenced 
by biogenesis as well as mitochondrial clearance.  
 
In the second chapter of this thesis, a range of different patient 
fibroblast lines with mitochondrial DNA disease were used to 
explore mitochondrial dysfunction. All these patients harboured a 
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mutation in the mitochondrial genome, however the presentations 
were heterogeneous. These included two sets of relatives; one of 
the sets included a symptomatic and an asymptomatic case, and 
the other set included two patients both presenting with the same 
phenotype. Furthermore, one patient had a mutation in a subunit of 
the ATP synthase but was clinically diagnosed as having Charcot-
Marie-Tooth hereditary neuropathy type 2 (CMT2).  
 
The aim of this chapter was to use this range of fibroblast lines to 
identify common characteristics between the lines in this cell type 
and investigate the induction of mitophagy. In the context of the 
main thesis hypothesis, using a range of lines it was possible to 
show significant impairment of mitofusin ubiquitination affected all 
patient fibroblasts, except for the CMT2 patient. Moreover, 
biogenesis was stimulated upon mitochondrial depolarisation in a 
manner not observed in control cells in all the lines which 
possessed a mutation in a mitochondrial tRNA gene. In these 
experiments, mRNA analysis of PGC-1α was used to indicate an 
upregulation of biogenesis, however this data would benefit from 
showing an increase in mtDNA copy number, and also the 
activation of TFAM (mitochondrial transcription factor A) expression. 
Interestingly, upon closer examination of one particular mutation, 
m.7472insC, similarities in both function and morphology were 
observed between these lines and PINK1 mutant fibroblasts. These 
findings supported the hypothesis of an impaired mitophagy 
pathway, however the process of mitophagy appears to be 
incomplete in this cell type. Studies in control, PINK1 and Parkin 
mutant fibroblasts have demonstrated that complete removal of 
mitochondria does not occur following mitochondrial membrane 
depolarisation even in wild-type fibroblasts, however the 
ubiquitination of mitofusins is dependent upon PINK1 or Parkin. 
Therefore the striking reduction of mitofusin ubiquitination, 
particularly in the m.7472insC mutant fibroblasts, strongly implicated 
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a disturbance to the normal mitophagy pathway since this effect has 
only previously been reported in PINK1 and Parkin mutants. 
 
The decision to study the m.7472insC mutation further was to 
enable more experiments to be performed in a shorter timeframe, 
since culturing large numbers of fibroblasts, which are slow growing 
and have a particularly low protein content, would limit the depth in 
which this hypothesis could be studied. Since fibroblasts are an 
unaffected tissue type in these diseases, the next experiments 
involved reprogramming fibroblasts to iPSCs and differentiating 
them into neurons and myotubes. As a result, only the m.7472insC 
fibroblasts were used since these processes are particularly time-
consuming. 
 
The objective of chapter three was to generate neuronal and 
myogenic cell models of mitochondrial DNA disease using the 
m.7472insC mutant fibroblasts. The mitophagy pathway has been 
most extensively characterised in immortalised cell lines, therefore 
how these known mechanisms translate in different cell types is not 
well understood. As a result, after generating mutation-containing 
iPSC-derived cell types, the aim was to attempt to induce 
mitophagy, using techniques used in SH-SY5Y cells, and assess 
whether defects could be observed in these cell types. Although 
complete mitophagy could not be detected in either cortical neurons 
or myoblasts, the accumulation of PINK1 and mitofusin degradation 
could be quantified.  
 
The same experiments were performed in the iPSC-derived cortical 
neurons and iPSC-derived myoblasts, and interestingly only a 
mitophagy-associated defect was identified in the myoblasts. 
Mitochondrial diseases are well known to affect tissues differently 
despite the presence of the mutation in all cells, so this effect was 
particularly interesting in the development of a valid mitochondrial 
disease model. No significant differences were observed in the 
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mutant neurons compared to those derived from control iPSC, 
however in the myoblasts, significantly reduced Complex I activity 
was reported. Furthermore, upon depolarisation of the mitochondrial 
membrane potential, a significant reduction in both PINK1 
accumulation and mitofusin 1 degradation was identified in the 
mutant myoblasts. Whilst these experiments were performed from 
only one induction, and more controls would be ideal for future 
experiments, it was particularly interesting to observe that in the 
neurons there was both no functional defect and no apparent 
mitophagy impairments, but in the myoblasts a functional defect 
was present with a seeming deficiency to the accumulation of 
PINK1 and downstream processes.  
 
If these experiments were to be repeated after further inductions, it 
would be particularly interesting to monitor mutant load throughout 
the duration. In the experiments conducted using fibroblasts, cortical 
neurons and myoblasts, mutant load was only assessed once in 
each cell type. It is well known that in the human disease and in 
cultured cells that mutant load can change over time, however it is 
not usually monitored throughout experimental studies. It would be 
beneficial when repeating experiments in triplicate to know if the 
mutant load was the same each time, since changes in load may 
correlate with phenotype. Since Next Generation Sequencing is the 
most accurate method of measuring mutant load, but also very 
expensive, it would be useful to obtain a cell ‘sample’ for each 
experiment conducted, for example by plating an extra well of cells 
for each experiment preparation. Cells could then be harvested for 
DNA extraction at the timepoint of each experiment, and ultimately 
all samples loaded onto a sequencing run to provide a comparison 
of mutant load across all experiments. 
 
Although more experiments are required, dysfunction in mitophagy-
associated proteins has been observed in cell types with 
compromised mitochondrial function (fibroblasts and iPSC-derived 
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myotubes), but not in cell types in which the same functional 
impairment is not observed (iPSC-derived cortical neurons). Any 
reductions in mitochondrial membrane potential did not seem to 
correlate with mitochondrial dysfunction or mitophagy-related 
impairments, which was in accordance with the findings in chapter 
one, which showed that membrane depolarisation is not required to 
stimulate mitophagy. Together the findings in this thesis provide 
evidence that mitophagy impairments are implicated in 
mitochondrial DNA disease and that this pathway could be a target 
for developing therapeutic strategies towards the management of 
these diseases. 
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Appendix 
 
Cell Type Treatment time Locus Position Change 
% 
Reads 
SH-SY5Y 1.5 H RNR2 2456 TA > T (del) 1.05 
    COX1 6691 GA > G (del) 1.03 
SH-SY5Y 14 H ND2 4604 CA > C (del) 1.01 
   COX1 6691 GA > G (del) 1.03 
   DLOOP3 16161 TA > T (del) 2.17 
   DLOOP3 16186 C > T (ts) 2.67 
   DLOOP3 16294 C > T (ts) 1.58 
   DLOOP3 16304 T > C (ts) 2.17 
    DLOOP3 16327 C > T (ts) 2.95 
Fibroblast 24 H DLOOP5 247 G > A (ts) 1.04 
   DLOOP5 302 A > AC (ins) 2.49 
   DLOOP5 309 C > CCT (ins) 3.63 
   DLOOP5 564 G > A (ts) 1.26 
   COX1 6691 GA > G (del) 1.01 
    ND3 10348 T > C (ts) 1.16 
Fibroblast  24 H DLOOP5 312 C > CA (ins) 1.57 
   ND2 4604 CA > C (del) 1.07 
   TRNS1 7506 G > T (tv) 1.05 
   ND4 10806 G > T (tv) 1.01 
    DLOOP3 16419 C > A (tv) 1.01 
 
Table shows the base changes observed by Next Generation 
Sequencing of different cell types (SH-SY5Y cells or fibroblasts) 
treated for different time periods (1.5 H – 24 H) with 2 µM 
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Rhodamine 6G, a summary of which is shown in Figure 17. Data 
shows mitochondrial genome base changes, the position and type 
of variant: tv = transversion, ts = transition, ins = insertion and del = 
deletion. The ‘Change’ shows the reference base and the change 
that occurred at that position. The ‘% reads’ is the percentage of 
reads (approx. 10,000 reads per base) containing the variant. 
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